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Summary  IV 
Summary 
Transmissible spongiform encephalopathies (TSEs), also termed prion diseases, are fatal 
neurodegenerative diseases of humans and animals, and include bovine spongiform 
encephalopathy (BSE) in cattle, scrapie in sheep, chronic wasting disease (CWD) in deer 
and elk and Creutzfeldt-Jakob disease (CJD) in humans. Whilst prion diseases share several 
pathological features with other neurodegenerative diseases such as Alzheimer’s disease 
and Parkinson’s disease, TSEs are unique in that they can propagate by either genetic, 
infectious or sporadic mechanisms. Prion disease in humans (and animals) can occur by 
peripheral infection of the host (e.g. via an oral route of infection or iatrogenic transmission). 
According to the “protein-only” hypothesis the major component of the prion agent is an 
abnormal variant of the cellular prion protein (PrPC), termed PrPSc. Intensive studies of prion 
pathogenesis suggest that the peripheral nervous system is a likely route of prion 
neuroinvasion to the central nervous system (CNS), but detailed knowledge on the 
mechanisms of intranerval prion propagation, such as the direction of prion spread or cell 
types involved, remains elusive.  
In the first part of my thesis I pursued a combination of in vivo and in vitro approaches to 
study prion propagation in peripheral neurons. In a transgenic mouse model of impaired 
retrograde transport, no correlation was observed between axonal transport and prion 
propagation.  However, in an in vitro model of prion spread using compartmented cultures of 
peripheral neurons it was possible to demonstrate anterograde as well as retrograde 
intraneural spread of prions without requirement for accessory cells. 
Once in the brain, prions typically induce histopathological changes that involve neuronal 
vacuolation (spongiosis), neuronal death and pronounced activation of glial cells, invariably 
leading to death of the affected individual. Whilst morphologically well characterized, the 
molecular origin of neurodegeneration is not understood. Therefore, in the second, third and 
fourth part of my thesis I sought to identify molecular modifiers of prion pathogenesis. The 
second part describes a candidate approach taken under the reasoning that the NF-κB 
signalling pathway might be involved in prion pathogenesis. However, a role for neither the 
canonical nor the alternative NF-κB pathway could be confirmed in mice with impaired NF-κB 
signalling.  
The third and fourth part describe screens for genes that are differentially regulated upon 
prion infection or which modify PrPSc levels in cell culture models of prion infection. In the 
third part comparative transcriptional analyses revealed transcriptional stability of cultured 
neuroblastoma cells upon prion infection. Although highly infected, cells did not display 
consistent changes in transcriptional profiles as a response to prion infection. Several 
transcripts previously reported by others to be differentially expressed in prion-infected cells 
could not be confirmed in our assays. Most likely these discrepancies can be attributed to the 
technical stringency of the current study which was performed under conditions designed to 
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minimize potential genetic drifts. Therefore, it is concluded there are no universal 
transcriptional changes induced by prion infection of neuronal cells in vitro.  
The conformational conversion of PrPC to the pathogenic state of PrPSc is central to the 
protein-only hypothesis and thus to prion diseases in general. However, the molecular 
mechanisms underpinning the biogenesis of PrPSc and its clearance in vivo remain elusive. 
In order to elucidate putative regulators of the PrPC:PrPSc conversion process and/or of PrPSc 
clearance I employed a phenotype-driven screen of a library of 266 synthetic precursor 
miRNAs in an in-house developed assay in order to identify candidates that significantly alter 
PrPSc levels in a cell culture model of prion infection. Overexpression of one miRNA (miR-
142-3p) consistently resulted in elevated PrPSc abundance independently of endogenous 
PrPC expression levels in both a cell-type and a prion strain independent manner. 
Subsequent high density oligonucleotide arrays in combination with bioinformatic analyses 
identified six potential target candidate mRNAs to be downregulated as a result of miR-142-
3p overexpression. Whether any of these six candidate mRNAs alone or a combination of 
them results in elevated PrPSc levels, thereby potentially representing putative cellular 
modulators of PrPSc abundance, is currently under investigation. 
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Zusammenfassung 
Übertragbare spongiforme Enzephalopathien (TSEs), sog. Prionenerkrankungen 
verursachen tödliche, neurodegenerative Erkrankungen wie z.B. die Creutzfeldt-Jakob-
Krankheit (CJD) beim Menschen, die bovine spongiforme Enzephalopathie (BSE) bei 
Rindern oder Scrapie bei Schafen. TSEs teilen charakteristische pathologische 
Eigenschaften mit anderen neurodegenerativen Erkrankungen wie z.B. Alzheimer`s oder 
Parkinson`s Erkrankung, sind jedoch einzigartig in bezug auf ihre Ursache, die entweder 
genetisch, sporadisch oder durch eine Infektion bedingt sein kann. So können 
Prionenerkrankungen z.B. durch orale Aufnahme oder ärztliche Behandlung auf den Wirt 
übertragen werden. Entsprechend der “protein-only”-Hypothese besteht der Erreger der 
Prionenerkrankungen hauptsächlich aus einer abnormalen Variante des zellulären Prion 
Proteins (PrPC), genannt PrPSc. Ausführliche Studien der Prionen-Pathogenese lassen 
vermuten, dass Prionen über das periphere Nervensystem im Körper verbreitet werden und 
somit auch ins Gehirn gelangen. Detailliertes Wissen über die Art und Weise der 
Prionenausbreitung in peripheren Nerven, wie z.B. die Richtung und der Mechanismus der 
intranervalen Verbreitung oder die beteiligten Zelltypen fehlt bisher. 
Im ersten Teil meiner Doktorarbeit habe ich in vivo und in vitro Methoden kombiniert, um die 
Ausbreitung von Prionen in peripheren Neuronen zu untersuchen. In einem transgenen 
Mausmodel mit gestörtem retrograden Transport konnte keine Korrelation zwischen 
Prionenausbreitung und axonalem Transport festegestellt werden. In einem in vitro Model 
konnte jedoch retrograde und anterograde Ausbreitung von Prionen in peripheren Neuronen 
ohne die Beteiligung von anderen Zelltypen wie z.B. Schwann-Zellen gezeigt werden. 
Haben Prionen erst einmal das Gehirn erreicht, induzieren sie histopathologische 
Veränderungen wie Absterben der Neuronen, Spongiose und ausgeprägte Aktivierung der 
Glia-Zellen, die ausnahmslos zum Tod der betroffenen Individuen führen. Während die 
prioneninduzierte Neurodegeneration morphologisch detailliert charakterisiert ist, bleiben ihre 
molekularen Ursachen ungewiss. In den weiteren Teilen meiner Doktorarbeit habe ich mich 
daher mit Regulatoren der Prionenerkrankung befasst.  
Im zweiten Teil der Arbeit wird ein möglicher Einfluss des NF-κB Signalweges auf die 
Prionenpathogenese untersucht. Es konnte jedoch weder in Mausmodellen mit gestörtem 
„canonical“ noch gestörten „alternative“ NF-κB Signalweg eine Veränderung der Prionen-
Pathogenese festgestellt werden. 
Der dritte und vierte Teil dieser Arbeit beschreiben die Suche nach Genen die durch 
Prioneninfektion beeinflusst werden oder welche PrPSc Konzentrationen in chronisch 
prioneninfizierten Zellkulturmodellen verändern. Im dritten Teil zeigen vergleichende 
Transkriptomanalysen unveränderte mRNA-Profile in Neuroblastom-Zellen nach 
Prioneninfektion. Obwohl die Zellen hochgradig infiziert waren, konnten keine konsitenten 
Veränderungen des Transkriptoms festgestellt werden. Einige Transkripte, die in anderen 
Studien als von Prionen beeinflusst gefunden wurden, konnten hier nicht bestätigt werden. 
Zusammenfassung  VII 
Diese Unterschiede sind wahrscheinlich auf die strigentere Versuchungsdurchführung 
zurückzuführen, die genetischen Drift minimieren sollte. Zusammenfassend kann 
festgehalten werden, dass keine universellen Veränderungen im Transkriptom durch 
Prioneninfektion hervorgerufen werden. 
Die Umfaltung von PrPC in die pathogene Form PrPSc ist ein zentrales Element der “protein-
only“-Hypothese und daher essentiell für Prionenerkrankungen. Die molekularen Grundlagen 
der Entstehung und des Abbaus von PrPSc sind bisher unbekannt. Um mögliche Regulatoren 
dieser Prozesse zu identifizieren wurden 266 synthetische Vorläufer-miRNAs in einem 
eigens dafür entwickelten Verfahren auf ihr Potential hin untersucht, PrPSc Level in einem 
Zellkulturmodel für Prioninfektion  zu verändern. Überexpression einer miRNA (miR-142-3p) 
führte zu erhöhten PrPSc-Niveaus unabhängig von PrPC-Expression, Zelltyp oder 
Prionenstamm. Anschliessende Transkriptomanalysen in Kombination mit bioinformatischen 
Analysen identifizierten sechs mRNAs als mögliche Zielmoleküle der miR-142-3p. Ob einer 
dieser Kandidaten isoliert oder im Verbund mit weiteren Kandidaten den PrPSc-Level erhöhen 
kann und somit einen potentiellen Regulator des PrPSc-Niveaus darstellt, ist zur Zeit 
Gegenstand weiterer Forschungen. 
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Definitions 
(adapted from Charles Weissmann and Adriano Aguzzi; (Weissmann, 2004; Aguzzi and 
Heikenwalder, 2006; Aguzzi et al., 2007))  
 
Transmissible spongiform encephalopathy (TSE): A synonym for prion disease and a 
general term that refers to all diseases that are associated with the presence of prions 
in vacuolated central nervous system tissue. Prions from TSE-affected brains can be 
transmitted from one affected host to another host. 
Prion (for proteinaceous, infectious only): Prions are the agents of transmissible 
spongiform encephalopathy (TSE), with unconventional properties, such as 
resistance to high temperatures, formaldehyde treatment or UV irradiation. The term 
“prion” does not have any structural implications other than that a protein is an 
essential component of the transmissible agent. 
PrPC (for cellular prion protein): The physiologically occurring, mainly GPI-linked form of 
PrP, or prion protein, that can be glycosylated on one or both of two asparagine 
residues with a variety of glycans. As shown by NMR and X-ray crystallography, it is 
rich in α-helical structure and contains only a little β-sheet structure. 
PrPSc (for scrapie prion protein): An isoform of PrPC that is almost invariably detected in 
TSE-infected tissues and cells and therefore serves as surrogate marker for prions It 
comprises a carboxy-proximal segment of about 140 residues that is resistant to 
defined conditions of proteinase K treatment. The term PrPSc is used by some 
interchangeably with prion, a usage that should be avoided. PrPSc designates a 
structure, prion is a functional concept. The implication that a particular form of PrP is 
the only essential constituent of the prion remains to be proven. Nonetheless, it is 
widely accepted that prions mainly consist of PrPSc. Since it remains to be formally 
proven whether the infectious unit consists primarily or exclusively of (i) a subspecies 
of PrPSc, (ii) an intermediate form of PrP (termed PrP*), (iii) other host-derived 
proteins or (iv) non-protein compounds (e.g. nucleic acids < 50 nucleotides), it seems 
wise to avoid equating prion infectivity and PrPSc at the present time. 
Scrapie: A TSE that affects sheep and goats. It has been known since at least the 
eighteenth century, hundreds of years before prions were first defined. Scrapie was 
shown to be transmissible 60 years ago.  
 
Abbreviations  - IX 
Abbreviations 
 
AA  amino acid 
bp  base pair 
BM  bone marrow 
BSA  bovine serum albumin 
cDNA  complementary DNA 
CJD  Creutzfeldt-Jakob-disease 
CNS  central nervous system 
cT  threshold cycle 
Ctrl  control 
CWD  chronic wasting disease 
DNA  deoxyribonucleic acid 
dpi  days post infection 
ECL  enhanced chemiluminescence 
EDTA  ethylendiamintetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
FDC  follicular dendritic cell 
FFI  fatal familial insomnia 
GALT  gut associated lymphoid tissue 
GAPDH glyceralaldehyde 3-phospate deghydogenase 
GFAP  glial acidic fibrilarry protein 
GPI  glycosylphosphatidylinositol 
GSS  Gerstmann-Sträussler-Scheinker disease 
H&E  hematoxylin and eosin 
HRP  horseradish peroxidase 
IHC  immunohistochemistry 
IKK  IkB kinase  
i.p.  intraperitoneal 
kD  kilo dalton 
LD  lethal dose 
LRS  lymphoreticular system 
M  molar 
MBA  mouse bioassay 
miRNA  microRNA 
mRNA  messenger RNA 
NEMO  NF-κB essential modifier 
NF-κB  nuclear factor of κB 
NLS  nuclear localization signal 
Abbreviations  - X 
ORF  open reading frame 
PAGE  polyacrylamid gel electrophoresis 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
PK  proteinase K 
PNS  peripheral nervous system 
RML  Rocky mountain laboratory (prion strain) 
RNA  ribonucleic acid 
RT  room temperature 
RT-PCR reverse transcription PCR 
SAF  scrapie associated fibrils 
SAF84  antibody used to visualize PrPSc in IHC 
SCA  scrapie cell assay 
SCEPA  scrapie cell assay in end point format 
sCJD  sporadic CJD 
SDS  sodium dodecyl sulfate 
siRNA  small interfering RNA 
TCIU  tissue culture infectivity unit 
TSE  transmissible spongiform encephalopathies 
TME  transmissible mink encephalopathy 
U  unit 
vCJD  variant CJD 
wt  wild-type 
w/v  weight/volume 
-  negative for 
+  positive for 
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1 Introduction 
The introduction of my Ph.D. thesis is a modified and extended version of the publication:  
 
Prions and peripheral nerves: A deadly rendezvous. 
Heikenwalder, M., Julius, C., and Aguzzi, A.  
Department of Pathology, Institute of Neuropathology, University Hospital of Zürich, Zürich, 
Switzerland. 
Published in Journal of Neuroscience Research; 2007: 85(12):2714-25. 
 
1.1 Transmissible spongiform encephalopathies (TSEs) 
Transmissible spongiform encephalopathies (TSEs), also called prion diseases, are fatal 
neurodegenerative diseases of humans and animals (Aguzzi, 2006). Animal TSEs include 
amongst others scrapie in sheep and goat, bovine spongiform encephalopathy (BSE) in 
cattle, transmissible mink encephalopathy (TME) and chronic wasting disease (CWD) in deer 
and elk, whereas human TSEs include sporadic or variant Creutzfeldt-Jakob disease (sCJD 
or vCJD), Fatal Familiar Insomnia (FFI), Gerstmann-Sträussler-Scheinker-syndrom (GSS) 
and Kuru (Aguzzi and Polymenidou, 2004; Aguzzi et al., 2007). In contrast to 
neurodegenerative diseases like Alzheimer’s and Parkinson’s disease, TSEs are infectious 
and can be transmitted by peripheral infection of the host (e.g. oral infection or iatrogenic 
transmission)(Aguzzi and Heikenwalder, 2006). Although scrapie was recognized in the 19th 
century and first cases of Creutzfeldt-Jakob disease were described eight decades ago 
(Creutzfeldt, 1920; Jakob, 1921), it took till the second half of the 20th century to identify 
prions as the infectious agents causing TSEs. According to the “protein-only” hypothesis, 
which was formulated in its original form in 1967 (Griffith, 1967) and refined by Stanley 
Prusiner in 1982 (Prusiner, 1982), the major component of the prion agent is an aggregated 
variant of the cellular prion protein PrPC, termed PrPSc. 
Prion diseases have been responsible for various tragic episodes. In the past 20 years more 
than 280’000 cattle succumbed to BSE. This provoked a worldwide major food crisis with 
huge economic consequences for the European Union and other countries. In the last 
quarter of the 20th century, iatrogenic transmission of prion contaminated gonadotropins into 
humans caused over 250 victims of Creutzfeldt-Jakob disease. Furthermore, the emergence 
of a variant form of CJD (vCJD) in the United Kingdom in 1996 has been causally and 
experimentally linked to the UK BSE epidemic in the 1980s and early 1990s. At the 
beginning of the 21st century transmission of BSE to humans is believed to have so far 
caused 201 cases (as of July 2007) of a new variant of Creutzfeldt-Jakob disease (vCJD) 
(Collinge et al., 1996; Hill et al., 1996; Will et al., 1996; Aguzzi and Polymenidou, 2004; 
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http://www.cjd.ed.ac.uk/vcjdworld.htm, http://www.cjd.ed.ac.uk/PROTOCOL.HTML, 2002, 
July 2007). 
Even though the incidence of BSE has dramatically decreased in all affected Western 
European countries in the last years, first BSE cases have been documented in the United 
States of America (USA) as well as in countries previously believed to be BSE free (e.g. 
Sweden, Austria). Additionally, scrapie outbreaks are being constantly documented in 
Europe.  
The fact that most likely millions of people (primarily in the United Kingdom) have been in 
contact with BSE contaminated meat initiated a widespread health scare, since no therapy 
other than palliation is available to date. Human-to-human prion transmission via blood 
transfusions was reported (Aguzzi and Glatzel, 2006) and this has alerted health authorities 
worldwide to tighten the quality control of blood and blood products (Llewelyn et al., 2004). 
Therefore, prion diseases still present a major challenge and danger to society.  
 
 
1.1.1 Human prion diseases 
Prion diseases in humans can be dominantly inherited, acquired or classified as sporadic if a 
genetic or infectious transmission can be excluded. Inherited forms of prion disease are FFI 
and GSS, whereas acquired conditions include diseases transmitted by dietary infections, 
such as Kuru and vCJD or by other infection routes like iatrogenic contact with infected 
material during brain surgery. Irrespective of the cause for the individual prion disease, brain 
tissue of CJD patients harbours prion infectivity that can be transmitted to non-human 
primates by ingestion or inoculation (Johnson and Gibbs, 1998).  
Accounting for 75% of all cases, sporadic Creutzfeldt-Jakob disease (sCJD) is the most 
common prion disease in humans and surveillance shows a yearly incidence of one case per 
million population and year across the world (Brandel et al., 2000; Aguzzi et al., 2001). Men 
and women are equally affected and the average age of onset is 60 years. By now the 
aetiology of sCJD remains elusive, but somatic PRNP mutations, or the spontaneous 
conversion of PrPC into the disease associated PrPSc as a rare event are hypothesised. 
Furthermore, homozygosity at a common coding polymorphism at codon 129 of PRNP 
encoding either methionine or valine predisposes to the development of sporadic and 
acquired CJD (Aguzzi et al., 2007).  
Iatrogenic and vCJD represent approximately 17% of the cases (Andrews et al., 2003; 
http://www.cjd.ed.ac.uk/vcjdworld.htm, http://www.cjd.ed.ac.uk/PROTOCOL.HTML, 2002, 
July 2007);. vCJD was first reported in 1996 in the UK and has been causally and 
experimentally linked to the UK BSE epidemic. The course and pathology of vCJD differs 
from that of sCJD in terms of younger age of onset, prominent psychiatric and sensory 
symptoms, and a longer disease course (Spencer et al., 2002). Since prion diseases typically 
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exhibit very long latency periods between the time of infection and the clinical manifestation, 
some individuals exposed to BSE or harbouring another form of human prion disease, might 
be asymptomatic carriers of the infectious agent and possibly pose a risk of further 
transmission of the infection to others (Brandel et al., 2000; Houston et al., 2000; Llewelyn et 
al., 2004; Aguzzi and Glatzel, 2006). Exposure to prion infectivity from such individuals 
during surgical procedures like transplantation of human dura mater, or corneal grafts can 
cause iatrogenic CJD. Furthermore, stereotactically implanted electroencephalography 
electrodes as well as treatment with human cadaveric pituitary growth hormone and 
gonadotrophins are possible sources of prion infectivity (Brown et al., 2006).  
With 7% of the cases inherited forms are the third largest group of human prion diseases. 
FFI and GSS are associated with autosomal dominant pathogenic mutations in PRNP. How 
pathogenic mutations in the gene encoding PrP cause prion disease has yet to be resolved; 
however, in most cases, the mutation is thought to lead to an increased tendency of PrPC to 
form PrPSc. 
Symptoms of human prion diseases can be fatigue, sleep disturbance, and diminished 
appetite. Furthermore patients present with behavioural or cognitive changes or focal 
neurological signs such as visual loss, cerebellar ataxia, aphasia, or motor deficits (Johnson, 
2005). The disease progresses rapidly with prominent cognitive decline and the development 
of myoclonus. For sCJD, the median survival time from the onset of disease is only five 
months and 90% of the patients die within one year (Johnson and Gibbs, 1998).  
Moreover, ritualistic anthropophagy of CNS derived tissues in New Guinea tribes caused 
Kuru, which was the prime cause of death until the middle of the 20th century in Papua New 
Guinea (Gajdusek and Zigas, 1957).  
 
1.1.2 Animal prion diseases 
Animal TSEs include amongst others scrapie in sheep and goat, bovine spongiform 
encephalopathy (BSE) in cattle, transmissible mink encephalopathy (TME) and chronic 
wasting disease (CWD) in deer and elk (Aguzzi and Polymenidou, 2004). The first form of 
natural animal TSEs to be reported in the 19th century was scrapie, which is characterised by 
scraping of fleece, stumbling and behavioural changes of affected animals. Scrapie shows a 
progressive course, leading to death in 3 to 6 months (Cuille and Chelle, 1939). Similar to 
sCJD, the cause for scrapie remains elusive. Scrapie infectivity persists in pastures for years 
after the removal of infected animals (Pattison and Millson, 1961). Lambs exposed to this 
land show infectivity first in tonsils, retropharyngeal lymphnodes, and intestine suggesting 
uptake of prion infectivity by ingestion (Hadlow et al., 1982). By now, there are no known 
genetic cases of prion diseases in animals comparable to those seen in humans, but allelic 
variations in the Prnp sequence do occur also in animals, and variation at several residues in 
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the PrP amino acid sequence influences susceptibility to both natural and experimental 
scrapie infection (Goldmann et al., 1994). 
Chronic wasting disease (CWD) is known since the late 1960s and was first reported as fatal 
wasting disease in captive mule deer in Colorado (Sigurdson and Aguzzi, 2007). To date 
10% of the wild deer population in Colorado and Wyoming is suggested to be affected. In line 
with sCJD and scrapie the origin of CWD remains elusive. The finding of prion infectivity in 
saliva of experimentally infected animals suggests a possible route for horizontal 
transmission (Mathiason et al., 2006). 
The first cases of BSE have been reported in the United Kingdom in 1985. BSE is suggested 
to be initiated by scrapie contaminated meat and bone meal prepared from contaminated 
carcasses (Aguzzi and Polymenidou, 2004). Exported cattle and contaminated feed spread 
BSE to various countries in continental Europe and all over the world. The BSE epidemic 
peaked in the first half of the 1990s. Since then, the BSE incidence declined due to 
regulations that prevent feeding ruminant meat and bone meal to ruminants and stringent 
prion testing of slaughtered cattle.  
 
1.2 The cellular prion protein (PrPC) 
1.2.1 Expression pattern and biosynthesis of PrPC 
The cellular prion protein (PrPC) is a highly conserved protein in mammals and paralogues, 
present in turtle (Simonic et al., 2000), fish (Rivera-Milla et al., 2003) and even amphibians 
(Strumbo et al., 2001). The murine Prnp gene encoding the cellular isoform of the prion 
protein is located on chromosome 2 in mice and the mature form of murine PrPC consists of 
210 amino acids (Basler et al., 1986). No natural Prnp null alleles were described despite 
negative evolutionary pressure (Mead et al., 2003). The broad, diverse expression pattern of 
PrPC with expression in skeletal muscle, kidney, heart, pancreas, secondary lymphoid organs 
and the CNS presumably points to a general, conserved and broad function (Ford et al., 
2002; Aguzzi and Polymenidou, 2004). Within the CNS and peripheral nervous system 
(PNS) PrPC expression levels can be detected in synaptic membranes of neurons as well as 
in oligodendrocytes, Schwann cells and astrocytes (Moser et al., 1995). In the periphery, 
PrPC expression is reported on lymphocytes and at high levels on a stromal cell of the 
immune system: the follicular dendritic cell (FDC), located in organs of the lymphoreticular 
system (LRS). Moreover, PrPC expression was shown to be developmentally regulated 
during mouse embryogenesis (Manson et al., 1992; Miele et al., 2003).  
PrPC is a glycosyl phosphatidyl inositol (GPI)-linked glycoprotein, and can be either un-, 
mono- or diglycosylated (Figure 1.1A). It is mainly located in lipid rafts of the extracellular 
membrane. The three dimensional structure of mature PrPC from mouse, humans, cattle and 
Syrian hamster shares common features e.g. a long, flexible N-terminal tail (residue 23-121), 
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three α-helices, and a two-stranded anti-parallel β-sheet that flanks the first α-helix (Riek et 
al., 1997). The C-terminus is stabilized by a disulfide bond linking α-helices two and three 
(Riek et al., 1996).  
 
1.2.2 Physiological function of PrPC 
Many different functions have been attributed to PrPC: This includes regulation of the immune 
system, signal transduction, copper binding, synaptic transmission, inducing apoptosis or 
being anti-apoptotic etc. (Caughey and Baron, 2006). Recent data indicate that PrPC is 
expressed on long-term repopulating hematopoietic stem cells, important for their self-
renewal (Zhang et al., 2006). Furthermore, PrPC positively regulates neural precursor 
proliferation during neurogenesis (Steele et al., 2006), but postnatal depletion of PrPC in 
neurons does not result in neurodegeneration (Mallucci et al., 2002). Moreover, intracranial 
delivery of cross-linking anti-PrP antibodies induces neuronal apoptosis in hippocampus and 
cerebellum (Solforosi et al., 2004). 
PrPC was shown to be conveyed by fast axonal transport with a velocity of about 1 cm/hour 
(Borchelt et al., 1994) (Figure 1.1B). Retrograde as well as anterograde transport 
mechanisms are discussed for PrPC (Moya et al., 2004; Butowt et al., 2005). PrPC was 
shown to be enriched and PrPC transport enhanced during axonal regeneration (Moya et al., 
2005). 
Whatever the role of PrPC, aside from conversion to PrPSc, may be remains elusive by now, 
but different functions of PrPC in different cell types seem plausible. However, understanding 
the role of PrPC in the brain could give insights into prion pathogenesis (Aguzzi and 
Polymenidou, 2004).   
 
1.3 The connection between prion infectivity, PrPSc and 
neurotoxicity 
In the CNS, prion infections cause characteristic accumulation of abnormally folded host-
encoded prion protein (PrPSc), neuronal cell loss and neuropathological lesions with 
spongiform vacuolation accompanied by proliferation of astrocytes. Prion pathology also 
goes along with large-scale activation and proliferation of microglia (Aguzzi and 
Polymenidou, 2004).  
 
1.3.1 The protein-only-hypothesis 
The precise physiological nature of the prion agent is still the subject of intensive scientific 
scrutiny. PrPC is a protease sensitive cell surface protein with a cell type dependent turnover 
of a few hours. Prion infected cells harbour on addition the partially protease resistant form 
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PrPSc which also shows a longer half life than PrPC (Lehmann and Harris, 1996). PrPSc is 
believed to be the major component of prion infectivity and may or not be fully congruent with 
the infectious agent (Aguzzi and Polymenidou, 2004). Prion infectivity owns specific 
biochemical properties: Resistance to high temperatures, high pressure, formaldehyde 
treatment or UV-irradiation (Prusiner et al., 1981; Prusiner et al., 1993). In line with these 
findings, PrPSc is enriched in β-sheet content and is characterized by its poor solubility in 
non-denaturing detergents, propensity for aggregation, and partial resistance to proteinase K 
(PK) digestion (McKinley et al., 1983).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Structural features of the cellular prion protein. (A) Scheme of the primary structure of the cellular 
prion protein and its posttranslational modifications. A secretory signal peptide resides at the extreme N-terminus. 
The numbers describe the position of the respective amino acids. CC (red) defines the charged cluster. HC 
(green) defines the “hydrophobic core”. S-S indicates the single disulfide bridge. The proteinase K (PK) resistant 
core of PrPSc is depicted in grey; the approximate cutting site of PK within PrPSc is indicated by the arrow. MA 
denotes the membrane anchor region. GPI depicts the glycosyl phosphatidyl inositol anchor. OR stands for octa-
repeats. The size of the PK resistant fragment is variable, being cut at various positions between amino acids 78 
to 102. (B) Differences in velocity of axonal transport. “Slow a” (slow component a) or “slow b” (slow component 
b) depends on the solubility of the cargo. Proteins that form the core of the insoluble cytoskeletal structure are 
transported by “slow a”, cytosolic proteins by “slow b” (Hirokawa, 1998; Hirokawa and Takemura, 2005). PrPC 
seems to be transported by extremely fast mechanisms (Borchelt et al., 1994) (1 cm/h), whereas prions or PrPSc 
are believed to be transported much slower (0.7 to 3.3 mm/day) (Bartz et al., 2002; Kunzi et al., 2002). However, 
it has to be pointed out that no data unambiguously show anterograde axonal transport of PrPSc. APP: amyloid 
precursor protein. 
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It is believed that PrPC acts as a substrate for the conversion process of the abnormally 
folded variant of PrPC, termed PrPSc (Weissmann, 2004). The conversion from PrPC to PrPSc 
is suggested to rely on a physical interaction between host-encoded PrPC and exogenous 
PrPSc as a template, resulting in the PrPSc conformation being imposed on PrPC. How PrPC is 
turned into PrPSc remains elusive by now, but two likely conversion processes, the “refolding” 
model and the “seeding” model (Gajdusek, 1988; Jarrett and Lansbury, 1993; Cohen et al., 
1994), are depicted in Figure 1.2.  
Refolding model 
 
 
 
 
 
 
 
Seeding model 
 
 
 
 
 
 
 
 
Figure 1.2: Models for the conformational conversion of PrPC into PrPSc. Schematic of the refolding or 
template-directed assistance model (A) and the seeding or nucleation-polymerization model (B); adapted from 
(Aguzzi and Sigurdson, 2004). 
 
a) The refolding model presumes that the conformational change is kinetically controlled and 
a high activation energy barrier prevents spontaneous conversion at detectable rates. 
Exogenous PrPSc exerts a catalytic action and thereby the energy barrier may be overcome. 
Furthermore, unknown enzymes or chaperones may be involved in this action (Prusiner, 
1991). Consequently, the conversion process yields into an exponential cascade. In familial 
prion diseases, pathogenic mutations are suggested to lower the energy barrier, thereby 
favouring spontaneous conversion into PrPSc without the necessity for contact with 
exogenous PrPSc. 
b) The seeding model assumes that PrPC and PrPSc are in a reversible thermodynamic 
equilibrium, strongly favouring PrPC. PrPSc can be stabilized in a highly ordered seed and 
further monomeric PrPSc can be recruited resulting in aggregated amyloid. Subsequent 
B 
A 
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fragmentation of PrPSc aggregates increases the number of seeds, which can recruit further 
PrPSc and thus results in apparent replication of the agent. Here, the rate limiting step is the 
formation of the seed. Aggregates need to be continuously fragmented, generating an 
increasing number of seeds to result in exponential accumulation of PrPSc(Aguzzi and 
Sigurdson, 2004). 
Further evidence for the protein-only hypothesis is complete resistance of Prnp-/- mice to 
prion infection (Büeler et al., 1993). In addition, brains of Prnp-/- mice inoculated with prions 
do not harbour prion infectivity (Sailer et al., 1994). Reintroduction of Prnp by transgenesis 
restores susceptibility and prion replication in Prnp-/- mice (Fischer et al., 1996) (Flechsig et 
al., 2000) (Shmerling et al., 1998). All this suggests that PrPC acts as an essential substrate 
for the propagation of the infectious agent. 
At present, it is widely accepted that prions mainly consist of PrPSc. However, it remains to be 
formally proven whether the infectious unit consists primarily or exclusively of (i) a 
subspecies of PrPSc, (ii) an intermediate form of PrP (termed PrP*) (Weissmann, 1991; 
Silveira et al., 2005), (iii) other host-derived proteins (Telling et al., 1995) or (iv) non-protein 
compounds (e.g. nucleic acids < 50 nucleotides) (Deleault et al., 2003; Priola et al., 2003). 
We still do not know whether the prion hypothesis is correct in its entirety - even though 
recent reports indeed appear to indicate that prion infectivity can be generated (or at least 
amplified) in vitro (Legname et al., 2004; Castilla et al., 2005). Therefore, it seems wise to 
avoid equating prion infectivity and PrPSc at the present time. 
 
1.3.2 Prion strains: The second dimension 
The idea of the existence of prion strains emerged from the finding that distinct versions of 
prion diseases, differing at the symptomatic (e.g. onset of disease; clinical signs; 
histopathology in the brain) and biochemical level, can occur within inbred individual animals, 
even though the Prnp gene is identical in these animals (Dickinson and Meikle, 1971). These 
properties may also influence whether a prion strain is lymphotrophic or neurotrophic 
(Aguzzi, 2004).  
It has been heavily discussed whether strain-specific properties of prions may be encoded by 
a nucleic acid genome. However, no evidence for such a hypothesis has been forthcoming 
(Weissmann, 1991). Within the framework of the protein-only hypothesis, if prions really 
consist only of protein, PrPSc must exist in a variety of distinct pathological conformations, 
each one of which could faithfully impart its own conformation onto PrPC, resulting in distinct 
pathologies. Strain phenotypes may be encoded within different conformations of PrPSc 
which have distinct stabilities against chaotropic salts and heat. This indeed was 
demonstrated in the yeast Sup35 prion model (King and Diaz-Avalos, 2004; Tanaka et al., 
2004; Tanaka et al., 2006) but it still remains to be shown whether similar phenomena occur 
in mammalian species (Aguzzi, 2004).  
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1.3.3 PrPC, a mandatory molecule for prion induced neurotoxicity and 
prion transport 
One essential requirement for prion pathogenesis has been established beyond all 
reasonable doubt: If indeed prions multiply by imparting their conformation on to PrPC, 
infected hosts devoid of PrPC should be resistant to prions. Indeed, lack of the Prnp gene 
confers absolute resistance against cerebral and peripheral scrapie infection (Büeler et al., 
1993).  
Intriguingly, if a neurograft from a wild-type mouse is introduced into Prnp-/- mice and such 
mice are infected intracerebrally (i.c.) with scrapie prions, the graft but not the surrounding 
tissue shows scrapie pathology (Brandner et al., 1996b). This indicates that PrPC is essential 
for neuronal damage caused by prion infection in the CNS (Brandner et al., 1996a). 
However, the exact mechanisms of how neurodegeneration is elicited remain unknown. One 
could speculate that the (still elusive) function of PrPC, upon conversion to PrPSc, is altered 
unspecifically or rendered as an inactive moiety leading to neurodegeneration (Aguzzi and 
Heikenwalder, 2003; Aguzzi and Polymenidou, 2004). Neuronal apoptosis in hippocampus 
and cerebellum following intracranial delivery of monoclonal PrP antibodies has been 
demonstrated in vivo (Solforosi et al., 2004). Only dimerization of PrPC was shown to induce 
this phenotype pointing to the fact that PrPC dimerization induces an apoptotic signal. 
Moreover, caspase-12 and endoplasmic reticulum stress were reported to mediate 
neurotoxicity of pathological prion protein in vitro (Hetz and Soto, 2003). Even though 
neurotoxic, quite surprisingly, high prion titers in the lymphoreticular system (LRS) are not 
accompanied by significant histopathological changes (Clarke and Haig, 1971; Dickinson et 
al., 1972). The LRS includes primary and secondary lymphoid tissues. In primary lymphoid 
organs (e.g. bone marrow and thymus) the cells are generated, whereas the secondary 
lymphoid tissue is the location where the cells of the LRS function (e.g. spleen, lymph nodes, 
and the mucosa associate lymphoid tissue). Furthermore, murine scrapie infection was 
recently reported to cause an abnormal germinal centre reaction in the spleen (McGovern et 
al., 2004).  
Importantly for understanding the basics of prion transport from the periphery into the CNS, 
PrP-expressing neurografts in Prnp-/- mice do not develop scrapie histopathology after 
intraperitoneal (i.p.) or intravenous (i.v.) inoculation with scrapie prions (Blättler et al., 1997). 
Therefore, PrPC paves a road for prion transport that executes prion neuroinvasion from the 
periphery to the CNS. 
Prion titres were undetectable in spleens of inoculated Prnp-/- mice, but were restored to wild-
type levels upon reconstitution with wild-type bone marrow (BM) cells. Surprisingly, even 
though high titers of prion infectivity were found in spleens of reconstituted Prnp-/- mice (Prnp-
/- mice engrafted with wild-type BM), mice did not succumb to scrapie after i.p. inoculation 
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with prions (Blättler et al., 1997; Kaeser et al., 2001). Therefore, transfer of prion infectivity 
from the spleen to the CNS, a process termed neuroinvasion, is crucially dependent on the 
expression of PrPC in a tissue compartment that cannot be reconstituted by BM transfer 
(Blättler et al., 1997; Kaeser et al., 2001). Thus, the requirement for PrPC in peripheral 
tissues represents a bottleneck for the spread of prions from peripheral sites to the CNS and 
- most likely - vice versa. Therefore, expression of PrPC is absolutely required for 
transportation of the infectious agent both from the peripheral sites to the CNS (Blättler et al., 
1997) and within the CNS (Brandner et al., 1996a).  
These data suggest that PrP+ hematopoietic cells transport prions from the entry site to the 
LRS, where prions are accumulated and replicated. Cells of the immune system including B 
lymphocytes (not necessarily expressing PrPC), are crucial for supporting peripheral prion 
replication (Klein et al., 1997; Klein et al., 1998; Montrasio et al., 2001). Indeed, the main 
compartment for neuroinvasion is a sessile cell of stromal origin, stably localized in germinal 
centers of the LRS, termed follicular dendritic cell (FDC). FDCs are involved in enabling the 
prion propagation towards the CNS (Mabbott et al., 2000; Montrasio et al., 2000). Conditional 
depletion or de-differentiation of FDCs in wild-type mice leads to a rescue upon peripheral 
(e.g. i.p.; oral) prion inoculation (Mabbott et al., 2003). Interestingly, inflammation in non-
lymphoid organs induced prion replication in organs that were previously believed to be 
prion-free (Heikenwalder et al., 2005; Ligios et al., 2005), but did not alter the incubation time 
of experimentally inoculated mice. Alternative pathways are, however, possible and may vary 
depending on the prion strain in question (McBride et al., 2001; Aguzzi, 2003; Bartz et al., 
2005).  
 
1.4 Neuroinvasion and peripheral prion propagation 
1.4.1 The possible mechanisms of prion encounter: A deadly rendez-
vous? 
In order to understand the mechanism by which prions take advantage of neuronal tracks to 
propagate from the periphery towards the CNS it is essential to gain insights into how and 
where prions encounter neurons. Conceivable scenarios might be uptake of (i) cell 
associated, (ii) vesicle bound or (iii) “free-floating” prion infectivity (Figure 1.3A).  
(i) Convincing evidence for contact mediated transmission of prion infectivity was presented 
in a study by Flechsig and co-workers, where the inherent capacity of prions to strongly 
adhere to steel wires was used to study contact-mediated prion infection (Kanu, Flechsig et 
al., 2001). Neuroblastoma cells adhering to such prion-coated steel wires become infected in 
tissue culture. Additionally, subsequent use of the identical steel wire efficiently mediates 
prion transmission to several indicator mice, overexpressing PrPC, in a short contact period 
of half an hour. Remarkably, this occurs without any reduction in prion infectivity. These data 
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strongly suggest that a contact mediated transmission rather than an exchange of the 
infectious agent is very likely to take place. In line with these findings, cell mediated infection 
was shown in a tissue culture model (Kanu et al., 2002). This study took advantage of 
genetically marked target cells together with scrapie mouse brain (SMB) cells chronically 
propagating PrPSc (Clarke and Millson, 1976). Several lines of evidence in this publication, in 
particular efficient transmission following aldehyde-fixation of the SMB cells, suggest that 
direct contact is responsible for the cell-to-cell transmission (Kanu et al., 2002) (Figure 1.3A).  
(ii) As a second possibility, neuronal prion transfer may be mediated by vesicle-associated 
infectivity. Exosome-bound prion infectivity has in fact been reported in two cell lines, Rov, a 
rabbit epithelial cell line and Mov, a neuroglial cell line, both expressing ovine PrP (Fevrier et 
al., 2004). This report of exosomes containing prions in vitro is in agreement with a recent 
report which suggests that retroviral infection strongly enhances prion infectivity release in 
cell culture (Leblanc et al., 2006) (Figure 1.3A). For example prion infectivity within 
exosomes, which in turn may be released by prion infected FDCs, may encounter peripheral 
nerves and contribute to neuroinvasion (Prinz et al., 2003b; Aguzzi and Heikenwalder, 2005).  
(iii) The third potential source of prion infectivity may be cell-free, free-floating oligomeric or 
protofibrillar infectious particles. Several cell lines can be infected with brain homogenates or 
brain fractions treated in a way that renders the existence of intact cells or exosomes highly 
unlikely. However, this most likely does not exclude the possibility of prion infectivity 
encapsulated in micellae. One recent study that favours the latter hypothesis investigated the 
relationship between infectivity, converting activity and the size of various PrPSc-containing 
aggregates. PrPSc was partially disaggregated, fractionated by size and analyzed by light 
scattering and non-denaturing gel electrophoresis (Silveira et al., 2005). Infectivity and 
converting activity peaked markedly with 17-27nm-sized (300-600 kDa) particles, whereas 
these activities were substantially lower in large fibrils and virtually absent in oligomers 
containing ≤ 5 PrP molecules. Therefore, non-fibrillar particles, with masses equivalent to 14 
to 28 PrP molecules, are the most efficient initiators of prion disease (Figure 1.3A). All of 
these mechanisms shown in vitro can be considered to play a possible role in vivo. However, 
up to date there is no convincing evidence that confirms an exclusive role of any of the three 
possibilities to play an essential role in prion uptake accomplished by peripheral nerves in 
vivo. Therefore, it is still plausible that more than one of the described pathways contributes 
to efficient prion uptake by peripheral nerves at the same time.  
Whether or not PrPC and PrPSc meet on the surface of the cell and whether this is likely to 
take place in lipid rafts is still being discussed (Morris et al., 2006). The lack of knowledge 
about the precise nature of the infectious agent eliminates the possibility to stain or mark 
prions and follow their journey through the body and into cells. To circumvent this obstacle 
Caughey and colleagues fractionated brain homogenate to obtain scrapie associated fibrils 
(SAFs) which are by now the purest source of infectivity available. These SAFs were 
fluorescently labelled and in vitro uptake experiments were performed (Magalhaes et al., 
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2005). Without any doubt these experiments allow first insights into the uptake mechanism of 
fibrils, but work from the same laboratory indicates that oligomers rather than fibrils are the 
most infectious entity (Silveira et al., 2005). Whether the infectious agent, which is possibly 
only a small part of the fluorescently labelled fraction, shares the same uptake mechanisms 
with the fibrils, remains to be established.  
 
1.4.2 Strains and prion transport 
The existence of multiple prion strains is likely to make neuronal transport even more 
complex (Aguzzi, 2004; King and Diaz-Avalos, 2004; Tanaka et al., 2004; Tanaka et al., 
2006). It is conceivable that distinct strains employ different mechanisms for prion uptake 
and transport (Bartz et al., 2005). This may not only affect the mechanisms of prion uptake 
by different neuronal cell populations, cell-to-cell transmissions but may also alter the route 
of neuroinvasion, type of transport, lesion profile or the incubation time of an infected host 
(Aguzzi, 2004). This could influence whether a prion strain is more lymphotrophic or not. 
Regardless of the format of prion infectivity encountering neurons, we still do not know 
whether neurons take up infectivity and transport it as a conventional cargo or, alternatively, 
whether neurons propagate prions on their cell surface. 
 
1.4.3 Mechanisms of prion transport: “Streetcar” versus “domino” 
hypothesis 
The mechanism by which prions travel along peripheral nerves or propagate from one 
neuronal cell to another is not completely understood. Here we discuss two main hypotheses 
for prion spread via neurons (Figure 1.3B). In these models PrPSc, the only known 
component of prions, is used as a marker for prion infectivity.  
(i) Prion propagation could occur on the surface of a neuronal cell exemplified by the 
“domino” hypothesis (Glatzel and Aguzzi, 2001). Because PrPC is a GPI-anchored membrane 
protein, a “domino” mechanism is conceivable by which incoming PrPSc converts resident 
PrPC on the axolemmal surface, thereby spatially propagating the infection (Figure 1.3B). (ii) 
Secondly, prion transport could occur within the axons of peripheral nerves as known from 
normal cargo proteins. This is depicted by the “streetcar” hypothesis (Aguzzi et al., 2003) 
(Figure 1.3B). In the “streetcar” hypothesis, PrPSc is taken up at nerve endings and then 
transported retrogradely, presumably by a microtubule based mechanism, to the CNS.  
Alternatively, propagation of prion infectivity by exosomes floating along neuronal tracks is 
feasible. Additional non-neuronal cells, such as Schwann cells, may play a role. Despite 
evidence that neurons are the key players in prion propagation towards the CNS, low-
efficiency alternatives such as transport via blood can not be completely excluded. Prion 
infectivity could directly invade the brain via the blood brain barrier (BBB) (Banks et al., 
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2004). The cellular and molecular preconditions for such a process remain elusive. However, 
invasion of prion infectivity through the BBB could depend on the prion strain and the dose of 
administered prions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Models of prions encountering neurons and prion propation along neuronal processes. PrPSc, 
the only known component of prions, is used as a marker for infectivity. (A) (i) Cell associated, (ii) vesicle bound 
or (iii) “free-floating” prion infectivity approaching a synaptic ending of a neuron. In grey an up to date unidentified 
cell could be responsible for the transmission of prions to neurons. Possible candidates for this cell are 
lymphocytes, dendritic cells, macrophages or stromal cells. Similar processes are also conceivable at the cell 
body of a neuron. (B) (i) “Domino” and (ii) “streetcar” hypothesis of prion transport. (i) Prion propagation on the 
surface of a neuronal cell by a “domino-like” mechanism. PrPSc converts resident GPI-anchored PrPC on the 
axolemmal surface, thereby spatially propagating the infection. (ii) In the “streetcar” hypothesis vesicle bound or 
free-floating PrPSc is taken up at nerve endings and transported retrogradely, presumably by a microtubule based 
mechanism, to the CNS. Similar mechanisms are conceivable for prion propagation from the cell body to the 
endings of dendrites and axons. 
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1.4.4 Experimental models investigating the velocity of neuronal prion 
transport 
Even though technical advances have been achieved in order to measure the velocity of 
protein transport in vivo via axons, measuring the transport of prion infectivity seems to be 
more than an easy task. First of all, due to the lack of prion specific immunoreagents, it is 
currently impossible to directly stain and track prion infectivity. Alternatively, PrPSc can be 
used as a surrogate marker of prion infectivity in order to investigate the dynamics and the 
velocity of prion transport. In a study conducted by Bartz and colleagues (Bartz et al., 2002) 
retrograde transport of transmissible mink encephalopathy was investigated in a hamster 
model. In this study the velocity of the occurrence of PrPSc in the vertebral level of the spinal 
cord after sciatic nerve inoculation was defined as 3.3 mm/day. These data were acquired 
via Western-blot analysis and quantification of PrPSc.  
Using the difference in incubation times upon foot pad (f.p.) and intranerval (i.n.) inoculation 
Künzi and colleagues attempted to estimate the velocity of prion transport in the peripheral 
nervous system (PNS) (Kunzi et al., 2002). The distance between the footpad and the mid 
sciatic nerve, where the i.n. injection was performed, is 2.1 cm on average. The difference in 
incubation times of the i.n. and f.p. injected mice was about 30 days. The speed of transport 
in the PNS was calculated by dividing the distance between the different sites of inoculation 
by the difference in incubation time. The calculated rate of spread of infectivity was 
0.7 mm/day. This velocity is similar to that reported for wild-type mice where the rate of 
spread was calculated to be around 1 to 2 mm per day (Kimberlin, 1983). These values point 
to slow axonal transport (McEwen and Grafstein, 1968) whereas PrPC was reported to be 
transported with fast axonal transport with a velocity of about 1 cm/hour (Borchelt et al., 
1994). The possibility that the transport of PrPSc in the PNS may not occur through axonal 
transport mechanisms was raised recently (Groschup et al., 1999; Hainfellner and Budka, 
1999) and is compatible with data presented by Künzi and colleagues (Kunzi et al., 2002).  
Even though recent data provide an approximate idea of the velocity of PrPSc transported by 
neurons, comparisons to known axonal transport mechanisms should be taken with 
precaution. This is because velocities calculated for these neuronal transport paradigms are 
a result of single cell measurements in contrast to the in vivo measurements of prion 
propagation which most likely also include cell-to-cell transmission at synaptic clefts in the 
case of spread over several neurons, and ancillary cells (such as Schwann cells) when 
measurements within a single bundle of axons (such as the sciatic nerve) were taken. 
Two recent studies tried to elucidate the mechanisms underlying prion transport using mouse 
models with impaired retrograde transport. The first study (Kunzi et al., 2002) investigated 
neuronal prion transport in transgenic mice overexpressing four-repeat human tau protein, 
which leads to a defective fast axonal transport. These mice showed unaltered 
neuroinvasion, suggesting that transport mechanisms distinct from fast axonal transport 
affect prion neuroinvasion along peripheral nerves.  
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In a second study prion propagation was investigated in a mouse mutant for the cytoplasmic 
dynein heavy chain subunit (Legs at odd angles (Loa) mouse) (Hafezparast et al., 2005). 
Cytoplasmic dynein is the major retrograde transport molecular motor, and its function is 
impaired in this model (Hirokawa and Takemura, 2005). The role of cytoplasmic dynein in the 
transmission of prions within neurons was investigated by i.c. and i.p. inoculation of 
heterozygous Loa mice with mouse-adapted scrapie prions (Hafezparast et al., 2005). The 
incubation period to onset of clinical prion disease, however, was similar to that of wild-type 
littermates. 
Do these studies exclude a role for fast axonal transport in prion propagation? Not quite! In 
fact, these studies illuminate the intrinsic problems met when investigating neuronal prion 
transport in vivo. None of these experiments can formally rule out a relevance of retrograde 
transport, because it is not possible to completely inhibit retrograde transport in vivo without 
lethal consequences for the animal. Therefore the remaining retrograde transport activity 
could be sufficient to transport prions towards the brain. Mouse models with a complete 
inhibition of either transport mechanisms are not available due to embryonic or postnatal 
lethality (e.g. Loa-/-mice (Hafezparast et al., 2003)). Therefore, future experiments may need 
to focus on in vitro models using primary cell culture systems that allow conditional and 
pharmacological inhibition of specific transport mechanisms.  
Despite the fact that the clear molecular mechanisms underpinning neuronal prion transport 
are partially unsolved it is clear that neurons play an essential role in the propagation of 
prions towards the brain. The following section describes in vivo experiments to elucidate if 
prions indeed propagate along neuronal tracks and how the distance between lymphoid 
compartments and peripheral nerves influences the onset of prion diseases. 
 
1.4.5 A role of peripheral nerves in neuroinvasion and prion transport  
Studies on the temporal and spatial dynamics of neuroinvasion suggest that the nervous 
system might be responsible for transport from lymphoid organs to the CNS (Clarke and 
Kimberlin, 1984; Cole and Kimberlin, 1985; McBride and Beekes, 1999). The innervation 
pattern of lymphoid organs is primarily sympathetic (Felten et al., 1988), and many studies 
suggest that the autonomic nervous system might be responsible for transport of the prion 
agent from lymphoid organs to the CNS (Clarke and Kimberlin, 1984; Cole and Kimberlin, 
1985; McBride and Beekes, 1999; McBride et al., 2001). The sympathetic nervous system 
also is involved in vCJD and contains PrPSc in various subpopulations of thyrosine 
hydroxylase positive peripheral nerves (e.g. celiac ganglia; stellate ganglia) (Haik et al., 
2003). Sympathectomy delays the onset of scrapie following i.p. inoculation of the infectious 
agent in mouse models (Glatzel et al., 2001). In contrast, sympathetic hyperinnervation 
enhances splenic prion replication and neuroinvasion, suggesting that innervation of 
secondary lymphoid organs is a rate limiting step to neuroinvasion (Glatzel et al., 2001). The 
1 Introduction  16 
 
detection of PrPSc in spleens of sCJD patients (Glatzel et al., 2003) and tonsils of patients 
suffering from vCJD suggests that the interface between cells of the immune system and 
peripheral nerves might also be of relevance in human prion diseases (Ironside, 1998).  
Even though there is no direct physical synapse between FDCs and sympathetic nerve 
endings (Heinen et al., 1995) there is strong evidence that the distance between FDCs and 
splenic nerves affects the velocity of neuroinvasion (Prinz et al., 2003b). FDC positioning 
was manipulated by ablation of the CXCR5 chemokine receptor, which directs lymphocytes 
towards specific micro-compartments (Forster et al., 1996). In this model the distance 
between germinal center associated FDCs and nerve endings was greatly reduced (Forster 
et al., 1996; Prinz et al., 2003b). CXCR5 deficiency did not affect any aspect of prion 
pathogenesis within the CNS. Although following peripheral administration of high doses of 
prion inocula velocity of pathogenesis was similar in CXCR5-/- and wild-type mice, delivery of 
smaller inocula resulted in a dose dependent increase in incubation periods in wild-type 
mice. Measurement of the kinetics of prion infectivity titers in the thoracic spinal cord showed 
that increased velocity of prion entry into the CNS in CXCR5-/- mice is due to repositioning of 
FDCs in juxtaposition with highly innervated, splenic arterioles (Figure 1.4). This was 
validated by prolongation of incubation periods in CXCR5-/- mice depleted for mature FDCs.  
In conclusion, following peripheral exposure - be it by ingestion or by parenteral infection - 
prion pathogenesis is a dynamic process consisting of spatially and temporally distinct 
phases (Figure 1.4): (1) In the first phase, after initial peripheral prion infection, prions 
accumulate in the LRS (e.g. the spleen or the GALT). The mechanisms which underlie this 
transport are not clearly understood. It is very well possible that cells of the immune system 
(e.g. dendritic cells) (Huang et al., 2002) contribute to prion transport to the LRS or directly to 
the CNS (Aucouturier et al., 2001). Additionally, components of the complement system (e.g. 
C3; C4 and C1qa) were demonstrated to strongly support efficient prion transport from the 
periphery to the LRS (Klein et al., 2001). 
After peripheral prion replication in germinal centers located in B-cell follicles of the spleen, 
lymph nodes or Peyer’s patches, prions migrate from the peripheral sites of prion replication 
to the hot spots of peripheral innervation in lymphoid organs (e.g. to thyrosine hydroxylase+ 
nerves located around central arterioles). Whether this underlies an active (e.g. prion 
transport by cells) or passive process (e.g. passive diffusion) is not well understood and 
matter of intensive investigation. It should be pointed out that after oral inoculation several 
prion strains were reported to progress along the fibres of the parasympathetic nervous 
system independent of the LRS (McBride et al., 2001; Bartz et al., 2005). (2) Once prions 
have infected peripheral nerves, they are believed to be transported towards the spinal cord, 
reaching the brain. (3) There, prions cause fatal progressive neurodegeneration, spongiosis, 
and gliosis. Again, the mechanism of prion propagation through the peripheral nervous 
system remains poorly understood. As discussed above, PrPC was shown to be the 
mandatory molecule that enables transport via the peripheral nervous system into the brain. 
1 Introduction  17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Transport of prion infectivity from sites of prion uptake and replication to the brain. After 
accumulation and replication of prions in the spleen (e.g. upon peripheral prion uptake) or in the GALT (e.g. upon 
oral uptake) disease associated PrPSc spreads from the intestine (grey arrows) or the spleen (black arrows) to the 
CNS (McBride et al., 2001). Two distinct neuroanatomical pathways allow transport of prion infectivity from the gut 
to the CNS: One route occurs through the sympathetic nerve fibres to the mid-thoracic spinal cord (grey arrows). 
The other occurs independently of the spinal cord through parasympathetic fibres of the vagus nerve to the 
medulla oblongata of the brain (grey arrows) (McBride and Beekes, 1999; Mabbott and MacPherson, 2006). Prion 
spread from the spleen to the brain is primarily believed to occur via the fibres of sympathetic nerves that line to 
the thoracic spinal cord (e.g. level 7 - 9) (black arrows) (Glatzel et al., 2001; Prinz et al., 2003b). Importantly, to 
invade the CNS from the periphery the prion agent has to accomplish transmigration between nerves that are 
connected via synapses. It is also possible that prions invade the CNS via alternative pathways, for example 
through the BBB as a cargo in blood (e.g. cell dependent or independent). In lymph follicles of CXCR5-/- mice 
FDCs are atypically localized around innervated central aterioles. (1) depicts the stages of prion accumulation and 
replication, number, (2) the process of prion transport and (3) the process of neurodegeneration. Juxtaposition of 
FDCs to hot spots of innervation was shown to shorten the incubation time after peripheral prion exposure. It was 
demonstrated that prion infectivity arises much earlier in the thoracic level 7 - 9 of the spinal cord of CXCR5-/- 
mice when compared to wild-type mice (Prinz et al., 2003b).  
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1.4.6 Prion-mediated pathology within peripheral tissues 
Even though prions are neurotoxic (Clarke and Haig, 1971; Dickinson et al., 1972; Aguzzi 
and Heikenwalder, 2005) no overt pathology is detected in lymphoid organs with high titers of 
prion infectivity. A mild pathological phenotype induced by prions may be masked by a high 
turn over of lymphocytes or myeloid cells. Depending on the tropism, the prion agent could 
possibly induce pathology in various cell types of the periphery. Indeed, prion-mediated 
pathology has been demonstrated at other peripheral sites. Reported abnormalities include 
damage of the retina, the optic nerve (Kercher et al., 2004; Hortells et al., 2006) and non-
neuronal cells (e.g. oligodendrocytes) (Sponne et al., 2004) with microglia recruitment at 
these sites (Marella and Chabry, 2004). Prion mediated myelin-damage was reported in mice 
infected experimentally with the Fujisaki strain of CJD (Liberski et al., 1991), which in turn 
might affect prion transport along neurons.  
A transgenic mouse expressing PrP without a GPI anchor was generated (Chesebro et al., 
2005), leading to a monomeric, soluble secreted form of PrPC. Upon prion infection, GPI-
negative PrP transgenic mice did not develop clinical prion disease after a long period of 
time. However, their brains contained PrPSc plaques. Therefore, prion inoculation of GPI 
negative transgenic mice did not lead to signs of scrapie but lack of the GPI anchor 
preserved the competence to support prion replication (Chesebro et al., 2005). Additionally, 
brain, blood, and heart of GPI negative PrP transgenic mice contained both abnormal 
protease-resistant prion protein as well as prion infectivity (Trifilo et al., 2006).  
 
1.4.7 Prion transport after oral or corneal infection 
Upon oral challenge, early rise in prion infectivity can be detected in the distal ileum of 
infected hosts: this applies to several species but was most extensively investigated in sheep 
(Wells et al., 1994; Vankeulen et al., 1996). Immunohistochemical stains with antibodies to 
the prion protein typically reveal a robust signal in primary B-cell follicles and germinal 
centers in a wide variety of secondary lymphoid organs including appendix and tonsils (Hill et 
al., 1997). Western blot analysis has not left any doubt about the fact that Peyer’s Patches 
(PPs) do accumulate the disease-associated form of the prion protein.  
The latter is true also in the mouse model of scrapie, which is being used as a convenient 
experimental paradigm by many laboratories including ours. Administration of mouse-
adapted scrapie prions induces a surge in intestinal prion infectivity as early as a few days 
after inoculation (Mabbott et al., 2003; Prinz et al., 2003a). All of the above suggests that 
PPs may represent one possible portal of entry for orally administered prions on their journey 
from the luminal aspect of the gastroenteric tube to the central nervous system. 
Nevertheless, the exact cellular basis for prion transmigration from the gut into the LRS is 
poorly understood. Membranous epithelial cells (M cells), whose maturation is dependent on 
signals transmitted by intraepithelial B cells, are the major entry sites for enteric pathogens in 
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the gut via transepithelial transport (Neutra et al., 1996). Efficient in vitro systems have been 
developed, in which epithelial cells can differentiate to cells resembling M cells by 
morphological and functional-physiological criteria (Kerneis et al., 1997). This led to the 
presumption that M cells may be a candidate for the mucosal portal of prion infection – a fact 
substantiated in co-culture models (Heppner et al., 2001a). These findings also suggest that 
prions might exploit the M-cell−dependent transcytosis to encounter the immune system.  
Whether the same applies for BSE-affected cattle is less clear. In a study of BSE 
pathogenesis in cattle carried out at the UK Veterinary Laboratory Agency a transient surge 
in infectivity in the distal ileum of cows at approximately six months post infection was 
discovered (Bradley, 2000). Infectivity then subsides, but it appears to return to the terminal 
ileum at the end stages of disease, maybe by means of some sort of retrograde transport 
(Wells et al., 1998). Although this was not formally confirmed, it appears likely that PPs are 
the sites of prion accumulation in the gastrointestinal tract of cattle challenged orally with 
prions.  
Upon oral infection in mouse models prions were shown to propagate via the gut associated 
lymphoid system (GALT) and via innumerable neuronal pathways towards the brain, of which 
various routes have been proven experimentally (Beekes and McBride, 2000; McBride et al., 
2001; Mabbott et al., 2003). Several independent findings suggest that prions invade the 
CNS via the splanchnic and vagus nerve after ingestion of infectivity (Aguzzi et al., 2003). 
The involvement of the enteric nervous system (ENS) and the GALT in prion pathogenesis 
was addressed after oral infection (Beekes and McBride, 2000). Immunocytochemistry was 
used for the detection of PrPSc in the duodenum and ileum of hamsters fed with the 263K 
scrapie strain. The experiments revealed early infection of various GALT components and of 
submucosal and myenteric ENS ganglia. Hence the ENS plays an important role in scrapie 
neuroinvasion and in centripetal vagal spread of infection from the gut to the brain after oral 
uptake of agent. Moreover, using the 263K scrapie strain in a hamster model, the infectious 
agent primarily uses synaptically linked autonomic ganglia and efferent fibers of the vagus 
and splanchnic nerves to invade initial target sites in the brain and spinal cord (McBride et 
al., 2001).  
Bartz and colleagues investigated the role of prion infection of LRS tissues in neuroinvasion 
following oral and i.p. inoculation with the HY and DY strains of the transmissible mink 
encephalopathy (TME) agent (Bartz et al., 2005). In contrast to the HY TME agent the DY 
TME agent infectivity was not detected in spleen or lymph nodes following i.p. or oral 
inoculation. Following intratongue inoculation, the DY TME agent caused prion disease and 
was detected in the tongue and brainstem nuclei that innervate the tongue, but PrPSc was not 
detected in the spleen or lymph nodes. These findings indicated that DY TME agent can 
spread from the tongue to the brain along cranial nerves and does not appear to require 
agent replication in the LRS. 
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Ocular administration of prions has proven useful to study neural spread of the agent, since 
the retina is a part of the CNS and intraocular injection does not induce direct physical 
trauma to the brain, which may disrupt the BBB and impair other aspects of brain physiology. 
Diachronic spongiform changes along the retinal pathway following intraocular infection 
suggests nerval spread of prions (Fraser, 1982). In line with these findings are reports of 
iatrogenic transmissions in humans via cornea transplants, implying that prions propagate 
retrogradely towards the cornea and anterogradely from the cornea to the brain (Duffy et al., 
1974). 
To investigate whether spread of prions within the CNS is dependent on PrPC expression in 
the visual pathway, PrP-producing neural grafts were used as sensitive indicators of the 
presence of prion infectivity in the brain of Prnp-/- hosts. Following inoculation with prions into 
the eye of grafted Prnp-/- mice, none of the grafts showed signs of scrapie. Therefore, it was 
concluded that infectivity administered to the eye of PrP-deficient hosts cannot induce 
scrapie in a PrP-expressing brain graft (Brandner et al., 1996a). 
 
1.5 Outline of the work presented in this thesis 
In recent years a wealth of data has been acquired in the understanding of how prion 
infectivity or PrPSc is transported with the help of the PNS from the periphery into the brain. 
Mouse, rat and hamster models still prove extremely useful to elucidate the different routes 
of prion propagation dependent on the type of prion administration (e.g. oral; i.v.; i.p.; corneal 
etc.), the type of host, the dose of prion inoculum and the prion strain.  
Therefore, we first tried to study neuronal prion propagation in a mouse model of impaired 
retrograde transport (LaMonte et al., 2002). In line with results of Künzi et al. (Kunzi et al., 
2002) and Hafezparast et al. (Hafezparast et al., 2005) we failed to show an impact of the 
retrograde transport machinery in prion propagation. This shows that investigation of the 
precise molecular transport mechanisms within neurons is much more difficult than might 
have been previously thought. It seems to be difficult, if not impossible, to test the 
significance of retrograde neuronal transport in prion pathogenesis in vivo since a complete 
block of this transport system is incompatible with long-term survival. Conversely, those 
mouse models with partially impaired transport mechanisms that have been tested did not 
display altered pathogenesis - yet such negative results by no means disprove a role for 
axonal transport.  
One possible tool to overcome the problems of in vivo studies may be the usage of cell 
culture models. Therefore, we established prion inoculation of peripheral neurons in a 
compartmented culture system that allows the study of prion transport. Employing this 
system we approached basic, by now unsolved questions in peripheral prion propagation: (i) 
do neurons spread prions, (ii) does this spread rely on accessory cells, and (iii) does this 
spread occur anterograde and / or retrograde? 
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In the second, third, and fourth part of this thesis we tried to identify prion modifiers. While 
the second part represents a candidate approach with the starting assumption that the NF-
κB signalling pathway could be involved in prion pathogenesis in mouse models, the third 
and fourth part describe screens for genes, that are differentially regulated upon prion 
infection or modify PrPSc levels in cell culture models of prion infection.  
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2.1 Introduction 
2.1.1 Outline of this work  
Studies of prion pathogenesis suggest that the peripheral nervous system is a likely route for 
prion entry into the brain, but detailed knowledge on intranerval prion propagation remains 
elusive. Although former attempts to demonstrate an influence of the axonal transport 
machinery in peripheral prion spread using transgenic mice impaired in retrograde transport 
failed (Hafezparast et al., 2005) (Kunzi et al., 2002), we intended to investigate peripheral 
prion propagation in a further mouse model of impaired axonal transport (LaMonte et al., 
2002). In line with the findings of Hafezparast and Künzi et al, we could not find evidence for 
an involvement of axonal transport in prion propagation in our mouse model used. 
Nonetheless, a role of retrograde transport in prion spread can not be excluded based on 
these data, since (i) the impairment of retrograde transport in the animal model used was 
maybe not impaired enough to see an effect or (ii) alternative mechanisms of prion 
propagation could mask an effect.  
To overcome these obstacles we opted to focus our efforts on an in vitro system of prion 
spread in peripheral neurons. To investigate whether peripheral neurons may transport prion 
infectivity, we first investigated internalization of fluorescently labelled scrapie associated 
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fibrils (SAFs) by primary cultures derived from superior cervical ganglia (SCGs). Next we 
employed a compartmented culture system which allows the investigation of prion 
propagation by physically separating the liquid environment of cell bodies and neurite 
endings of SCGs. Utilizing this system we demonstrate anterograde as well as retrograde 
intraneuronal propagation of prion infectivity in peripheral neurons without the involvement of 
accessory cells.  
 
2.1.2 A role for peripheral nerves in prion propagation 
In contrast to other neurodegenerative diseases such as Alzheimer’s or Parkinson’s disease, 
TSEs are infectious and can be transmitted by peripheral infection of the host. For many 
prion diseases, including sheep scrapie, CWD, BSE, Kuru and vCJD, the prion entry route is 
likely by ingestion (Beekes and McBride, 2007) (Heikenwalder et al., 2007). Several lines of 
evidence suggest that the peripheral nervous system links the periphery and the CNS: (i) 
Both in natural and experimental infections neural spread of infection is observed from the 
periphery via the autonomic nervous system to the spinal cord and subsequently to the brain 
(Clarke and Kimberlin, 1984; Cole and Kimberlin, 1985; McBride and Beekes, 1999; Glatzel 
et al., 2001; McBride et al., 2001; Kunzi et al., 2002; Bartz et al., 2005; Beekes and McBride, 
2007). PrPSc can also be found in the sympathetic nervous system of vCJD patients (Haik et 
al., 2003). (ii) Prion propagation follows defined neuroanatomical projections (Fraser, 1982) 
(Duffy et al., 1974). (iii) Sympathectomy delays the onset of scrapie following intraperitoneal 
inoculation of mice, whereas sympathetic hyperinnervation enhances splenic prion 
replication and neuroinvasion, suggesting that innervation of secondary lymphoid organs is a 
rate limiting step to neuroinvasion (Glatzel et al., 2001). (iv) PrPC is a prerequisite for prion 
replication (Büeler et al., 1993). Furthermore, in vivo experiments show a requirement for a 
PrP-expressing tissue for transfer of scrapie infectivity from spleen to brain, which turns out 
to be the peripheral nervous system (Blättler et al., 1997; Kaeser et al., 2001). Hence, in vivo 
data suggest a crucial role for peripheral nerves in prion propagation towards the brain.  
However, the details of intranerval prion propagation remain poorly understood and several 
different mechanisms are possible: (i) The “street car” hypothesis claims axonal transport to 
be involved in intraneuronal prion propagation, whereas (ii) the “domino” hypothesis 
suggests a serial neighbour-to-neighbour conversion of PrPC into PrPSc on the surface of 
neurons. Furthermore, (iii) passive translocation in exosomes floating along neuronal tracks, 
(iv) sequential infection of Schwann cells or (v) cell-free or cell associated spread in neural 
interspaces or blood is conceivable (Heikenwalder et al., 2007). 
To gain insights into the involvement of the axonal transport machinery in prion propagation 
we first opted to study prion disease in a transgenic mouse model (C57BL/6 Thy1.2p50flag) 
with impaired axonal transport (LaMonte et al., 2002). Here, neuron specific overproduction 
of dynamitin, a component of dynactin, renders dynactin nonfunctional. Since dynactin plays 
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an essential role in the dynein dependent microtubule based transport, these mice show 
impaired retrograde axonal transport. If prions are transported axonally through the 
retrograde transport machinery, we expect the dynamitin mice to show a lower velocity of 
prion propagation and a delay in the development of prion disease after peripheral challenge 
with prions. 
 
2.2 Prion spread is not affected in an in vivo model of impaired 
retrograde transport 
2.2.1 Impairment of retrograde transport in neurons does not affect prion 
disease duration 
To study the role of axonal transport on prion propagation in peripheral nerves, we inoculated 
C57BL/6 Thy1.2p50flag (henceforth named for simplification dynamitin) and negative 
littermates as controls intraneurally (i.n., sciatic nerve), intraperitoneally (i.p.) and 
intracerebrally (i.c.) with RML prions. The velocity of prion propagation in the sciatic nerve, 
the spinal cord and in the brain was measured by the onset of disease in the dynamitin mice 
and compared to control mice (Figure 2.1).  
We did not observe any significant differences in the onset of clinical signs and disease 
duration between dynamitin or control animals inoculated either i.n., i.p. or i.c. with RML 
prions (Figure 2.1). The mean survival of dynamitin mice after i.n. prion inoculation was 153 
days, whereas the mean survival of the negative littermates was 168 days. Similar results 
were found for mice inoculated i.c. with a low dose of prion inoculum with 164 days for 
dynamitin mice and 165 days for negative littermates. In line with these results low dose i.p. 
prion inoculation studies of dynamitin and control animals resulted in mean incubation 
periods of 230 days for dynamitin mice and 217 days for negative littermates. Therefore, 
impairment of the axonal transport machinery did not impair prion disease period after 
peripheral or i.c. inoculation in the mouse model investigated.  
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Figure 2.1: Impairment of the retrograde transport machinery in neurons does not affect prion disease 
duration. Kaplan-Meier survival plots of prion-infected dynamitin and control animals. Mice were screened for 
signs of scrapie after i.n., i.c., or i.p. inoculation with RML prions.  
 
2.2.2 Impairment of retrograde transport in neurons does not affect prion 
pathology or PrPSc deposition 
To verify these findings on histopathological level we investigated brain sections of terminal 
mice inoculated i.n., i.c. or i.p. with prions for spongiform changes (haematoxylin-eosin; H&E) 
and deposition of disease-specific PrP (SAF84; Figure 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Histology of prion-infected dynamitin and control animals. Dynamitin as well as control animals 
show prion derived spongiosis in the haematoxylin-eosin (H&E) stain and PrP deposits (SAF84).  
 
No differences between the dynamitin mice and respective littermates were detectable. In 
addition we did not observe differences in the abundance of PrPSc in homogenates of spinal 
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cord, brain or spleen of terminally sick dynamitin and control animals as determined by 
Western blot analysis (Figure 2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: PrPSc in tissue homogenates of dynamitin and control animals. Western blot of tissue 
homogenates with (PK+) or without (PK-) proteinase K digestion of dynamitin and control mice that had 
developed terminal scrapie after intranerval inoculation with scrapie prions. A) brain, B) spleen, C) spinal cord 
(thoracic), and D) spinal cord (cranial). 
 
In summary, we did not observe any impact of the impairment of axonal transport in prion 
disease in vivo in the mouse model investigated here. 
 
2.3 Interim discussion of the results in vivo 
Here we investigated the impact of the axonal transport machinery on prion propagation by 
prion inoculation studies of transgenic mice impaired in retrograde axonal transport. We were 
not able to observe obvious differences between dynamitin and control animals, neither in 
disease period nor on histological or biochemical level. Therefore we have no evidence for 
the involvement of dynein dependent transport in this model of impaired axonal transport in 
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neurons. Since, (i) the impairment of retrograde transport was maybe not impaired enough to 
see an effect or (ii) alternative mechanisms of prion propagation could mask an effect, this 
does not allow the conclusion that retrograde transport is not involved in prion propagation 
along neuronal tracks. Obviously, it is not possible to completely inhibit axonal transport in a 
living animal due to lethal consequences of such an inhibition. This, in combination with the 
publications of Hafezparast (Hafezparast et al., 2005) and Künzi (Kunzi et al., 2002), who 
both failed to show an involvement of retrograde transport in prion propagation lead us to the 
conclusion that the very complex mouse model is not the appropriate model to approach this 
question. We therefore tried to circumvent these obstacles by establishing an in vitro model 
of prion propagation which is described in the following.  
 
2.4 Prion spread occurs retrograde and anterograde in peripheral 
neurons in vitro 
2.4.1 The need for an in vitro model of prion spread in neurons 
In vivo tracing experiments of the prion agent are hampered by the lack of knowledge about 
the precise nature of the infectious agent and absence of PrPSc-specific antibodies. Since it is 
not possibility to stain or mark prions and follow their uptake and intracellular transport, we 
approach the question of prion propagation in peripheral neurons in vitro, using 
compartmented cultures (Campenot, 1979). We ask (1) do peripheral neurons internalize 
scrapie associated fibrils (SAFs), (2) can peripheral neurons propagate prions without the 
help of accessory cells like Schwann cells and (3) is prion propagation retrograde or 
anterograde in peripheral neurons? 
 
2.4.2  Characterization of PrPC in primary neuronal cells isolated from 
superior cervical ganglia 
A prerequisite for PrPSc propagation is proper biosynthesis and localization of PrPC in the cell 
model to be infected (Büeler et al., 1993). We opted to study prion propagation in 
compartmented cultures. The compartmented cell culture system allows the physical 
separation of cell bodies and neurite endings of neurons (Campenot, 1979). Primary neurons 
are plated in the center compartment of a Teflon divider and neurites, guided by scratches in 
the surface of the culture dish, grow through a silicone grease barrier in the side 
compartments. The grease barrier, in combination with the Teflon divider, allows the 
investigation of axonal transport by maintaining different culture conditions in the 
compartments (Campenot, 1979). Therefore, first we investigated surface localization of PrPC 
in cultures of primary neurons derived from superior cervical ganglia (SCGs) by 
immunocytochemistry (Figure 2.4A-H). Whereas PrPC is detected on the surface of SCG 
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cells isolated from wild type mice (Prnp+/+), no signal is detected in cells derived from Prnp-/- 
animals. 
We next checked the integrity of the compartmented culture system by labelling neuronal 
processes in the side compartments with the fluorescent dye FM 1-43 over night. FM1-43 is 
a water-soluble dye of 612 Da that is non-toxic to cells and virtually non-fluorescent in 
aqueous medium, while efficiently fluorescent after excitation when associated with the 
plasma membrane. In active neurons, the dye is internalized and transported retrograde to 
the cell body in cycling vesicles. Labelling of distal axons represents surface and internalized 
FM 1-43, whereas labelling of the cell bodies represents internalized and retrogradely 
transported FM 1-43. The absence of staining in cell bodies without axons in the side 
chamber proves the absence of diffusion of fluorescent FM 1-43 between compartments. 
Subsequently, we characterized the biochemical properties of PrPC in axons and cell bodies 
of SCG cells in compartmented cultures (Figure 2.4I-L). Therefore, we harvested cell bodies 
and axons from centre and side chambers of one week old cultures. Gel electrophoresis and 
subsequent immunoblotting with PrP antibodies shows PrPC in homogenates of cell bodies 
as well as axons harvested from the centre or side compartment of compartmented cultures 
of Prnp+/+, but not Prnp-/- cells. The ratio of di-, mono- and unglycosylated PrPC differs 
between cell bodies and axons, with the axons containing less di- and monoglycosylated 
PrPC than cell bodies or N2a cells. We can conclude that PrPC is properly glycosylated in cell 
bodies and axons of primary neurons in compartmented cultures.  
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Figure 2.4: Characterization 
of PrPC in primary neuronal 
cells isolated from superior 
cervical ganglia. A-H) PrPC is 
detected on the plasma 
membrane of SCG cells 
isolated from wild type (Prnp+/+, 
A, B, E, F), but not Prnp-/- mice 
(C, D, G, H) by 
immunocytochemistry and 
confocal microscopy. Panels a-
h show SCGs that have been 
cultured for one week by 
differential interference contrast 
microscopy (A-D) and after 
staining with the PrP antibody 
POM1 detected by a Cy3-
coupled secondary IgG1-
antibody (red; panels E-H). 
Nuclei are stained with DAPI 
(blue). I-K) Primary neurons 
after one week in a 
compartmented culture. The 
horizontal lines represent 
scratches in the collagen 
substratum to form tracks upon 
which axons grow to the left 
and right. Neuronal processes 
in the side compartments were 
labelled over night with FM 1-
43 (Molecular Probes). 
Labelling of distal axons 
represents surface and 
internalized FM 1-43, whereas 
labelling of the cell bodies 
represents internalized and 
retrogradely transported FM 1-
43. The absence of staining in 
cell bodies without axons in the 
side chamber indicates no 
diffusion of fluorescent FM 1-
43. L) Di-, mono- and 
unglycosylated PrPC is 
detected in cell bodies (Cb) 
and axons (A) of SCG cells by 
immunoblot for PrPC in cell 
homogenates derived from 
Prnp+/+, but not Prnp-/- cells. In 
lane 1 50.000 N2a cells were 
loaded as a positive control for 
PrP, whereas in lanes 2 - 5 
lysate from 4 compartmented 
cultures and in lanes 6-9 lysate 
from 2 compartmented cultures 
was pooled. 
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2.4.3 Primary neurons derived from SCGs internalize scrapie associated 
fibrils (SAFs) 
The lack of knowledge about the precise nature of the infectious agent and absence of PrPSc-
specific antibodies eliminates the possibility to stain or mark prions and follow their uptake 
and intracellular transport. Recently, Magalhaes et al., tried to circumvent this obstacle by 
utilizing fluorescently labelled scrapie associated fibrils (SAFs; (Magalhaes et al., 2005)). 
SAFs are enriched from fractionated brain homogenate of scrapie sick mice and probably 
represent by now the purest source of infectivity available. In vitro experiments with the 
neuronal cell line SN56 and primary neuronal cells derived from hamster brain suggest SAF 
internalization by a pinocytic mechanism (Magalhaes et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Uptake of scrapie associated fibrils (SAFs) by primary neurons derived from SCGs. 
Deconvolution of fluorescence microscopy images of cells derived from SCGs in steps of 0.1 µm. SCGs are 
incubated with SAFs (pink; A-C, E) or not (D) and anti-Thy 1.2 antibody (green) at 10°C to allow binding of the 
compounds to the cells, but inhibit endocytosis. After a temperature shift to 37°C uptake of SAFs was investigated 
after 3, 5 and 10 minutes. Nuclei are stained with DAPI (blue). 
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We investigated SAF uptake by primary cells derived from mouse SCGs to determine 
whether peripheral neurons used for compartmented cultures also internalize SAFs (Figure 
2.5). Here, primary cells derived from SCGs were incubated with fluorescently labelled SAFs 
as well as fluorescently labelled Thy1.2 antibody at 10°C to allow binding of the compounds 
to the cells but inhibit internalization. After removal of unbound compounds by washing, a 
temperature shift to 37°C was performed to allow internalization of SAFs. Three minutes after 
the temperature shift red SAFs are bound to the cell membrane, which is marked in green 
with Thy 1.2 (Figure 2.5A). After 5 and 10 minutes SAFs are internalized (Figure 2.5B, C), 
whereas Thy 1.2 remains surface bound. No red SAF signal is detectable in control cells 
treated with Thy 1.2 only (Figure 2.5D). SAFs can also be observed adjacent to axons, but 
the resolution limit of the microscope does not allow to judge whether these fibrils are on the 
surface or inside the axons (Figure 2.5E). Thus, these uptake studies show, that primary 
cells derived from SGCs take up SAFs very fast, suggesting these cells also to be able to 
take up prions (Magalhaes et al., 2005).  
 
2.4.4 PrPSc in cell bodies of primary neurons whose neurites have been 
inoculated with prions 
To determine whether neurons propagate prions retrogradely, we inoculated neuronal 
processes in the side chambers of one week old compartmented cultures with either RML 
prions or mock brain homogenate of healthy control animals (Figure 2.6A-C). After four 
weeks the integrity of the chambers and cells was evaluated by administration of the 
fluorescent dye FM 1-43 to the side compartments over night (Figure 2.6A-I) (Campenot and 
MacInnis, 2004). Cell bodies with axonal connections to the side chambers showed green 
fluorescence, indicating retrogradely transported FM 1-43, whereas cell bodies without 
neurite endings in the side chambers were unstained.  
Subsequently, the cell bodies in the centre compartment of seven chambers were harvested 
and pooled. To differentiate PrPSc from PrPC, the cell lysate was subjected to proteinase K 
(PK) digestion of various concentrations with subsequent gel electrophoresis and 
immunoblotting for PrP (Figure 2.6K). Concentrations of 5 or 10 µg/ml of PK were not 
sufficient to fully digest PrPC in the samples derived from the mock treated cultures (Figure 
2.6K, lanes 4 and 5), whereas 20 µg/ml of PK allowed discrimination of PrPSc from PrPC 
(Figure 2.6K, lanes 3 and 6). PrPSc represents the first hint for prion propagation along 
neuronal processes towards the cell bodies (Figure 2.6K, lane 6). 
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Figure 2.6: PrPSc in cell bodies of 
primary neurons after retrograde 
infection with prions. A-I) Side (A, C, 
D; F, G, I) and centre (B, E; H) 
compartments of SCG cultures, where 
neuronal endings were either left 
untreated (A, C), axotomized with 
regrowth blocked by NGF antibody 
supply and NGF withdrawal in side 
compartments (D; F), or axotomized 
and allowed to regrow (G, I). The side 
compartments have been inoculated 
with either prions (RML) or brain 
homogenate of a healthy mouse 
(Mock). Four weeks after inoculation the 
integrity of the chambers and cells was 
evaluated by administration of FM 1-43 
to the side compartments over night. 
Subsequently, the cell bodies of four (K) 
or seven (L) chambers were harvested, 
pooled and processed for detection of 
PrPSc by proteinase K (PK) digestion 
and Western blotting. K) Immunoblot of 
cell body lysates treated with different 
concentrations of PK. (M: Mock brain 
treated; R: RML brain treated) L) PrPSc 
is detected in cell bodies where axons 
have been inoculated with prions, 
whereas PrPSc is absent in cell bodies 
of axotomized controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Prion spread in peripheral neurons   33 
 
As a further control we axotomized the cells in the compartmented cultures. This is achieved 
by cutting the axons in the side chambers with a jet of cold water. Regrowth of axons is 
inhibited by withdrawal of nerve growth factor (NGF) and addition of NGF antibody to block 
remaining NGF (Figure 2.6D-F). This procedure does not harm the primary cells in the centre 
compartment, since addition of NGF and RML to the side chamber that has been axotomized 
leads to regrowth of axonal processes (Figure 2.6G-I). This shows, that axotomization and 
co-culture of neuronal processes with RML does not impair regeneration of the axons. PrPSc 
was detected only in cell bodies with axonal connections to the side chambers, whereas 
PrPSc is absent from cell bodies that have been axotomized, as determined by PK digestion 
and subsequent immunoblotting (Figure 2.6L, lanes 7 and 10). 
These experiments show that PrPSc is delivered to cell bodies of peripheral neurons whose 
neuronal endings have been selectively exposed to prion infectivity, suggesting retrograde 
spread of the prion agent. 
 
2.4.5 Retrograde prion spread in peripheral neurons 
Since the amount of PrPSc may not directly correlate with the level of infectivity (Lasmezas et 
al., 1997), we performed mouse bioassays utilizing tga20 mice, which overexpress murine 
Prnp (Fischer et al., 1996). We inoculated neurites in the side chambers of compartmented 
cultures with prions (Figure 2.7A). After four weeks the cell bodies of seven chambers were 
pooled and inoculated intracerebrally (i.c.) into four indicator mice. This was repeated two 
times. 9 of 12 mice displayed signs of prion disease (Figure 2.7B) as well as PrP aggregates 
by immunohistochemistry and PrPSc by immunoblotting. Since it is discussed that prion 
infectivity is shed into the medium by infected cells in vitro we also tested medium from the 
centre compartment for prion infectivity (Schätzl et al., 1997; Fevrier et al., 2004). Two of four 
mice developed terminal prion disease, suggesting that primary neurons also release 
infectivity to the medium. Culture medium from the side chambers with residual RML6 
inoculum was used as an input control. Here, four out of four mice succumbed to prion 
disease. Axotomized cultures served as a control for the compartmented culture system 
integrity. None of the mice inoculated with cell bodies derived from axotomized cultures 
whose side chambers have been inoculated with RML6 for four weeks showed either signs 
of prion disease or PrPSc on histological and biochemical level. In addition, no prion infectivity 
was detected by mouse bioassay in cell culture medium derived from the centre 
compartment of axotomized control chambers (Figure 2.7). Hence, axonal endings exposed 
to RML6 propagate prion infectivity to cell bodies of peripheral neurons in vitro. Furthermore, 
the absence of prion infectivity in cell bodies and culture medium derived from centre 
compartments of axotomized cultures indicates that axons are needed for retrograde prion 
transport towards the cell bodies and excludes the existence of non-axonal diffusion of the 
prion agent between side and centre compartments. 
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Figure 2.7: Retrograde and 
anterograde spread of prion infectivity 
in primary neurons. A) Schematic of the 
in vitro infection procedure. Side 
chambers of three-compartmented 
cultures were inoculated with prions for 
four weeks. Axotomized chambers 
served as control. B) Kaplan-Meier-
survival-plot of tga20 indicator mice 
inoculated with lysate of cell bodies or 
medium of compartmented cultures of 
Prnp+/+ SCG cells. Side medium 
containing RML inoculum served as an 
input control (black triangles). A fraction 
of the mice inoculated with lysate of cell 
bodies connected by axons to the side 
chambers (red diamonds) or with centre 
medium (red squares) developed scrapie, 
whereas mice inoculated with cell bodies 
(green diamonds) or centre medium 
(green squares) derived from axotomized 
control cultures did not show signs of 
prion disease. C) Kaplan-Meier-survival-
plot of tga20 indicator mice inoculated 
with lysate of cell bodies or medium of 
compartmented cultures of Prnp-/- SCG 
cells. Side medium containing RML 
inoculum served as an input control 
(black triangles). None of the mice 
inoculated with lysate of cell bodies 
connected by axons to the side chambers 
(pink diamonds) or with centre medium 
(pink squares) displayed signs of prion 
disease. D) Schematic of the in vitro 
infection procedure. Centre 
compartments of three-compartmented 
cultures were inoculated with prions for 
four weeks. Axotomized chambers 
served as control. E) Kaplan-Meier-
survival-plot of tga20 indicator mice 
inoculated with lysate of neurites or 
medium of compartmented cultures of 
Prnp+/+ SCG cells. Centre medium 
containing RML inoculum served as an 
input control (black triangles). A fraction 
of the mice inoculated with lysate of 
neurites connected to the centre 
compartment (red diamonds) or with side 
medium (red squares) developed scrapie, 
whereas mice inoculated with control 
material (side compartment, green 
diamonds; side medium, green squares) 
derived from axotomized control cultures 
did not show signs of prion disease. 
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It has been shown that PrPC does not mediate internalization of PrPSc (Magalhaes et al., 
2005) (Paquet et al., 2007). We therefore investigated the PrPC dependence of neuronal 
prion propagation. We exposed axonal endings of SCG neurons derived from Prnp-/- mice to 
prions and tested for prion infectivity in cell bodies by mouse bioassay. Although replication 
of prions is absent due to the lacking PrPC, it is conceivable that prions are transported PrPC-
independent towards the cell bodies in Prnp-/- cells. Since it is possible that Prnp-/- neurons 
degrade transported prions we harvested and tested the cell bodies not only after four 
weeks, but also already after one week of inoculation with RML6. Given that this experiment 
was performed in parallel to the prion propagation studies using Prnp+/+ cells, the same side 
medium with residual inoculum served as an input control. None of the indicator mice 
inoculated with Prnp-/- cell bodies whose axons have been exposed to prions for one or four 
weeks succumbed to prion disease. Since the sensitivity of the mouse bioassay may be not 
high enough to measure minute amounts of prion infectivity that have been transported in a 
PrPC-independent manner we can not fully exclude this possibility. But, in addition to the 
absence of prion infectivity in the axotomized Prnp+/+ control chambers this shows integrity of 
the system, meaning no passive diffusion of prion inoculum from the side to the centre 
compartment. 
 
2.4.6 Anterograde prion spread in peripheral neurons 
Prion infectivity in non-neural organs and muscles of patients suffering from CJD suggests 
anterograde prion propagation from the brain towards the periphery (Heikenwalder et al., 
2007). Therefore, we next tested whether prions could be transported anterograde in primary 
neurons in the compartmented culture system. We exposed cell bodies in the centre 
compartment with RML prions (Figure 2.7D). Four weeks later, neurites in the side 
compartment of seven chambers were harvested, pooled and inoculated into three tga20 
indicator mice. The whole experiment was repeated two times. Four out of nine mice 
inoculated with neuronal endings of cell bodies which have been exposed to prion infectivity 
developed prion disease, suggesting anterograde prion propagation from cell bodies to the 
neuronal endings. We assessed whether prion infectivity was released to the medium by the 
axons by inoculating medium into indicator mice. Here, one out of seven mice succumbed to 
prion disease, showing minute amounts of infectivity was released to the medium by the 
axons. Axotomized chambers served as a negative control. Using mouse bioassay, no prion 
infectivity could be detected in material from the side compartment of axotomized chambers. 
Medium from the centre compartment containing residual inoculum was used as input 
control. Here four out of four mice succumbed to prion disease. 
Although prion infectivity in the neuritis was low, the results unequivocally demonstrate 
anterograde spread had occurred in primary neurons derived from SCGs in the 
compartmented culture system.  
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2.5 Discussion 
Here we show that peripheral neurons incorporate and spread prions both anterograde and 
retrograde. First we demonstrate that primary neurons derived from SCGs express PrP on 
their surface and are able to take up SAFs. While these experiments give first insights into 
the uptake of fibrils by peripheral neurons, recent research indicates that oligomers rather 
than fibrils are the most infectious entity (Silveira et al., 2005). Whether the infectious agent, 
which is possibly only a small part of the fluorescently labelled fraction, shares the same 
internalization mechanisms as the fibrils remains to be established.  
It is becoming clear, that in vivo experiments are only of limited expressiveness in order to 
identify the responsible cell types in nerves or the mechanism of prion transport. Inoculation 
experiments utilizing transgenic mice impaired in axonal transport failed to show an impact of 
the neuronal transport machinery on prion propagation (Kunzi et al., 2002; Hafezparast et al., 
2005). Furthermore, the propagation of scrapie in peripheral nerves after footpad infection 
was unaltered in neurotoxin exposed hamsters compared to control animals (Kratzel et al., 
2007). Whether in vivo experiments failed to show an impact of neuronal transport on prion 
spread due to the impossibility to completely control the complex axonal transport machinery 
in vivo or due to the possibility that neuronal transport is not involved in prion propagation 
remains elusive.  
Therefore, we studied neuronal prion propagation in a compartmented culture system, which 
physically separates the liquid environment of cell bodies and axons. We detected PrPSc in 
cell bodies after retrograde infection with prions and show retrograde as well as anterograde 
spread of the prion agent in primary neurons derived from SCGs in the compartmented 
culture system. The integrity of the compartmentalized cultures must be strictly controlled, 
and the exclusion of diffusion between compartments has to be assured. We checked for 
integrity by adding fluorescent dyes to the medium. In addition, we included axotomized 
control chambers in our experiments. Since we detected neither PrPSc nor prion infectivity in 
compartments adjacent to RML inoculated compartments in these control chambers, we can 
not only exclude passive diffusion of infectivity, but also farfetched alternative explanations 
for prion infectivity spread in this system such as migratory cells that possibly could cross the 
grease barrier. 
Although in vivo data suggests that neurons transport prions anterogradely and retrogradely, 
it has been exceedingly difficult to study prion transport (Heikenwalder et al., 2007). Here we 
use a compartmented culture system to demonstrate that peripheral neurons can propagate 
prions anterogradely, retrogradely and autonomous from other cell types residing in 
peripheral nerves like Schwann cells in vitro.  
Despite evidence that neurons are the key players in prion propagation towards the CNS, 
low-efficiency alternatives, such as blood cell transporters are not completely excluded 
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(Aguzzi, 2004). In addition, non-neuronal cells like Schwann cells may play a role in 
modulating prion propagation in vivo.  
The existence of diverse prion strains complicates the understanding of neuronal prion 
transport even more (Aguzzi, 2004; King and Diaz-Avalos, 2004; Tanaka et al., 2004; 
Tanaka et al., 2006). Prion strains can occur within inbred animals, harbouring the identical 
Prnp gene, and differ at the symptomatic (e.g. onset of disease; clinical signs; histopathology 
in the brain) and biochemical level (Dickinson and Meikle, 1971). These properties may also 
influence whether a prion strain is lymphotrophic or neurotrophic (Aguzzi, 2004), which leads 
to the assumption, that distinct strains may employ different mechanisms for prion uptake 
and transport (Bartz et al., 2005). Taking this into account, the in vitro system of prion 
propagation in peripheral neurons presented here could be used to study details of prion 
transport, i.e. by modulating axonal transport or the integrity of the cytoskeleton.  
Human prion diseases end fatally without exception and to date, neither an applicable 
immunotherapy or a treatment after clinical onset of the disease is available. Understanding 
the basic principles of prion transport could lead to strategies that block the spread of prions 
in the body after peripheral uptake, improve TSE diagnostics and therefore help in the 
abatement of prion disease. 
 
2.6 Materials and Methods 
2.6.1 Prion inoculations  
Mice were maintained in accordance with the cantonal legislation for animal experiments. 
Following anaesthesia with Xylazin/Ketamin, mice were infected either i.c. (dynamitin+: 8; 
dynamitin-: 11 mice) with 30μl inoculum containing 3x102 LD50 units of the Rocky Mountain 
Laboratory (RML) scrapie strain (passage 6) or i.p. (dynamitin+: 13; dynamitin-: 11 mice) with 
100μl inoculum containing 103 LD50. For i.n. injections mice (dynamitin+: 15; dynamitin-: 13 
mice) were anaesthetized with Xylazin/Ketamin and the left sciatic nerve was surgically 
exposed by dislodging the M. gluteus superficialis and the M. biceps femoris. The nerve was 
placed onto a metal plate (20x5x0.5 mm), and 1μl of 1% RML6 was injected with a 34-gauge 
Hamilton syringe over a period of 2 min. To increase the efficiency of uptake, the injected 
nerve was gently squeezed with a microsurgical forceps (Vercelli et al., 2000). The nerve 
was anatomically repositioned and the skin was closed with USP 4.0 nylon sutures. Mice 
were monitored every second day, and scrapie was diagnosed according to clinical criteria 
including ataxia, kyphosis, tail rigidity and hind leg paresis. Mice were sacrificed upon onset 
of terminal disease, which was diagnosed when mice were no longer able to reach for food. 
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2.6.2 Western blot detection of PrPSc  
Homogenates were adjusted to 5mg/ml protein and run natively or after treatment with 
proteinase K (5-20μg/ml, 30 min, 37oC). 50µg of total protein were electrophoresed through 
12% SDS-PAGE. Proteins were transferred to nitrocellulose by wet blotting. Membranes 
were blocked with TBST/ 5% non-fat milk, incubated with antibody POM1 and developed by 
enhanced chemiluminescence (ECL, Amersham). 
 
2.6.3 Sympathetic neuron cultures 
Superior cervical ganglia were isolated from 0–2-day-old C57/BL6 mice. Neurons were 
dissociated and plated in the center compartments of three-compartmented cultures at a 
density of 0.5 ganglia per culture as previously described {Campenot and Martin, 2001}. 
Cultures were maintained in L-15 medium (Gibco–Invitrogen, Burlington, ON, Canada) 
modified as previously described {Campenot and Martin, 2001}. NGF (2.5S NGF from 
Alamone Laboratories, Jerusalem, Israel) was provided in distal compartments and in mass 
cultures at 50 ng/ml and at 10 ng/ml in cell body compartments. Medium provided to cell 
body compartments and to mass cultures contained 2.5% rat serum and 280 μM vitamin C 
(Sigma–Aldrich, Oakville, ON, Canada). Distal compartments were provided with medium 
lacking rat serum or vitamin C (Campenot, 1979). During the first week in culture, 10 μM 
cytosine arabinoside (Sigma–Aldrich) was supplied to center compartments and mass 
cultures to kill non-neuronal cells. 
 
2.6.4 Confocal microscopy 
Superior cervical ganglia cells were isolated as described above and cultured on a 2-well or 
4-well chambered slide (Lab-Tek Chamber - Coverglass, Nunc). The cells were washed with 
Opti-MEM I medium (Invitrogen) and incubated with anti-PrPC monoclonal antibodies such as 
6H4 (Prionics, Switzerland), POM1, POM2, POM3, or POM4 (Polymenidou et al., 2005) in 
Opti-MEM I medium at the concentration of 500 ng/ml for 15 min. The 1st antibodies were 
detected with Cy3-conjugated secondary antibodies, anti-mouse IgG (The Jackson Lab.). 
The cells were incubated with Hochst 33258 (Molecular Probe) for 5 min. Alternatively, the 
cells were fixed with 1% PFA (Paraformaldehyde) and then incubated with the 1st antibodies. 
The cells were placed in Opti-MEM I medium after extensive wash and the images were 
recorded with a confocal laser scanning system TCS-SP5 (Leica Microsystems GmbH). The 
fluorescence images were generated using the Imaris software (Bitplane, Zurich, 
Switzerland). 
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2.6.5 In vitro prion infection 
After one week in culture either the cell bodies in the centre compartment or the neurites in 
the side compartments were inoculated with prions (10% RML6 homogenate diluted 10-2 in 
medium). Culture medium was changed twice a week. After four weeks of exposure to prions 
the culture medium was removed and the cells were washed carefully twice with PBS. The 
material (cell bodies or neurites) was harvested either in PBS for inoculation in indicator mice 
or in cell lysis buffer (50 mM Tris.HCl (pH 8), 150 mM NaC, 0,5 % Na deoxycholate and 0,5% 
Triton X-100 in H20) for Western blotting. 
 
2.6.6 SAF enrichment and labelling  
Isolation of scrapie associated fibrils 
Groups of C57BL/6 wild-type mice were intra-cerebrally/peritoneally inoculated with 100ųl of 
1% brain homogenate prepared from animals previously infected with the mouse adapted 
ME7 strain of scrapie. Animals were sacrificed when adjudged to have reached terminal 
stages of illness. Individual brains were snap frozen and stored at -80°C before processing. 
SAFs were prepared from batches of frozen brains according to Hope et al (Hope et al., 
1986) whereby 10% brain homogenate was subjected to sequential centrifugation steps that 
isolate the insoluble fibrillar infectious agent. The original protocol was altered in that the 
preparation was not treated with proteinase K at any point during the process. The final 
pellets obtained were air dried then snap frozen before storage at –80°C. 
 
Fluorescent labelling of SAFs 
To follow the short term propagation of the infectious agent, SAFs were directly conjugated 
to a fluorescent label. Alexa Fluor 488/594/700nm succinimidyl esters which react with amine 
groups on the target protein, were coupled to SAFs according to the manufacturer’s 
instructions (Molecular Probes). Unreacted label was removed by dialysis with a cut-off at 
10kDa. Immediately prior to use, aliquots of SAFs were thoroughly sonicated for 2h to ensure 
complete dispersal of the fibrils.  
 
2.6.7 Uptake studies 
Sonicated and Alexa594 labelled fibrils are diluted to 5µg protein/ml in culture solution, and 
added to the cells at 10°C. Furthermore, Alexa488 labelled anti-Thy1.2 antibody (1:500) was 
added at 10°C. After 20 min cells were washed two times with 10°C cold medium to remove 
unbound compounds. Subsequently, cultures were shifted to 37°C to initiate endocytosis. 
After 3, 5 and 10 min, cells were washed with PBS, fixed with 4% PFA and stained with 
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DAPI. Pictures were taken with an Olympus fluorescent microscope set-up with motorized 
stage allowing to take stacks of images of 0.1 µm depths of the specimen.  
 
2.6.8 Infectivity bioassays with tga20 indicator mice  
From each sample 30 µl was inoculated intracerebrally into each of three or four tga20 mice, 
which overexpress Prnp and are utilised as sensitive indicators for prion infectivity (Fischer et 
al., 1996). Mice were monitored clinically every second day, and scrapie was diagnosed 
according to clinical criteria including ataxia, kyphosis, priapism, tail rigidity and hind leg 
paresis. All aspects of animal procedures, including criteria for termination at onset of 
terminal disease, were approved by local authorities. 
 
2.6.9 Histology and immunohistochemistry  
Tissues were fixed in 4% buffered formalin and treated with 98% formic acid for 1 hour then 
fixed for >24 hours prior to paraffin embedding. 2µm thick sections were cut onto positively 
charged glass slides and stained with hematoxylin and eosin, or immunostained using 
antibodies for PrP (SAF84), for astrocytes (GFAP), or microglia (Iba1). For PrP staining, 
sections were deparaffinized and incubated for 6 min in 98% formic acid, then washed in 
distilled water for 5 min. Sections were heated to 100°C in a pressure cooker in citrate buffer 
(pH 6.0), cooled for 3 minutes, then washed in distilled water for 5 minutes. 
Immunohistochemical stains were performed on an automated Nexus staining apparatus 
(Ventana Medical Systems) using an IVIEW DAB Detection Kit (Ventana). After incubation 
with protease 1 (Ventana) for 16 min, sections were incubated with anti-PrP SAF-84 (SPI bio; 
1:200) for 32 min. Sections were counterstained with hematoxylin. GFAP (1:1000 for 24 min.; 
DAKO) immunohistochemistry for astrocytes and Iba1 (1:2500 for 32 min.; Wako Chemicals) 
for microglia was similarly performed, however with antigen retrieval by heating to 100°C in 
EDTA buffer (pH8.0) within a steamer. 
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3.1 Introduction 
3.1.1 Outline of this work 
Prions induce histopathological changes that involve neuronal vacuolation (spongiosis), 
neuronal death and pronounced activation of glial cells, invariably leading to death of the 
affected individual. Whilst morphologically well characterized, the molecular origin of 
neurodegeneration is not understood. Following prion infection, concomitant with first 
neuronal pathological changes, Nuclear Factor-κB (NF-κB) activity in the brain has been 
shown to be enhanced. The NF-κB pathway plays an essential role in proliferation, regulation 
of apoptosis and immune responses involving induction of inflammation. The IκB kinase 
(IKK) signalosome is essential for NF-κB signalling and consists of the IKKα and IKKβ 
catalytic as well as the IKKγ regulatory subunit. It remains elusive whether NF-κB signalling 
supports protective or pathogenic mechanisms in prion diseases. Since rendering the 
classical NF-κB pathway non-functional is lethal in mice, we investigated prion propagation in 
mouse models with a CNS-restricted ablation of IKKβ and IKKγ. The impact of the alternative 
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NF-κB pathway in prion disease was assessed in the IKKαAA/AA mouse model containing 
alanines in place of serines in the activation loop of IKKα, thereby rendering it non-functional. 
We did not observe evidence to support the hypothesis that impaired NF-κB signalling in the 
CNS would impact prion pathogenesis.  
 
3.1.2 NF-κB signalling and prion pathogenesis 
Many neurodegenerative disorders share common pathological features, such as 
accumulation of misfolded proteins in the brain, ultimately leading to neuronal cell death 
(Aguzzi and Haass, 2003). These include Alzheimer’s disease, Parkinson’s disease and 
transmissible spongiform encephalopathies (TSEs). Prion diseases converge with other 
neurodegenerative diseases in many pathogenetic aspects and likely share common 
molecular features responsible for neurodegeneration. The histopathological changes that 
accompany TSEs include neuronal vacuolation (spongiosis), neuronal death and pronounced 
glial reactions (activation of astrocytes and microglia), which invariably lead to the death of 
the affected individuals (Aguzzi, 2006). Neuronal cell death is a concomitant feature of prion 
pathogenesis and has been proposed to occur via apoptotic mechanisms (Hetz et al., 2003; 
Cronier S, 2004; Fuhrmann et al., 2007). However, the precise molecular and biochemical 
mechanisms underpinning subsequent neuropathology are not understood.  
The Nuclear Factor-κB (NF-κB) pathway plays an essential role in immune responses 
involving induction of inflammation, proliferation as well as the regulation of apoptosis 
(Bonizzi et al., 2004; Karin, 2006). Consequently NF-κB is involved in a variety of 
physiological and pathological cellular responses, raising the possibility that it may also be 
implicated as a regulator of neurodegenerative processes. Here activation of NF-κB can 
either promote survival of neurons by inducing the expression of genes encoding anti-
apoptotic proteins or aid in neuronal degeneration by inducing the production and release of 
inflammatory cytokines, reactive oxygen molecules or excitotoxins in microglia and 
astrocytes. In acute as well as in chronic neurodegenerative conditions such as Alzheimer’s 
disease NF-κB is activated in neurons and glial cells. Here both, deleterious and beneficial 
role of NF-κB signalling is possible (Mattson, 2005). In prion disease NF-κB activity in the 
brain was shown to be enhanced in vivo in parallel with first detectable neuronal pathological 
changes (Kim et al., 1999). Furthermore, the cytotoxic synthetic peptide PrP106-126 activates 
NF-κB in microglial cells in vitro (Bacot et al., 2003). Despite these findings it remains elusive 
whether NF-κB activation is protective or pathogenic in prion disease. The IκB kinase (IKK) 
signalosome, consisting of the IKKα and IKKβ catalytic subunits and the IKKγ (also known as 
NEMO) regulatory subunit, is essential in the NF-κB pathway and necessary for NF-κB 
activation through pro-inflammatory signals (Ghosh and Karin, 2002).  
To study the impact of the canonical NF-κB pathway in prion disease we utilised a recently 
available murine model (van Loo et al., 2006). Here, CNS-restricted ablation of the IKK 
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subunits β or γ, is achieved by crossing mice carrying loxP-flanked alleles encoding IKKβ or 
IKKγ to Nestin-Cre transgenic mice. The Cre recombinase under the control of the Nestin-
promoter mediates excision of loxP-flanked sequences in early neuronal precursors during 
embryonic life, resulting in target gene inactivation in nearly all neuroectodermal cells of the 
CNS, including neurons, astrocytes and oligodendrocytes. In the latter study, it was shown 
that CNS-restricted ablation of NF-κB activators IKKβ or IKKγ but not IKKα ameliorate 
disease pathology in a mouse model of multiple sclerosis (van Loo et al., 2006), suggesting a 
mainly pathogenic function in autoimmune demyelinating disease for canonical NF-κB 
activation in cells of the CNS. Accordingly, we investigated the role of the IKK signalosome, 
as an essential regulator of the NF-κB pathway in prion disease. Since rendering the 
classical NF-κB pathway non-functional is embryonic lethal in mice, we investigated prion 
propagation in mouse models in which CNS-restricted ablation of IKKβ and IKKγ had been 
achieved.  
In contrast to global ablation of the β or γ subunit of the IKK signalosome, rendering the α 
subunit non-functional does not provoke lethality in mice. Cao et al., generated a mouse 
model with an IkkαAA knock-in allele containing alanines in place of serines in the activation 
loop rendering IKKα non-functional (Cao et al., 2001). Apart from a severe lactation defect 
due to impaired proliferation of mammary epithelial cells in females, IkkαAA/AA mice are 
healthy and fertile.  
However, none of the investigated NF-κB signalling pathways were shown to impact 
considerably on prion pathogenesis in our analyses. Therefore, we conclude that NF-κB 
signalling in the brain is not a determining feature of pathogenesis of prion diseases.  
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3.2 Results 
3.2.1 Inhibition of the “canonical” NF-κB pathway in cells of neuronal 
origin does not impair prion pathogenesis 
To study the impact of the canonical NF-κB pathway in prion disease we inoculated IKKβCNS-
KO and IKKγCNS-KO as well as age matched littermates carrying the respective loxP-flanked 
alleles lacking expression of the Cre recombinase intracerebrally (i.c.) with the mouse 
adapted prion strain RML 6 (Rocky Mountain Laboratory strain, (Bourteele et al., 2007)) 
(Figure 3.1). Since the IKKβCNS-KO and IKKγCNS-KO mice were generated with a C57BL/6-
derived embryonic stem cell line and have been backcrossed onto C57BL/6 at least seven 
generations, we inoculated C57BL/6 animals as a further control. We did not observe any 
significant differences in the onset of clinical signs and disease duration between IKKβCNS-KO 
or control animals inoculated with either a high dose (3x105 LD50) or a low dose (3x102 LD50) 
RML prions (Figure 3.1A, B). The mean survival of IKKβCNS-KO mice after high dose i.c. 
inoculation was 159 ± 9 days, whereas the mean survival of the littermates without Nestin-
Cre was 161 ± 5 days and for the wt control animals 153 ± 4 days. Similar results were found 
for mice inoculated with a low dose of prion inoculum with 194 ± 9 days for IKKβCNS-KO mice, 
194 ± 8 days for Nestin-Cre negative littermates and 185 ± 9 days for wt control animals. In 
line with these results low dose prion inoculation studies of IKKγCNS-KO and control animals 
resulted in mean incubation periods of 187 ± 8 days for IKKγCNS-KO mice and 193 ± 5 days for 
Nestin-Cre negative littermates (Figure 3.1C). Again, the CNS-specific ablation of one of the 
IKK subunits, IKKγ did not impair disease period in any of the mouse models used.  
To verify these findings on histopathological level we investigated brain sections of terminal 
mice inoculated with a low dose of prions for spongiform changes (H&E), activation of 
astrocytes (GFAP), deposition of disease-specific PrP (SAF84) and activation of microglia 
(Iba1) (Figure 3.1D, E). The corresponding analysis of brain sections derived from terminal 
mice inoculated with a high dose of prions is shown in Figure 3.4A. Again, no differences 
between the IKKβCNS-KO, IKKγCNS-KO and respective littermates were detectable. In addition we 
did not observe differences in the abundance of PrPSc in brain homogenates of terminally 
sick IKKβCNS-KO, IKKγCNS-KO and control animals as determined by Western blot analysis 
(Figure 3.1F, G). To reassure the efficiency of CNS-specific ablation in the identical mice 
used for our studies we quantified the abundance of the IKKβ and IKKγ protein in brain 
homogenate of the respective animals (Figure 3.2A, B). In line with the data published by van 
Loo et al., we estimated approximately 60% less IKKβ protein in brains of IKKβCNS-KO animals 
compared to brains of control animals. IKKγCNS-KO animals contain approximately 90% less 
IKKγ protein than brains of control animals. Since the total brain homogenate used for this 
verification also contains non-CNS derived cells like microglia, which also contain the IKK 
signalling complex, the reduction of IKKβ and IKKγ protein in neuronal cells is likely to be 
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1 
even be higher. We did not observe any impact of modulation of the canonical IKK signalling 
in prion disease in vivo in the mouse models investigated here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Signalling via the “canonical” NF-κB pathway is not involved in prion disease. A and B) Kaplan-
Meier survival plots of prion-infected IKKβCNS-KO and control animals. IKKβfloxed, IKKβCNS-KO and C57Bl/6 mice were 
screened for scrapie symptoms after intracerebral inoculation with 3x105 LD50 (A) or 3x102 LD50 (B) scrapie 
prions. C) Kaplan-Meier survival plots of IKKγCNS-KO and IKKγfloxed control animals after i.c. inoculation with 3x102 
LD50 scrapie prions. Triangles represent IKKγCNS-KO, whereas squares depict IKKγfloxed mice. D and E) Histology of 
low dose prion-infected IKKβCNS-KO (D) and IKKγCNS-KO (E) as well as respective control animals. All mice show 
prion derived spongiosis in the haematoxylin-eosin (H&E) stain, gliosis (immunostain for glial fibrillary acidic 
protein (GFAP)), PrP deposits (SAF84) and activated microglia (Iba1). Scale bar 200µm. F and G) Western blot of 
brain homogenates with (PK+) or without (PK-) proteinase K digestion of IKKβCNS-KO and IKKγCNS-KO as well as 
control animals that had developed terminal scrapie after intracerebral inoculation with 3x102 LD50 scrapie prions.  
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Figure 3.2: Efficiency of CNS-specific deletion of IKKβ and IKKγ in brain. A) Western blot analysis of total 
brain homogenate of wt, IKKβfloxed and IKKβCNS-KO for IKKβ and actin as a loading control. B) Ratio of IKKβ to 
actin based on the quantification of the immunoblot-signal normalized to wt IKKβ levels. C) Western blot analysis 
of total brain homogenate of wt, IKKγfloxed and IKKγCNS-KO for IKKγ and actin as a loading control. D) Ratio of IKKγ 
to actin based on the quantification of the immunoblot-signal normalized to wt IKKγ levels.  
 
3.2.2 Inhibition of the “alternative” NF-κB pathway does not impair prion 
pathogenesis 
In order to assess the impact of the alternative NF-κB pathway in prion disease we 
inoculated IKKαAA/AA and IKKαAA/wt mice (Cao et al., 2001) intracerebrally (i.c) with high 
(3x105 LD50) or low (3x102 LD50) doses of RML prions. Since the IKKαAA/AA mice derive from a 
129/C57BL/6 mixed background we crossed them to 129/C57BL6 F1 progeny in order to 
receive IKKαAA/wt mice. In contrast to the inoculation experiments performed with the IKKβCNS-
KO and IKKγCNS-KO mice we observed a marginally significant (p value: 0.02728; Mann-
Whitney-U-Test) reduction in disease period of 26 days after i.c. inoculation of a high dose of 
prions. However, the IKKαAA/AA survival curve appeared to be broadly distributed and showed 
a mean survival period of 127±19 days compared to 153 ± 12 days for IKKαAA/wt mice (Figure 
3.3A). This difference in disease period is reduced to 15 days after low dose i.c. inoculation 
of prions. Although a trend is observable, the survival curves do not differ significantly (p 
value: 0.1453). Whereas mean survival of IKKαAA/AA mice was 167 ± 21 days, in IKKαAA/wt 
mice this was 182 ± 11 days. We concede the mixed background of the animals used here 
as a limitation of the study. In summary, a marginal significance of the difference in 
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incubation period, a broad distribution of the IKKαAA/AA survival curve compared to the control 
group and no significant difference after low dose i.c. inoculation with prions was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Signalling via the “alternative” NF-κB pathway and prion disease. A and B) Kaplan-Meier 
survival plots of prion-infected IKKαAA/AA and IKKαAA/wt control animals. IKKαAA/AA and control mice were screened 
for scrapie symptoms after intracerebral inoculation with 3x105 LD50 (A) or 3x102 LD50 (B) scrapie prions. 
Triangles represent IKKαAA/AA, whereas squares depict IKKαAA/wt mice. C) Histology of low dose prion-infected 
IKKαAA/AA and IKKαAA/wt control animals. All mice show prion derived spongiosis in the haematoxylin-eosin (H&E) 
stain, gliosis (immunostain for glial fibrillary acidic protein (GFAP)), PrP deposits (SAF84) and activated microglia 
(Iba1). Scale bar 200µm. D) Western blot of brain homogenates with (PK+) or without (PK-) proteinase K 
digestion of IKKαAA/AA and IKKαAA/wt control animals that had developed terminal scrapie after intracerebral 
inoculation with 3x102 LD50 scrapie prions.  
1
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Histopathological evaluation of brain sections of low dose inoculated animals did not reveal 
any differences in spongiform changes (H&E), activation of astrocytes (GFAP), deposition of 
PrPSc (SAF84) or activation of microglia (Iba1) between IKKαAA/AA and IKKαAA/wt mice (Figure 
3.3B). The corresponding analysis of brain sections derived from terminal mice inoculated 
with a high dose of prions is shown in Figure 3.4B. In addition, we could not observe 
differences in the abundance of PrPSc in brain homogenates of terminally sick IKKαAA/AA and 
IKKαAA/wt mice as determined by Western blot analysis (Figure 3.3C). Consequently, we did 
not observe an impact of the alternative IKK signalling via IKKα in prion induced pathology 
and disease duration in the investigated mouse model after i.c. prion inoculation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Unchanged histopathological features in terminal IKKβCNS-KO and IKKαAA/AA mice i.c. inoculated 
with a high dose of prions. A) IKKβCNS-KO and B) IKKγCNS-KO mice develop prion induced spongiosis as detected 
by the haematoxylin-eosin (H&E), gliosis (immunostain for glial fibrillary acidic protein (GFAP)), display PrP 
deposits (SAF84) and activated microglia (Iba1) similar to control animals. Scale bar 200µm. 
 
3 NF-κB signalling and prion pathogenesis   49 
 
3.3 Discussion 
Here we have investigated a possible influence of IKK dependent NF-κB signalling in prion 
disease. We i.c. inoculated mice with non functional IKKα or mice lacking IKKβ or IKKγ in 
cells of the CNS with varying doses prions and studied various measures of prion 
pathogenesis. The IKKβCNS-KO and IKKγCNS-KO mouse model allow the depletion of the 
canonical NF-κB signalling pathway specifically in neuroectoderm-derived cells in an in vivo 
system, whereas other cell types including lymphocytes, macrophages, microglia and 
endothelial cells retain intact IKK signalling. Recently, it was demonstrated that the 
progression of experimental autoimmune encephalitis (EAE) was ameliorated in IKKβCNS-KO 
and IKKγCNS-KO mice, which had only mild clinical signs of disease and had less CNS 
inflammation and tissue damage (van Loo et al., 2006). This emphasized that CNS-specific 
reduction of IKKβ and IKKγ protein was sufficient to impair the course of EAE. However, 
conversely, deletion of IKKα did not impair the progress of EAE. Therefore, in neuroectoderm 
cells of the CNS, NF-κB activation through the canonical, IKKβ and IKKγ dependent pathway 
has a deleterious effect in autoimmune demyelinating disease, whereas the IKKα controlled 
alternative pathway does not appear to be implicated. Hence, non–microglial CNS-resident 
cells such as neurons, astrocytes and oligodendrocytes amplify the inflammatory response 
locally in the CNS parenchyma by expressing proinflammatory mediators (van Loo et al., 
2006).  
In contrast to observations from EAE studies our experiments formally exclude a role of the 
canonical NF-κB signalling pathway in neuroectoderm derived cells influencing the course 
and severity of prion disease. Therefore, we conclude that IKKβ or IKKγ dependent signalling 
in neuroectoderm-derived cells is not involved in prion pathogenesis. Whether IKKβ or IKKγ 
are involved in microglial related prion pathogenesis was not specifically investigated in this 
study and therefore remains elusive.  
In addition, our studies utilizing the IKKαAA/AA mouse model do not suggest a role of the 
alternative NF-κB signalling pathway in prion disease. Importantly, several observations lend 
support to our interpretation of a lack of involvement of IKKα in prion pathogenesis: (1) The 
marginal significance of the difference in incubation period, (2) the broad distribution of the 
IKKαAA/AA survival curve compared to the control group as well as the fact that (3) the groups 
inoculated with a low dose of prions do not differ in disease period.  
In summary we did not observe any evidence to indicate correlation between the 
manifestation of prion disease and NF-κB signalling in these mouse models. The finding that 
depletion of either classical or alternative NF-κB signalling does not impair prion 
pathogenesis in the brain is surprising since the NF-κB signalling pathways represent crucial 
triggers in proliferation, induction of inflammation, regulation of apoptosis and immune 
responses involving induction of inflammation. Interestingly, Bourteele et al. suggest that NF-
κB activity leads to mitochondrial apoptosis after prion infection (Bourteele et al., 2007). 
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However, it should be noted that in the latter study, Nfkb2-/- and Bcl-3-/- mice show only a mild 
reduction of 11 and 15 days in disease progression after prion inoculation, whereas Nfkb1-/- 
and p65CNS-KO animals behave similar to control animals (Bourteele et al., 2007). Taken 
together we conclude that NF-κB signalling is not a major determinant of prion disease 
pathogenesis.  
Despite much effort in prion research the mechanisms of neuronal loss are still elusive 
(Aguzzi et al., 2007). Understanding the molecular and cellular underpinnings of neuronal 
loss during prion disease could help developing possible treatments. Furthermore, 
knowledge of the impact of protein aggregates on neuronal cell survival could shed light on 
other protein aggregation diseases like Alzheimer’s and Parkinson’s disease. 
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3.4 Materials and Methods 
3.4.1 Prion inoculations 
Mice were maintained in accordance with the cantonal legislation for animal experiments and 
infected i.c. with 30μl inoculum containing 3x102 LD50 or 3x105 LD50 units of the Rocky 
Mountain Laboratory (RML) scrapie strain (passage 6). Mice were monitored every second 
day, and scrapie was diagnosed according to clinical criteria including ataxia, kyphosis, tail 
rigidity and hind leg paresis. Mice were sacrificed upon onset of terminal disease, which was 
diagnosed when mice were no longer able to reach for food. 
3.4.2 Histology and immunohistochemistry  
Tissues were fixed in 4% buffered formalin and treated with 98% formic acid for 1 hour then 
fixed for >24 hours prior to paraffin embedding. 2m thick sections were cut onto positively 
charged glass slides and stained with hematoxylin and eosin, or immunostained using 
antibodies for PrP (SAF84), for astrocytes (GFAP), or microglia (Iba1). For PrP staining, 
sections were deparaffinized and incubated for 6 min in 98% formic acid, then washed in 
distilled water for 5 min. Sections were heated to 100°C in a pressure cooker in citrate buffer 
(pH 6.0), cooled for 3 minutes, then washed in distilled water for 5 minutes. 
Immunohistochemical stains were performed on a automated Nexus staining apparatus 
(Ventana Medical Systems) using an IVIEW DAB Detection Kit (Ventana). After incubation 
with protease 1 (Ventana) for 16 min, sections were incubated with anti-PrP SAF-84 (SPI bio; 
1:200) for 32 min. Sections were counterstained with hematoxylin. GFAP (1:1000 for 24 min.; 
DAKO) immunohistochemistry for astrocytes and Iba1 (1:2500 for 32 min.; Wako Chemicals) 
for microglia was similarly performed, however with antigen retrieval by heating to 100°C in 
EDTA buffer (pH8.0) within a steamer. 
3.4.3 Western blot detection of PrPSc  
Western blot analysis: Brain homogenates were adjusted to 5mg/ml protein and run natively 
or after treatment with proteinase K (50μg/ml, 30 min, 37oC). 50µg of total protein were 
electrophoresed through 12% SDS-PAGE. Proteins were transferred to nitrocellulose by wet 
blotting. Membranes were blocked with TBST/ 5% non-fat milk, incubated with antibody 
POM1 and developed by enhanced chemiluminescence (ECL, Amersham). 
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4.1 Introduction 
4.1.1 Outline of this work  
Prion infections induce severe disruption of the central nervous system with neuronal 
vacuolation and extensive glial reactions, and invariably lead to death of affected individuals. 
The molecular underpinnings of these events are not well understood. In order to better 
define the molecular consequences of prion infections, we analyzed the transcriptional 
response to persistent prion infection in a panel of three murine neuronal cell lines in vitro. 
Colony spot immunochemistry assays indicated that 65-100% cells were infected in each 
line. However, we were unable to detect any consistent changes in the transcriptional profile 
as a response to prion infection. Several transcripts previously reported to be derailed in 
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prion-infected cells could not be confirmed in the present study. We attribute these 
discrepancies to the experimental stringency of the current study, which was performed 
under conditions designed to minimize potential genetic drifts. These findings are at variance 
with gene expression studies performed on whole brains upon prion infections in vivo, 
suggesting that many of the latter changes represent secondary reactions to infection. We 
conclude that, surprisingly, there are no universal transcriptional changes induced by prion 
infection of neuronal cells in vitro.  
 
 
4.1.2 Transcriptional changes in response to prion infection 
Although prion replication can occur in extraneural tissues prior to neuroinvasion after 
peripheral challenge, pathological changes have only been observed in the central nervous 
system (CNS) (Fraser and Dickinson, 1970; Prinz et al., 2003b). These include neuronal 
vacuolation (also termed spongiosis), neuronal death and pronounced glial reactions, which 
invariably lead to death of the affected individuals (Aguzzi, 2006).  
The molecular mechanisms underlying prion replication and pathways leading to subsequent 
neural damage are not well understood (Weissmann, 2005). Transcriptional profiling is a 
powerful technology that allows for interrogating very large datasets without the need to 
place the typical constraints of hypothesis-testing experimentation. The inherent lack of bias 
reflects the strength of this approach. The transcribed genome has been analyzed in whole 
brains of rodents experimentally infected with various prion strains (Riemer et al., 2000; 
Riemer et al., 2004); (Xiang et al., 2004), spleens of prion-infected mice (Miele et al., 2001), 
primary cells isolated from tissues (Baker and Manuelidis, 2003), and prion-infected cell lines 
(Doh ura et al., 1995; Greenwood et al., 2005).  
Previous analyses of whole brains, or of isolated microglia, identified a number of 
differentially expressed genes. However, since whole brains consist of many different cell 
types, and microglia are not infectible with prions in vivo (Priller, 2006), these candidates are 
likely to reflect secondary, systemic responses to prion infection. In contrast, studying the 
consequences of prion infection on clonal neuronal cell lines may identify cellular responses 
that are more directly related to prion infection. Also, the use of cell lines highly susceptible to 
prion infection at high infection rates circumvents potential issues with using either whole or 
dissected brain, where only a small proportion of the interrogated transcriptome is 
contributed by prion-infected cells. One such recent study has reported that a number of 
candidate genes are differentially expressed as a direct result of prion infection (Greenwood 
et al., 2005).  
Here we describe the outcome of transcriptional analyses of cultured cells in vitro under 
stringently controlled conditions. Our original aim was to identify changes in gene expression 
after prion infection conserved over different neuronal cell lines. Besides pointing to possible 
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players in the pathogenesis of prion diseases, any robust and consistent transcriptional 
changes could be utilized for constructing reporter systems, which in turn would allow for 
identifying and isolating single prion infected cells in intact tissues and in cell cultures.  
We employed high-density oligonucleotide microarrays analysis of N2aPK1 cells to identify 
gene expression changes directly resulting from prion infection. After exhaustive 
interrogation of datasets with several techniques of bioinformatics, we were only able to 
identify very modest differential expression, even under conditions of low filter stringencies. 
Subsequent quantitative PCR analyses confirmed modest but statistically significant 
differential expression of only one transcript termed Nav1. However, Nav1 was not 
differentially expressed in a different in vitro cell culture model of prion infection utilized in our 
laboratory. Our investigations of expression levels in independent cell culture models of prion 
infection of candidate genes previously reported by others to be profoundly differentially 
expressed (Greenwood et al., 2005) revealed that none of these were differentially 
expressed in any of the cell culture models of in vitro prion infection utilized here, including 
those employed by Greenwood et al. (Greenwood et al., 2005).  
Therefore, in contrast to reports by others (Doh ura et al., 1995; Greenwood et al., 2005), we 
provide conclusive evidence that prion infection does not alter the mRNA profile of a broad 
range of neuronal cells in vitro. We hypothesize that this discrepancy results from 
fundamental differences in the experimental design. We conclude therefore that prion agents 
in cultured neuronal cells infected at high rates do not induce general or specific changes in 
the transcriptome. 
4 Transcriptional profiles after prion infection   55 
 
4.2 Results 
4.2.1 In vitro cell culture models of prion infection 
In view of the potential impact of the choice of the cell culture model onto the transcriptional 
response to prion infection, we opted to compare results obtained in three distinct cell lines. 
We used murine N2aPK1, CAD, and GT1 cells, which are all of neuronal origin and can be 
infected to high rates with the mouse-adapted scrapie prion strain RML (Butler et al., 1988; 
Qi et al., 1997; Schätzl et al., 1997; Klohn et al., 2003). Subpopulations of prion infected GT1 
cells have been reported to develop features of apoptosis and vacuolarization resembling the 
pathology in brains of prion infected animals (Schätzl et al., 1997). Instead, prion infection 
seems to have no impact on cell viability or morphology in N2a or CAD cells (Mahal, pers. 
communication), although N2a cell subclones have been reported to be more sensitive to 
caspase-3 / -8 mediated apoptosis (Kristiansen et al., 2005).  
The following measures were taken to avoid the detection of potential clonal or stochastic 
artefacts. Firstly, prior to prion infection we split the respective parental cell line (N2aPK1, 
CAD, GT1) into eight batches (Figure 4.1). Four of these individual batches were infected 
with RML scrapie prions, and four were exposed to “mock” (uninfected) brain homogenate. 
Secondly, we strived to minimize the period between establishment of prion infection (or 
mock infection) of cells and harvesting, since long periods of serial passaging could result in 
clonal segregation. We opted to use the cells at the earliest time point at which no residual 
inoculum is detected, but at which the cells show a high degree of infection as measured by 
Western blot for PrPSc (Figure 4.2A-C) and infection ratio as measured by colony spot 
scrapie cell assay (Figure 4.2D-F) (Klohn et al., 2003). After eight passages we determined 
that all cell cultures inoculated with RML showed proteinase K (PK) resistant PrP, whereas 
this was consistently absent in mock infected control cells (N2aPK1mock, CADmock and 
GT1mock). In addition, we determined the prevalence of infection within the cell cultures that 
were studied. We reasoned that the infection rate of the cell cultures would directly impact 
the sensitivity with which any transcriptional changes would be detected. Whereas the four 
investigated Scrapie infected N2aPK1 cultures (N2aPK1RML) showed infection ratios of 65-
81% (Figure 4.2D), the GT1RML and CADRML cultures showed ratios close to 100% (Figure 
4.2E-F). Numeric values over 100% represent statistical artefacts, originating from variations 
in the number of cells seeded in each well. In summary we generated three murine neuronal 
cell culture models validated for prion infection for a comparison of gene expression with 
mock infected control cells. Each measurement, therefore, consisted of four true biological 
replicates for the infected or mock-infected groups, rather than “technical” replicates that 
would result from the splitting of parental infected or mock infected parental lines at the time 
of harvesting.  
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Figure 4.1: Schematic of the infection procedure. 17’000 cells (N2aPK1, CAD or GT1) were seeded in each of 
six wells of a 96 well plate. After 16h of incubation cells were infected with a 10-2 dilution of 10% homogenate of 
mock CD1 brain homogenate or 10% homogenate of RML infected brain homogenate, respectively. Independent 
infections were performed in quadruplicate to achieve four true biological replicates of Mock or RML infected cells. 
After three days of incubation cells were split three times (1:3) and subsequently a further three times (1:10). At 
that point six wells were pooled and cells were expanded in a T75 cell culture flask. At approximately 75% 
confluency cells were harvested for RNA isolation or split 1:10 to obtain material for Western blot analysis and 
clarification of the infection ratio. 
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Figure 4.2: Immunoblot analysis and quantitative infectivity assessment by Elispot assay of mock brain 
homogenate and RML brain homogenate infected cell lines. A) Western blot analysis for PrPC and PrPSc of 
monoclonal anti-PrP (POM1) probed protein homogenate of four mock infected and four RML infected biological 
replicates of N2aPK1 cells are depicted with the respective controls. Proteinase K (PK) digestion visualizes 
protease resistant and consecutively shifted PrPSc. 70 g of protein were loaded for PK+, 35 g of protein for PK- 
samples. B) and C) shows equivalent data from mock versus RML infected CAD and GT1 cells respectively. D) 
and E) The ratio of infected cells per biological replicate as assessed by Elispot assay (Klohn et al., 2003). Data 
are presented as arithmetic means +/- standard deviation.  
 
4.2.2 Transcriptional analysis of prion infected N2aPK1 (N2aPK1RML) 
versus control mock infected N2aPK1 (N2aPK1mock) cells 
For the identification of differentially expressed genes as a response to prion infection, we 
compared the expression profiles of N2aPK1mock vs. N2aPK1RML cells (Figure 4.1). We 
utilized the two algorithms, GCRMA and MAS5.0, for expression value calculation. We 
applied an equal-variance t-test significance threshold of p<0.05 and a fold change filter of 
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2.0 to the expression values. This procedure did not result in the detection of any 
differentially expressed genes. Therefore, we relaxed the fold change filter conditions to 1.5 
fold. Under these conditions we identified a core set of 82 candidates to be differentially 
expressed more than 1.5 fold in at least one of the two algorithms.  
According to the above, we classified genes as “candidates” if they fulfilled the statistical 
significance and fold-change criteria in at least one set of data preprocessed with either 
MAS5.0 or GCRMA. The intent of this strategy was not to increase the specificity of the 
results, but rather to raise the sensitivity of the testing procedure, as we wanted to minimize 
any chances of producing false negatives. Consequently, by relaxing the filter conditions we 
did not restrict our results but rather enlarged the number of candidates.  
Given the high number of Affymetrix qualifiers tested, the number of candidate genes 
identified here resembles that which might be expected to be determined by chance, raising 
the possibility at this stage that these candidates may not represent true differentially 
expressed transcripts. Of these 82 candidates, 58 out of these showed a level of differential 
gene expression between 1.5 and 2.2, whereas 24 candidate genes showed differential 
expression higher than 2.2 fold in at least one of the two algorithms applied. The highest 
degree of differential gene expression was observed for Gca (grancalcin; 12.7 fold, 
downregulated) and Asf1 (anti-silencing function 1 homolog A; 10.6-fold, upregulated) as a 
response to prion infection (Table 4.1). However, of these 24 candidates 18 tested positive 
only with the GCRMA algorithm, and 1 tested positive only with the MAS5.0 algorithm. 
Accordingly, only 5 candidates tested positive in both algorithms.  
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Table 4.1 Candidate genes resulting from microarray studies comparing 
N2aPK1mock vs. N2aPK1RML  
 
Affymetrix 
ID Gene name 
Mock/ 
RML 
GCRMA 
Stdev
Mock/ 
RML 
MAS5 
Stdev
Gene Id as 
indicated in 
figures 2 + 3 
Candidates 
identified in 
this study (X) 
1415834_at dual specificity phosphatase 6 1.601 0.212 1.737 0.470  X 
1416147_at heat shock protein 4 0.665 0.197 0.796 0.291  X 
1416196_at laminin receptor 0.983 0.533 1.414 2.586 lamR  
1416239_at Argininosuccinate synthetase 1 1.204 0.236 1.402 0.345 ass1  
1416516_at Fascin homolog 1 0.656 0.674 0.666 0.656 fscn1 X 
1416686_at 
procollagen lysine, 2-oxoglutarate 5-
dioxygenase 2 
0.539 0.207 0.683 0.285 plod1 X 
1416759_at 
NEDD9 interacting protein with calponin 
homology and LIM domains 
2.052 0.461 1.431 0.308  X 
1416922_a_at 
BCL2/adenovirus E1B 19kDa-interacting protein 
3-like 
0.621 0.214 0.671 0.301  X 
1417365_a_at calmodulin 1 0.989 0.199 1.171 0.280 calm1  
1417580_s_at Selenium-binding protein 2 0.824 0.497 0.816 0.347 selenbp2  
1417835_at murinoglobulin 1 0.987 0.794 7.85 13.518  X 
1417976_at adenosine deaminase 1.585 0.267 1.439 0.346 ada X 
1418175_at vitamin D receptor 1.634 0.233 1.713 0.388  X 
1418539_a_at protein tyrosine phosphatase, receptor type, E 1.86 0.375 1.411 0.337  X 
1418626_a_at clusterin 1.237 0.229 1.47 0.393 clu  
1418709_at cytochrome c oxidase, subunit VIIa 1 0.543 0.228 0.556 0.290 cox7a X 
1418835_at 
pleckstrin homology-like domain, family A, 
member 1 
1.626 0.214 1.735 0.313  X 
1419093_at tryptophan 2,3-dioxygenase 0.969 1.463 0.15 0.822  X 
1419157_at SRY box containing 4 0.662 0.707 0.645 0.666 sox4 X 
1419985_s_at 
DNA segment, Chr 11, ERATO Doi 461, 
expressed 
1.884 0.383 0.373 0.183  X 
1420376_a_at histone family 3 B 0.897 0.189 0.906 0.285 hf3B  
1420664_s_at protein C receptor, endothelial 1.654 0.228 2.178 0.504  X 
1420737_at polyamine modulated factor 1 binding protein 1 1.501 0.221 1.291 0.308  X 
1420760_s_at N-myc downstream regulated 1 0.553 0.208 0.637 0.293 ndrg1 X 
1421924_at Solute carrier family 2 0.479 0.526 0.506 0.522 slc2a2 X 
1422136_at 
kinase interacting with leukemia-associated 
gene (stathmin) 
0.642 0.216 0.818 0.295  X 
1423281_at Stathmin-like 2 1.054 0.202 1.249 0.342 stmn2  
1423748_at RIKEN cDNA D530020C15 gene 0.472 0.263 0.481 0.301  X 
1423946_at PDZ and LIM domain 2 1.714 0.299 1.379 0.294  X 
1424492_at 
Transient receptor potential cation 
channel,subfamily C, member 2 
1.074 0.191 1.139 0.297 trpc2  
1424698_s_at grancalcin 0.964 0.639 0.079 1.693  X 
1425140_at lactamase, beta 2 0.632 0.190 0.778 0.287  X 
1426092_a_at tripartite motif protein 34 0.964 0.622 0.098 1.386  X 
1426155_a_at odd-skipped related 2 (Drosophila) 0.96 0.893 0.125 1.210  X 
1427026_at myosin, heavy polypeptide 4, skeletal muscle 0.953 0.624 7.06 12.240  X 
1428517_at WD repeat and FYVE domain containing 3 1.503 0.215 0.668 0.107  X 
1428767_at RIKEN cDNA 1810036L03 gene 1.327 0.209 0.544 0.069  X 
1428774_at 
12 days embryo male wolffian duct includes 
surrounding region cDNA, RIKEN full-length 
enriched library, clone:6720429C22 
product:unknown EST, full insert sequence 
1.786 0.443 0.882 0.061  X 
1429146_at 
Adult male testis cDNA, RIKEN full-length 
enriched library, clone:4931406B08 
product:unknown EST, full insert sequence 
1.72 0.333 0.682 0.278  X 
1430584_s_at Carbonic anhydrase 3 0.96 0.276 0.499 0.572 car3 X 
1432205_a_at RIKEN cDNA C130038G02 gene 1.526 0.299 0.75 0.235  X 
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Affymetrix 
ID Gene name 
Mock/ 
RML 
GCRMA 
Stdev
Mock/ 
RML 
MAS5 
Stdev
Gene Id as 
indicated in 
figures 2 + 3 
Candidates 
identified in 
this study (X) 
1432638_at RIKEN cDNA 2810002N01 gene 0.981 3.143 0.241 0.291  X 
1433649_at amine oxidase, flavin containing 1 1.8 0.296 0.709 0.248  X 
1433855_at 
Transcribed sequence with strong similarity to 
protein ref:NP_065580.1 (M.musculus) 
hypothetical protein, I54 [Mus musculus] 
1.642 0.276 2.949 1.238  X 
1434099_at RIKEN cDNA A830037N07 gene 0.951 0.451 0.111 3.238  X 
1434338_at 
18-day embryo whole body cDNA, RIKEN full-
length enriched library, clone:1110029E03 
product:unknown EST, full insert sequence 
1.612 0.284 0.776 0.151  X 
1434969_at CDNA clone IMAGE:5683160, partial cds 1.6 0.246 0.653 0.191 RcDNA X 
1435033_at RIKEN cDNA 9330140K16 gene 1.54 0.288 0.906 0.185  X 
1435109_at RIKEN cDNA 3010001K23 gene 1.253 0.287 0.188 0.301  X 
1435483_x_at mitochondrial folate transporter/carrier 1.756 0.352 0.53 0.134  X 
1435543_at adenomatosis polyposis coli 1.767 0.340 0.799 0.068 apc X 
1435822_at 
16 days neonate heart cDNA, RIKEN full-length 
enriched library, clone:D830012I24 
product:unknown EST, full insert sequence 
1.642 0.327 0.584 0.187  X 
1436004_at ubiquitin specific protease 27, X chromosome 2.219 0.513 0.791 0.107  X 
1436195_at cDNA sequence BC046404 1.979 0.440 0.75 0.132  X 
1436448_a_at prostaglandin-endoperoxide synthase 1 2.003 0.337 2.386 0.693 ptgs1 X 
1436907_at neuron navigator 1 1.558 0.226 0.707 0.149 nav1 X 
1437414_at RIKEN cDNA 4933431C08 gene 1.692 0.286 0.63 0.231  X 
1437862_at RIKEN cDNA 2610015J01 gene 1.555 0.333 0.827 0.121  X 
1438083_at Hedgehog-interacting protein 0.995 0.543 7.458 18.137  X 
1438310_at 
10 days neonate cerebellum cDNA, RIKEN full-
length enriched library, clone:B930095L19 
product:unknown EST, full insert sequence 
1.651 0.356 0.776 0.180  X 
1438642_at 
AV278176 RIKEN full-length enriched, adult 
male testis (DH10B) Mus musculus cDNA clone 
4933400E08 3', mRNA sequence. 
1.031 0.310 6.987 24.796  X 
1438858_x_at histocompatibility 2, class II antigen A, alpha 0.94 0.477 5.011 1.945  X 
1440739_at vascular endothelial growth factor C 1.688 0.334 0.592 0.212  X 
1440966_at axotrophin 1.689 0.416 0.653 0.085 axot X 
1441894_s_at 
BB071890 RIKEN full-length enriched, 15 days 
embryo male testis Mus musculus cDNA clone 
8030499N14 3' similar to AF236099 Mus 
musculus GRP1-associated scaffold protein 
GRASP mRNA, mRNA sequence. 
1.694 0.346 0.829 0.197  X 
1442146_at 
H3079F10-3 NIA Mouse 15K cDNA Clone Set 
Mus musculus cDNA clone H3079F10 3', mRNA 
sequence. 
1.029 0.320 4.126 1.004 cDNAc X 
1446550_at G1 to phase transition 1 1.601 0.254 0.888 0.330  X 
1447139_at B-cell CLL/lymphoma 7C 1.195 0.286 0.232 0.126  X 
1448364_at cyclin G2 0.592 0.243 0.762 0.324 ccng2 X 
1448623_at RIKEN cDNA 2310075C12 gene 0.65 0.185 0.743 0.309  X 
1449275_at RIKEN cDNA 2310038H17 gene 0.649 0.228 0.77 0.278  X 
1450459_at RIKEN cDNA 2010106G01 gene 0.658 0.219 0.869 0.292  X 
1451110_at EGL nine homolog 1 (C. elegans) 0.662 0.224 0.614 0.309  X 
1451149_at phosphoglucomutase 2 0.6 0.204 0.714 0.314  X 
1451385_at RIKEN cDNA 2310056P07 gene 0.649 0.193 0.74 0.296  X 
1451386_at 
biliverdin reductase B (flavin reductase 
(NADPH)) 
1.549 0.206 1.75 0.416  X 
1451461_a_at aldolase 3, C isoform 0.527 0.246 0.625 0.349  X 
1452444_at 
N-ethylmaleimide sensitive fusion protein 
attachment protein beta 
0.583 0.225 0.696 0.287  X 
1452565_x_at 
envelope polyprotein; Mouse endogenous 
mammary tumor virus (MMTV) RNA, env gene 
and right LTR. 
0.953 0.997 0.116 1.103  X 
1452670_at myosin, light polypeptide 9, regulatory 0.403 0.266 0.494 0.304  X 
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Affymetrix 
ID Gene name 
Mock/ 
RML 
GCRMA 
Stdev
Mock/ 
RML 
MAS5 
Stdev
Gene Id as 
indicated in 
figures 2 + 3 
Candidates 
identified in 
this study (X) 
1453465_x_at RIKEN cDNA 4930402H24 gene 1.528 0.273 0.415 0.306  X 
1455099_at 
BB414982 RIKEN full-length enriched, 7 days 
embryo Mus musculus cDNA clone 
C430040E04 3', mRNA sequence. 
1.624 0.214 1.101 0.297  X 
1455210_at zinc fingers and homeoboxes protein 2 1.499 0.268 0.885 0.136  X 
1455403_at RIKEN cDNA 4932703L02 gene 1.841 0.386 0.658 0.175  X 
1456661_at 
Transcribed sequence with moderate similarity 
to protein pdb:1JZ5 (E. coli) B Chain B, E. Coli 
1.836 0.303 0.515 0.262  X 
1456930_at hypothetical protein 9530003A05 1.521 0.239 0.703 0.073  X 
1457004_at 
BB698378 RIKEN full-length enriched, 2 days 
neonate sympathetic ganglion Mus musculus 
cDNA clone 7120499J15 3', mRNA sequence. 
0.937 0.325 4.632 0.298  X 
1458173_at 
Transcribed sequence with moderate similarity 
to protein pir:S12207 (M.musculus) S12207 
hypothetical protein 
1.011 0.876 8.674 28.737  X 
1458232_at dickkopf homolog 1 (Xenopus laevis) 1.558 0.243 0.581 0.209  X 
1459882_at 
ASF1 anti-silencing function 1 homolog A (S. 
cerevisiae) 
1.069 0.323 10.582 14.669 asf1 X 
1460214_at Purkinje cell protein 4 0.991 0.206 1.074 0.400 pcp4  
 
Each of the 82 candidates described above was then tested by quantitative real-time 
reverse-transcription PCR (qPCR). For this, we pooled cDNA derived from RNA prepared 
from four independent cultures of N2aPK1mock and four cultures of N2aPK1RML cells, 
respectively (Figure 4.1). This pooled cDNA was split into three aliquots, each of which was 
individually examined for gene expression levels by qPCR. The spread among the three 
cDNA aliquots was taken as an indication of the technical variability of the assay. Sixty-eight 
candidate genes showed no differential expression between N2aPK1mock and N2aPK1RML. A 
total of 14 candidates showed statistically significant, but less than 5 fold up- or 
downregulation in the prescreen qPCR analysis. The expression ratios for these as 
determined by the MAS5.0 and GCRMA algorithms are shown in Figure 4.3A. The 
expression levels of these 14 transcripts in N2aPK1RML cells were analyzed further by 
performing three qPCR readings of each cDNA preparation synthesized from RNA obtained 
from four independent cultures of N2aPK1mock and four of N2aPK1RML cells (Figure 4.3B). Of 
these 14 candidates, we could only confirm statistically significant (p<0.0005) downregulation 
of the Nav1 transcript of <1.8 fold in response to prion infection in N2aPK1 cells. We were 
not able to confirm differential expression of any of the remainder of the potential candidate 
genes identified in our high-density oligonucleotide microarrays of N2aPK1mock compared to 
N2aPK1RML cells.  
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Figure 4.3: Gene expression analysis of mock versus RML infected N2aPK1 cells. A) High-density 
oligonucleotide chip analysis of mock (white bars) vs. RML (black bars) infected N2aPK1 cells as analyzed with 
MAS5.0 or GCRMA data analysis algorithm. Candidate transcripts originating from one of the two analysis 
algorithms were later subjected to quantitative real time PCR-analysis (qPCR; see also table 4.1). B) Verification 
of microarray data with qPCR in mock (white bars) versus RML (black bars) infected N2aPK1 cells and 
expression analysis of candidate genes in mock versus RML infected CAD cells normalized to Gapdh. The qPCR-
analysis was performed in four biological replicates of each mock and RML infected cell line and three technical 
replicates per biological replicate. The average of four mock biological replicates was set as one. Data are 
presented as arithmetic means +/- standard deviation.  
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4.2.3 Analyses of candidate gene expression in prion infected CAD 
(CADRML) cells 
The expression levels of the latter 14 candidate genes were also assessed in the CAD cell 
culture model of prion infection. Again, we could not detect differentially expressed genes as 
a response to prion infection (Figure 4.3B). In particular, we could not observe 
downregulation of Nav1 in the CADRML cells. Whilst this may certainly be of biological 
significance relevant to N2aPK1 cells, differential expression of this gene is not a feature 
common to prion infected neuronal cells in vitro. 
 
4.2.4 qPCR analyses of candidate differentially expressed genes in 
N2aPK1RML and GT1RML cell culture models reported by others 
Statistically significant, profound differential expression of several candidate genes has been 
recently reported (Greenwood et al., 2005) as a direct result of prion infection in N2aPK1 and 
GT1 cell culture models. The expression ratios for nine of those which showed highest levels 
of differential expression from that study were chosen for validation in our models. This is in 
stark contrast to the expression ratios determined by MAS5.0 and GCRMA algorithms in our 
transcriptional profiling analyses of N2aPK1RML and N2aPK1mock cells (Figure 4.4A). In the 
latter study, the genes encoding Selenium binding protein 2 (Selenbp2), Argininosuccinate 
synthetase 1 (Ass1) and Clusterin (Clu) were reported to be profoundly over-expressed in 
prion infected cell lines; in the case of Ass1 up to 40-fold in N2aPK1RML and GT1RML cells. In 
contrast, histone family 3b (Hf3b), Calmodulin 1 (Calm1) and Purkinje cell protein 4 (Pcp4) 
were reported to be downregulated as a response to prion infection (2-fold, 2-fold, and 5-fold 
respectively).  
However, in the analyses of prion infected neuronal cells reported above, we were unable to 
validate these findings, neither in the MAS5.0 or GCRMA interrogated microarray data 
(Figure 4.4A) or by qPCR analyses of our own prion infected N2aPK1RML or GT1RML cell 
culture models (Figure 3b). Whereas our qPCR studies were performed using Gapdh as the 
housekeeping gene for normalization of expression levels, Greenwood et al. used Polr2a 
(RNA Polymerase II) and Tbp (TATA box binding protein) for normalization. Although this 
detail is unlikely to account for the discrepancies between these studies, we formally 
investigated this possibility by determining the expression levels of Polr2a and Tbp relative to 
Gapdh in mock and prion infected N2aPK1, CAD and GT1 cell culture models (Figure 4.5). 
As expected, the expression levels of these relative to Gapdh are not altered in prion infected 
cells, thereby confirming that using these genes as normalization controls in our study would 
not alter the conclusions from our data.  
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Figure 4.4: Expression analysis of published differentially regulated genes as a response to prion 
infection. A) High-density oligonucleotide chip analysis of mock (white bars) vs. RML (black bars) infected 
N2aPK1 cells as analyzed with MAS5.0 or GCRMA data analysis algorithm. B) Results of qPCR analysis of mock 
(white bars) versus RML (black bars) infected N2aPK1 or GT1 cells. Relative gene expression levels of published 
transcripts in N2aPK1 and N2aPK1RML or GT1 compared to GT1RML cells normalized to Gapdh. Analysis was 
performed in four biological replicates of each mock and RML infected cell line and three technical replicates per 
biological replicate. The average of four mock biological replicates was set as one. Data are presented as 
arithmetic means and standard deviations.  
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Figure 4.5: Housekeeping gene expression analysis of mock versus RML infected cells. A-C) expression 
analysis of housekeeping genes in mock (white bars) versus RML (black bars) infected cells. The graph shows 
relative gene expression normalized to Gapdh for A) N2aPK1 cells, B) CAD cells and C) GT1 cells. Analysis was 
performed in four biological replicates of each mock and RML infected cell line and three technical replicates per 
biological replicate. The average of four mock biological replicates was defined as one. Data are presented as 
arithmetic means and standard deviations.  
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4.3 Discussion 
4.3.1 Prion infection does not induce general changes in RNA profiles of 
cells in vitro 
Here we have investigated the impact of prion infection on the transcriptome of chronically 
infected N2aPK1RML cells. We have complemented this unbiased approach with a targeted 
reappraisal of previously reported differentially expressed candidate genes. In order to 
identify potentially universal changes brought about by prion infection, we examined three 
independent neuronal cell culture systems infected with the mouse adapted scrapie strain 
RML.  
Although Western blotting analyses revealed very high concentrations of PrPSc in cell lysates, 
and colony spot immunochemistry identified 65-100% of the cells as prion-infected, we were 
unable to identify differences in gene expression between prion and mock infected cells that 
would hold true for the three cell lines investigated - and might therefore represent universal 
responses to prion infection. The only modest – yet statistically significant – changes in 
expression were identified for the Nav1 transcript in response to prion infection. Nav-1 
encodes the Neuron Navigator 1 protein, a microtubule-associated protein involved in 
neuronal migration. However, we could not observe downregulation of Nav1 in the CADRML 
cells. Therefore, despite a possible biological significance in N2aPK1 cells, differential 
expression of Nav1 is not a feature common to prion infected neuronal cells in vitro. 
In addition, our investigations of expression levels of previously reported candidate genes 
(Greenwood et al., 2005) revealed that none of these were differentially expressed in any of 
the cell culture models of in vitro prion infection utilized here. This discrepancy may result 
from differences in the experimental design of the various studies.  
 
4.3.2 The impact of the culture conditions onto the transcriptional 
response to prion infection 
The previous studies on the impact of prion infection on gene expression levels had 
compared subclones or separately passaged prion and uninfected control cells. These cells 
have been passaged over long periods or subcloning procedures have been performed prior 
to eventual biological comparisons. Immortalized cells can exhibit alterations in chromosomal 
composition, leading to profound heterogeneity of gene expression independently of prion 
infection, with gross differences in morphology or physiology of the cells (Doh ura et al., 
1995; Greenwood et al., 2005). Whereas this issue of clonal segregation of cells is discussed 
extensively by Doh-ura et al. with reference to the candidate gene subset presented in their 
study, subsequent publications describing differences in viability, apoptosis, iron regulation or 
gene expression profiling do not appear to have given much consideration to this alternative 
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explanation for their findings (Schätzl et al., 1997; Milhavet et al., 2000; Hetz et al., 2003; 
Fernaeus et al., 2005; Fernaeus and Land, 2005; Greenwood et al., 2005).  
The experiments reported here were designed with the specific goal of avoiding the potential 
pitfalls of genetic drifts within cultures. At the beginning of the experiment we split the 
respective parental cell lines (N2aPK1, CAD, GT1) into eight batches, four of which were 
independently infected with RML or mock-infected with non-infectious brain homogenate, 
respectively. This strategy was devised to generate true biological replicates, rather than 
mere technical replicates as would be the case when parental cell lines are passaged and 
then split into groups for comparison. Furthermore, we opted to use the cells at the earliest 
time point possible, i.e. the first point at which no residual inoculum is detected, but at which 
the cells show an acceptable degree of infection as measured by Western blot for PrPSc and 
a high infection ratio as measured by colony spot immunochemistry (Klohn et al., 2003). This 
procedure differs from prior studies in that of utilizing a more appropriate biological control: 
mock infection with healthy brain homogenate rather than uninfected cells. This appeared 
important since exposure to the detergent-like conditions of disrupted membranes, as in 
brain homogenate, was deemed likely to induce a transcriptionally visible stress response. In 
addition, and very importantly, we chose a procedure that would minimize the possible clonal 
segregation of cells of the same parental origin.  
Our transcriptional profiling data contradict the study by Greenwood et al. (Greenwood et al., 
2005). One might speculate that those results obtained with GT1 and N2a cells may be, at 
least partially, due to clonal differences. It is striking that, in that study, the overlap of 
differentially expressed genes in GT1 and N2a cells as a response to prion infection in that 
study was restricted to three genes (Selenbp2, Tmsb4x, H1F0), whereas the expression 
level of one (H1F0) was altered in an opposite manner. Furthermore, curing of ScN2a cells 
by pentosan polysulphate in the Greenwood study did not restore gene expression levels for 
all differentially expressed transcripts to the level of uninfected cells. The latter finding may 
be explained in many ways, but it is certainly compatible with the contention that the 
differential transcriptional response was due to clonal variations rather than to prion infection.  
In conclusion Greenwood et al. describe Selenbp2 as the only “true” differentially expressed 
gene in N2a and GT1 cells as a response to prion infection. The reason why we did not 
identify this candidate in our array study, or were able to confirm differential expression by 
qRT-PCR in three independent cell lines, might also be due to subtle differences between 
the present experimental design and that of the Greenwood study, such as the use of 3F4-
tagged murine PrP in addition to endogenous murine wtPrP, and the selection of stable 
clones using a Zeocine resistance marker. We are not able to assess the impact on these 
varieties to the observed differences between our and their studies.  
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4.3.3 Is a transcriptional response to prion infection in vitro to be 
expected? 
With the above experimental design and a combination of different statistical procedures, we 
did not find any statistically significant and/or biologically convincing, differentially expressed 
gene as a response to prion infection. In view of previous similar studies by others this was 
puzzling and also counterintuitive. But what reasons do we really have to expect changes in 
gene expression provoked by prion infection of neuronal cells? There is no evidence for 
impaired viability, morphology or physiology in most neuronal cell lines chronically infected 
with prions under “normal” cell culture conditions (Rubenstein et al., 1984; Butler et al., 
1988). Also, more recent studies show differences between prion infected and uninfected 
GT1 cells only after challenge with BOS, a gamma-glutamylcysteine synthetase inhibitor 
leading to reactive oxygen species induced stress (Milhavet et al., 2000), lactacystin 
(Kristiansen et al., 2005) or “in many but not all experiments” (Schätzl et al., 1997). 
Furthermore, caspase-12 and endoplasmatic reticulum stress were found to mediate 
neurotoxicity of pathological prion protein (Hetz et al., 2003), yet no differences in viability 
between ScN2a and N2a cells are observed under normal cell culture conditions in the 
absence of stressor. In conclusion many studies have shown that prion infected and 
uninfected cells do not differ in viability under normal culture conditions.  
It may be surprising to find no alterations in the transcriptional expression profile of cells after 
challenge with prions as a response to misfolded and aggregated protein in the cell. On the 
other hand it is very well possible that cells deal with prion infection by post-transcriptional or 
post-translational mechanisms which do not lead to differences in gene expression profiles. 
Similar studies in yeast also revealed no transcriptional changes after prion infection (Ross 
and Wickner, 2004). Lastly, it is conceivable that prion infection in cells in vitro has is entirely 
benign. 
In conclusion, we provide conclusive evidence that prion infection does not alter the mRNA 
profile of a broad range of neuronal cells in vitro. We conclude therefore that prion agents in 
cultured neuronal cells infected at high rates do not induce general or specific changes in the 
transcriptome. In view of the fact that prions represent a unique form of transmissible 
pathogens, it may be not be entirely surprising that that none of the cellular responses 
typically elicited in cells by infections with viruses or intracellular bacteria are observed in 
prion infected-cells. 
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4.4 Materials and Methods 
4.4.1 Cell culture (N2aPK1 cells, CAD cells, GT1 cells) 
The N2aPK1 subclone of mouse neuroblastoma N2a cells, which was selected for high 
susceptibility to prion infection, was kindly provided by Charles Weissmann and Peter Klöhn 
(MRC Prion Unit, The Institute of Neurology, London, UK) (Klohn et al., 2003). CAD cells, a 
subclone of the CNS catecholaminergic cell line Cath.a, were a gift of Dona Chikaraishi 
(Tufts University School of Medicine, Boston, Massachusetts, USA) (Qi et al., 1997). The 
mouse hypothalamic neuronal cell line GT1 was kindly donated by Ina Vorberg (Institute of 
Virology, Technical University of Munich, Germany). All cell lines were cultured in 
Optimem/10% FBS, Pen/Strep. N2aPK1 and CAD cells were split at confluency at a ratio of 
1:3 every three or 1:10 every four days. GT1 cells were split at confluency at a ratio of 1:3 
every four or 1:10 every five days. For RNA isolation and Western blot analysis, cells were 
grown to approximately 75% confluence. 
 
4.4.2 Prion infection of cell lines (N2aPK1RML, CADRML, GT1RML cells) 
Prion infection of cells was performed as reported previously (Klohn et al., 2003). Briefly, 
17’000 cells were seeded in each of six wells of a 96 well plate. After 16h of incubation cells 
were infected with a 10-2 dilution of 10% homogenate of mock CD1 brain homogenate or 
10% homogenate of RML infected brain homogenate, respectively. Independent infections 
were performed in quadruplicate to achieve four true biological replicates of Mock or RML 
infected cells. After three days of incubation cells were split three times (1:3) and 
subsequently a further three times (1:10). At that point six wells were pooled and cells were 
expanded in a T75 cell culture flask. At approximately 75% confluency cells were harvested 
for RNA isolation or split 1:10 to obtain material for Western blot analysis and clarification of 
the infection ratio. 
 
4.4.3 Assessment of the infection ratio in RML infected cells (N2aPK1RML, 
CADRML, GT1RML cells) 
To assess the proportion of prion infected cells in the N2aPK1RML, CADRML and GT1RML cells 
cultures we utilized the Elispot assay as described previously (Klohn et al., 2003). A dilution 
series of cells ranging from aliquots of 2000 to 8 cells per well was performed in a 96 well 
plate. The cells were transferred to a sterile Multi Screen Immobilon-P 96-well Filtration 
Elispot plate, activated with 70% ethanol (Millipore) and the cell suspension was filtered by 
vacuum filtration, followed by incubation for 1h at 50°C. Subsequently, 50 µl of proteinase K 
(PK; 0.25 µg/ml in lysis buffer [(50 mM Tris·HCl, pH 8.0/150 mM NaCl/0.5% sodium 
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deoxycholate/0.5% Triton X-100]) was added to each well, and the plates incubated for 90 
min at 37°C followed by removal of the proteinase K solution by vacuum filtration. The wells 
were washed several times with PBS, incubated with 2 mM PMSF for 10 min, and washed 
again several times with PBS. After incubation with 160 µl of 3 M guanidinium thiocyanate in 
10 mM Tris·HCl (pH 8.0) for 10 min, the filters were washed four times with PBS and 
incubated with 160 µl 5% TopBlock for 60 min. 50 µl of 0.4 µg/ml anti-PrP antibody POM1, in 
TBST/1% TopBlock, (Polymenidou et al., 2005) was added and the plates incubated at RT 
for 1h, followed by removal of the antibody solution. Next, the wells were washed eight times 
with TBST followed by addition of 50 µl of alkaline phosphatase-conjugated anti-mouse IgG1 
(Southern Biotechnology Associates; 1:4,500 in TBST/1% milk powder) was added for 1 h. 
Wells were washed eight times with TBST and dried at RT. 50 µl of alkaline phosphatase 
conjugate substrate (Bio-Rad) was added for 16 min followed by two washes with water. 
PrPSc positive cells were counted manually using an Olympus SZX12 stereo microscope. 
Mock control cells did not give rise to background. The infection ratio was calculated by 
division of total cells seeded by PrPSc positive spots counted per well. This was performed for 
three different dilutions. 
 
4.4.4 Western blot detection of PrPSc  
To confirm persistent prion infection, cells were screened for PrPSc content in the different 
independent biological replicates. For PrPSc detection, cells were grown on T75 flasks until 
approximately 75% confluent. Monolayers were rinsed with PBS, harvested and lysed in 
RIPA lysis buffer (10 mM Tris–HCl (pH 7.5), 100 mM NaCl, 10 mM EDTA, 0.5% (v/v) Triton 
X-100, 0.5% (v/v) (deoxycholate) followed by three freeze-thaw cycles. Following 
centrifugation at 1000xg for 5min the supernatant was removed and protein content 
quantitated by BCA-protein assay (BioRad) to allow equal amounts of protein to be applied 
the blot after either treatment with 20 mg/ml of proteinase K for 30 minutes at 37°C for PrPSc 
detection or no treatment (for PrPC detection). Proteins were subjected to SDS-PAGE (12.5% 
Bis-Tris gels, NuPAGE, Invitrogen). PrPC and PrPSc were detected using the mouse 
monoclonal antibody POM1 (1:10’000) followed by HRP-anti-mouse IgG1, and blots were 
developed with ECLplus according to the manufacturer’s instructions (Amersham 
Corporation).  
 
4.4.5 Preparation of labelled cRNA, microarray hybridization and data 
analysis 
Total RNA was extracted from all samples using TRIzol (Invitrogen Life Technologies) 
according to the manufacturer’s instructions. RNA was subjected to a further clean-up step 
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using RNeasy mini columns (Qiagen). RNA quality was assessed by Agilent 2100 
Bioanalyzer.  
Processing of 15µg of total RNA was continued to cDNA synthesis using a cDNA Synthesis 
kit (cat. no. 11917-010; Invitrogen Life Technologies) and primer 5'-
GGCCAGTGAATTGTAATACG ACTCACTATAGGGAGGCGG(dT)24–3'. Biotin-labelled 
cRNA was synthesized, using Enzo BioArray HighYield RNA transcript labelling kit (T7) 
(Enzo Biochem), purified using RNeasy mini columns, quantified by spectrophotometry, and 
quality was assessed again by Agilent 2100 Bioanalyzer. Labeled cRNA (15 µg) was 
fragmented in 40 mM Tris-acetate, 100 mM KOAc, 30 mM MgOAc, pH 8.1, at 95°C for 35 
min followed by hybridisation to Affymetrix MOE430A and MOE430B chips. All hybridizations 
were conducted for 16 h at 45°C at 60 rpm. After hybridization chips were washed and 
conjugated with streptavidin-PE according to the manufacturer’s instructions on the 
Affymetrix GeneChip Fluidics Station 450 with and scanned using the Affymetrix GS Scanner 
2500 in conjunction with Affymetrix Microarray Suite 5.0 software. 
All experiments were performed in biological triplicates. After hybridization and scanning, 
probe cell intensities were calculated with the MAS5.0 algorithm of the Affymetrix GCOS 
software (Santa Clara, CA). Summarization and normalization of intensities for the respective 
probe sets were carried in two independent approaches using two different algorithms. For 
the first approach the MAS5.0 algorithms was employed as detailed in (Hubbell et al., 2002), 
present and absent calls were calculated by application of a signed-rank call algorithm (Liu et 
al., 2002). Using the Genespring 7.3 software (Agilent, CA) results were median per-chip and 
median per-gene normalized. For the second approach, the GCRMA summary algorithm 
(Wu and Irizarry, 2004) as implemented in Genespring 7.3 was used to generate and 
normalize raw gene expression data from probe intensities. Independently of each other, 
genes were filtered out from the two lists of normalized expression values in Genespring 7.3 
when not showing an expression value of at least 50 in all replicate measurements of at least 
one condition. Subsequently, the significance of 1.5 fold changes in expression was tested in 
Genespring by an equal-variance t-test with a significance threshold of p< 0.05. Data sets 
have been deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/); 
accession number GSE7229. 
 
4.4.6 Quantitative RT-PCR 
cDNA of mock and RML infected cells was synthesized using the Quantitect reverse 
transcription kit (Qiagen, Switzerland) according to the manufacturers description. As 
negative controls, 1 µg of each RNA was processed without addition of reverse transcriptase. 
Complete removal of contaminating genomic DNA was confirmed by performing β-actin PCR 
on all samples. Specific primers (supplementary table 4.1) were designed using primer3-
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Quantitative real time 
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PCR analysis (Applied Biosystems Sequence Detection System 9330, Rotkreuz, 
Switzerland) using SYBR Green (Qiagen) was performed according to manufacturer’s 
instructions. Briefly, reactions consisted of 10 µL of cDNA diluted 1:100 out of the primary 
RT-reaction, 0.5 µM forward and reverse primer, 12.5 µL of Sybr Green master mix and 2.25 
µL water. Default PCR conditions of 40 cycles of 15’ seconds annealing at 60°C and 1 min 
denaturing at 95°C were utilized. All primers were assessed for efficiency using SybrGreen 
conditions prior to being utilized in qPCR studies. Gene expression levels were assessed in 
four biological replicate samples (and 4 technical replicates of each) from each group using 
the ΔΔCT method and normalization to Gapdh. Standard deviations were calculated using 
the values of the biological replicates of mock-infected and RML-infected cells. 
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Supplementary Table 4.1 Primer sequences used in qPCR analysis of 
candidates.  
Affymetrix ID Gene name fw primer rev primer 
1415834_at dual specificity phosphatase 6 5' caccaaaattgtgggttcact 5' cacgaacatcatggagcaag 
1416147_at heat shock protein 4 5' ttgaatgggacaggatgaga 5' gtagactggccccaggagta 
1416196_at laminin receptor 5' ctgctgctgagaaggctgtg 5' agctgctgaccaatcctcag 
1416239_at Argininosuccinate synthetase 1 5' tcgcagaggctcgtatacac 5' ctcatagtcgccctgcacgt 
1416516_at Fascin homolog 1 5' cctgccctgttggttgta 5' aggtgtctggagacgtggag 
1416686_at procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 5' tctcaggggaagctcatgtc 5' aggaacaggctcaaaaacca
1416759_at NEDD9 interacting protein with calponin homology and LIM domains 5' ggctacatgaatcgggaaga 5’ aggtacagcccttgtgatgg 
1416922_a_at BCL2/adenovirus E1B 19kDa-interacting protein 3-like 5' tgagaagcaggcttcgtttt 5' tgtaaggaatgacgccagtg 
1417365_a_at calmodulin 1 5' caacgaagtggatgctgatg 5' tccgtcgccatcaatatctg 
1417580_s_at Selenium-binding protein 2 5' agcactggctcacgagcttc 5' cagagatgctgctctacaga 
1417835_at murinoglobulin 1 5' agtgtgtcaggggaaggatg 5' cagcaatcaccatgttggag 
1417976_at adenosine deaminase 5' aggggacttgacaatcatgc 5' cgcttctgcaggaaagagac 
1418175_at vitamin D receptor 5' ctgggaggaaaagacagcag 5' ggtttggactcctcccctac 
1418539_a_at protein tyrosine phosphatase, receptor type, E 5' gcctccgtaagacacagagc 5' agtgaccaagagacgcacct 
1418626_a_at clusterin 5' gtgaagctgtttgactctga 5' acactcctacatataggaag 
1418709_at cytochrome c oxidase, subunit VIIa 1 5' aaaaccgtgtggcagagaag 5' tttgtccaagtcctccaagc 
1418835_at pleckstrin homology-like domain, family A, member 1 5' tcatcacagttgcaggaagc 5' ctttttctttttggcgagga 
1419093_at tryptophan 2,3-dioxygenase 5' cagccgagtacagtgacagc 5' cctcctaatcgctcaccatc 
1419157_at SRY box containing 4 5' agcattggcatggagaaact 5' gctactcccagcacatctcc 
1419985_s_at DNA segment, Chr 11, ERATO Doi 461, expressed 5' cccaatcccagatcatcagt 5' ggctagatgtggtgggacat 
1420376_a_at histone family 3 B 5' tgaagaagcctcaccgctac 5' ggcgtggatggcacacagat 
1420664_s_at protein C receptor, endothelial 5' agctcatatgacgccaaaca 5' cccccaagtctatggtctga 
1420737_at polyamine modulated factor 1 binding protein 1 5'  acccgaggatctgtgtcaag 5' ggggactcaatgtcctctga 
1420760_s_at N-myc downstream regulated 1 5' ggaacttgcttccctctcct 5' tgactcccaacgatcaagtg 
1421924_at Solute carrier family 2 5' cctctgctaggtggagcttg 5' acctcacacctttccattgc 
1422136_at kinase interacting with leukemia-associated gene (stathmin) 5' tgtggccaccctttatttgt 5' agagcatccagtgccagcta 
1423281_at Stathmin-like 2 5' gaaccttccaacgtgctgat 5' taatgcagcaaccagctcac 
1423748_at RIKEN cDNA D530020C15 gene 5' ggaaaacatgctttgccact 5' taaggatctgggctgaccac 
1423946_at PDZ and LIM domain 2 5' gaaggggtgatagcaggtga 5' ccatacgctttcgtgtcaaa 
1424492_at Transient receptor potential cation channel,subfamily C, member 2 5' tgggcaacagactgacagag 5' ccatcaaggccatctcctaa 
1424698_s_at grancalcin 5' aaacagaagccacaccatga 5' atgcaccgttgtttgaactg 
1425140_at lactamase, beta 2 5' acatggtgctggaaaaggag 5' aatagaaacggcccccatag 
1426092_a_at tripartite motif protein 34 5' ctggaccctgggagtttaca 5' ctgtgccctcttcacagtca 
1426155_a_at odd-skipped related 2 (Drosophila) 5' ggcagaacttctagcgaagc 5' ggtttggaagggggtagtgt 
1427026_at myosin, heavy polypeptide 4, skeletal muscle 5' gagctgaagaaggagcagga 5' gcttacgaagacccttgacg 
1428517_at WD repeat and FYVE domain containing 3 5' ttggcttcattgctcatctg 5' tcacacttgcacgctacaca 
1428767_at RIKEN cDNA 1810036L03 gene 5' tgtctggtgcttgactctgg 5' ggattcttttcatcccagca 
1428774_at 
12 days embryo male wolffian duct includes 
surrounding region cDNA, RIKEN full-length 
enriched library, clone:6720429C22 
product:unknown EST, full insert sequence 
5' ctgccagaagagcaaaggag 5' tctcagtgaagtcccaagca 
1429146_at 
Adult male testis cDNA, RIKEN full-length enriched 
library, clone:4931406B08 product:unknown EST, 
full insert sequence 
5' tttcctttggccatgtcttt 5' agagagcctttccacagtgc 
1430584_s_at Carbonic anhydrase 3 5' atgtgaaaaggcagggtcac 5' cccatgaatgcttcaattcc 
1432205_a_at RIKEN cDNA C130038G02 gene 5' ctcctctggaccctcctctc 5' taccaggatggtcttgcaca 
1432638_at RIKEN cDNA 2810002N01 gene 5' tgggaacctgtctgagatcc 5' gtccgacttcatgtccaggt 
1433649_at amine oxidase, flavin containing 1 5' cactcttctcccctgtcaaag 5' agcacacaaagctcaagtgc 
1433855_at 
Transcribed sequence with strong similarity to 
protein ref:NP_065580.1 (M.musculus)  
hypothetical protein, I54 [Mus musculus] 
5' gcttgtcagttgtgcaggaa 5' atgctcgctagctgtggttt 
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Affymetrix ID Gene name fw primer rev primer 
1434099_at RIKEN cDNA A830037N07 gene 5' ccctttttgatggctgtacg 5' ctcactttccctcttcagca 
1434338_at 
18-day embryo whole body cDNA, RIKEN full-
length enriched library, clone:1110029E03 
product:unknown EST, full insert sequence 
5' atttggatcgtggcagtagc 5' acagccctatcagccttcct 
1434969_at CDNA clone IMAGE:5683160, partial cds 5' cgcaccgtctagttcatgttt 5' gatttgccgttgagaagctc 
1435033_at RIKEN cDNA 9330140K16 gene 5' ccccagtgcacttgtaacct 5' cccagctacagggaactgtc 
1435109_at RIKEN cDNA 3010001K23 gene 5' gtttgctgctttgacccatc 5' accttgcagaagccactctc 
1435483_x_at mitochondrial folate transporter/carrier 5' ttgaaatttggggacaatgaa 5' acctgggagatctgaattgc 
1435543_at adenomatosis polyposis coli 5' ccagggtttctttgcagcta 5' cctgggtttacagaagtcacg 
1435822_at 
16 days neonate heart cDNA, RIKEN full-length 
enriched library, clone:D830012I24 
product:unknown EST, full insert sequence 
5' tctgccatacaaaggaatgaaa 5' gacccttgttcaaccttttcc 
1436004_at ubiquitin specific protease 27, X chromosome 5' gatggatggatggatggaac 5' cttcctcaacagggctacca 
1436195_at cDNA sequence BC046404 5' ttatccaccaaccagcacaa 5' tggcctgtaaggctgttctt 
1436448_a_at prostaglandin-endoperoxide synthase 1 5’ gaaggtcctgttcctggtca 5' gagtccatctgttccctcca 
1436907_at neuron navigator 1 5' cagagctgggtgttccaact 5' gaggcagttggaatggaaga 
1437414_at RIKEN cDNA 4933431C08 gene 5' gcaaggtgattgacaccatct 5' aatctgaaaggccccaaaat 
1437862_at RIKEN cDNA 2610015J01 gene 5' aacctggagggcagaagagt 5' cgagtggcaagctactgact 
1438083_at Hedgehog-interacting protein 5' gagtgaccagggcaggtatc 5' tgccaacatacatgctgagag 
1438310_at 
10 days neonate cerebellum cDNA, RIKEN full-
length enriched library, clone:B930095L19 
product:unknown EST, full insert sequence 
5' tttgccattgaaatggacct 5' cattaacaaagccacccaaa 
1438642_at 
AV278176 RIKEN full-length enriched, adult male 
testis (DH10B) Mus musculus cDNA clone 
4933400E08 3', mRNA sequence. 
5' ttgagttttgcctcaacacg 5' gggatgtgaggtatggatgg 
1438858_x_at histocompatibility 2, class II antigen A, alpha 5' gggcaccatcttcatcattc 5' acagcctcagggtcaagaga 
1440739_at vascular endothelial growth factor C 5' gggaagaagttccaccatca 5' ccatggtcccacagagtctt 
1440966_at axotrophin 5' gttggcgttgctttgttttt 5' ggcttattaccgctgcatgt 
1441894_s_at 
BB071890 RIKEN full-length enriched, 15 days 
embryo male testis Mus musculus cDNA clone 
8030499N14 3' similar to AF236099 Mus musculus 
GRP1-associated scaffold protein GRASP mRNA, 
mRNA sequence. 
5' ctttctgccctcccctaaac 5' tccatcgtggatctcctctc 
1442146_at 
H3079F10-3 NIA Mouse 15K cDNA Clone Set Mus 
musculus cDNA clone H3079F10 3', mRNA 
sequence. 
5' agggcaggaggatcagaaat 5' gtgtgtgtgcttgtgtgtgc 
1446550_at G1 to phase transition 1 5' ggcactaaagcgacctgaag 5' cacgccattcagaaaaagtct 
1447139_at B-cell CLL/lymphoma 7C 5' cgtgtctccctgtgatgtgt 5' cgcagacgtgacttgtccta 
1448364_at cyclin G2 5' gcacctgtgtgaaagcagaa 5' ccatcaccacacagaattgc 
1448623_at RIKEN cDNA 2310075C12 gene 5' gctgctgagaaagccacact 5' ccccaactcagtggaaatgt 
1449275_at RIKEN cDNA 2310038H17 gene 5' ctcccatggtgcagtctgtat 5' ctttggctggggacgtaata 
1450459_at RIKEN cDNA 2010106G01 gene 5' tgtaccaggcctgttgattg 5' tgctgcctttccagaacttt 
1451110_at EGL nine homolog 1 (C. elegans) 5' cattgttggcagaaggtgtg 5' ggggttaacggtcctgattt 
1451149_at phosphoglucomutase 2 5' gcccttgtctccctacatca 5' gcagatgggagatgcaaaat 
1451385_at RIKEN cDNA 2310056P07 gene 5' ttgatgctgcgaagaacaag 5' gccttactcctgggttttcc 
1451386_at biliverdin reductase B (flavin reductase (NADPH)) 5' gctgaaatacgtggcagtga 5' ccacctaggtcagggtgcta 
1451461_a_at aldolase 3, C isoform 5' attgctgtacccgagaccac 5' gagtcagggctggagttcac 
1452444_at N-ethylmaleimide sensitive fusion protein attachment protein beta 5' ctctgcctcccagttcagtc 5' tgcgggattacaagtgttca 
1452565_x_at 
envelope polyprotein; Mouse endogenous 
mammary tumor virus (MMTV) RNA, env gene and 
right LTR. 
5' tctgctgcaaacttggcata 5' tgaaggacaaagtcggtgtg 
1452670_at myosin, light polypeptide 9, regulatory 5' accctacaaggagggaccac 5' ggtgctgagacaactccaca 
1453465_x_at RIKEN cDNA 4930402H24 gene 5' gacaaggccaggtgtgtttt 5' ggaaagcacaggtttattcca 
1455099_at 
BB414982 RIKEN full-length enriched, 7 days 
embryo Mus musculus cDNA clone C430040E04 
3', mRNA sequence. 
5’ gtccctgatgctgcttcttc 5' cattaaggctggggaaactg 
1455210_at zinc fingers and homeoboxes protein 2 5' gctgaaatcttgccaaaagc 5' cctcagctggcttctcaact 
1455403_at RIKEN cDNA 4932703L02 gene 5' tgtacctgaagatcattgtgga 5' tgcaattccagctgtgtttc 
1456661_at Transcribed sequence with moderate similarity to protein pdb:1JZ5 (E. coli) B Chain B, E. Coli 5' acagcctgcatgaatcagtt 5' ggaagaatttgccacatggt 
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Affymetrix ID Gene name fw primer rev primer 
1456930_at hypothetical protein 9530003A05 5' tctgtgtcgatgtgggatgt 5' ttcaatgttgcctgaagcag 
1457004_at 
BB698378 RIKEN full-length enriched, 2 days 
neonate sympathetic ganglion Mus musculus 
cDNA clone 7120499J15 3', mRNA sequence. 
5' tccgatacccagcctacttg 5' atggaaaacgcaaacgagtc 
1458173_at 
Transcribed sequence with moderate similarity to 
protein pir:S12207 (M.musculus) S12207 
hypothetical protein 
5' ctacgtgattctccaggaactt 5' cccaggattttccattcaag 
1458232_at dickkopf homolog 1 (Xenopus laevis) 5' tggttggtgcttttgcctat 5' aatcacttgcttgggcattc 
1459882_at ASF1 anti-silencing function 1 homolog A (S. cerevisiae) 5' accccatatcctctggctct 5' ctcctgtgcatcatcaccat 
1460214_at Purkinje cell protein 4 5' tgatatcgacatggatgcac 5' tattgagtgaggatgacttc 
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5 miR-142-3p elevates PrPSc levels in vitro 
5.1 Introduction 
5.1.1 Outline of this work 
The conformational conversion of PrPC to the pathogenic state of PrPSc is central to the 
protein-only hypothesis and therefore prion diseases in general. However, whilst several in 
vitro and in vivo studies suggest involvement of additional cellular chaperones (Taraboulos et 
al., 1995; Telling et al., 1995; Bosque and Prusiner, 2000; Saborio et al., 2001; Vorberg et 
al., 2004; Chesebro et al., 2005; Deleault et al., 2005) it is currently unclear whether this 
conformational change occurs exclusively via PrPC and PrPSc interaction. Importantly, it is 
known that interference with PrPC:PrPSc interaction results in rapid clearance of PrPSc from 
cells in vitro and successive “curing” of infected cultures , implicating an efficient PrPSc 
clearance mechanism in vitro and in vivo (Enari et al., 2001; Heppner et al., 2001b; Peretz et 
al., 2001; Meier et al., 2003; Mallucci and Collinge, 2005; Weissmann and Aguzzi, 2005). 
However, the molecular mechanisms underpinning the biogenesis of PrPSc and its clearance 
in vitro remain to be defined. In order to elucidate putative regulators of the PrPC:PrPSc 
conversion process and/or of PrPSc clearance we employed a phenotype-driven screen of a 
library of 266 synthetic precursor miRNAs in an in-house developed assay in order to identify 
candidates that significantly alter PrPSc levels in N2aPK1RML cells chronically infected with 
prions, without affecting endogenous PrPC levels. We determined that overexpression of 
miR-142-3p consistently resulted in elevated PrPSc abundance autonomous of endogenous 
PrPC expression levels in both a cell-type and prion strain independent manner. Subsequent 
high density oligonucleotide arrays in combination with bioinformatic analyses identified a 
core set of 57 transcripts which are robustly differentially expressed in N2aPK1RML cells as a 
result of overexpression of miR-142-3p. Of these, six candidate mRNAs determined to be 
downregulated were predicted to be direct target mRNAs of miR142-3p. Whether 
downregulation of any of these six candidate mRNAs independently results in elevated PrPSc 
levels, thereby potentially representing a putative modulator of PrPSc abundance, is currently 
under investigation. 
 
5.1.2 miRNAs as possible regulators of PrPSc levels 
MicroRNAs (miRNAs) are essential regulators of gene expression and control diverse 
biological processes such as differentiation and development as well as growth and 
metabolism in plants and animals (Bartel, 2004). Furthermore, miRNAs have been 
suggested to exert substantial effects on viral evolution and may continue to influence the in 
vivo tropism of viruses (Cullen, 2006). Like transcription factors, miRNAs typically regulate 
several targets, with vertebrate miRNAs estimated to regulate the expression of on average 
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200 mRNAs (Krek et al., 2005). However, in contrast to transcription factors, which control 
gene expression by binding to DNA, short noncoding miRNAs exert their biological effects of 
abrogating protein synthesis by binding to partially complementary sites primarily in the 3’ 
untranslated region of target mRNAs, thereby leading to either inhibition of translation of 
mRNA targets or degradation of mRNA (He and Hannon, 2004). Frequently, several miRNAs 
are encoded in polycistronic clusters. These are transcribed as long primary transcripts (pri-
miRNAs) and are then processed further in the nucleus by the RNase III enzyme Drosha into 
small stem-loop structures termed precursor miRNAs (pre-miRNAs) (Seitz and Zamore, 
2006). These pre-miRNAs are exported and processed in the cytoplasm by the 
endonuclease Dicer into mature miRNAs of 19-22 nt length (Seitz and Zamore, 2006). The 
mature miRNA is incorporated into a protein complex that is similar, if not identical, to the 
RNA induced silencing complex (RISC) that supports RNA interference (RNAi) (Hutvagner 
and Zamore, 2002). In vitro, the biological effects of miRNA abundance can be mimicked by 
artificial synthetic pre-miR miRNA precursors (pre-miRs). Pre-miRs are small, chemically 
modified double-stranded RNA molecules similar to, but not identical to siRNAs and can be 
introduced into the cell by transfection, with pre-miRs resulting in mimicked overexpression 
of particular miRNAs. In contrast to pre-miRs, Antago-miRs are siRNA molecules 
complementary to existing miRNAs sequestering particular endogenous miRNAs, therefore 
abrogating their availability for target mRNA binding and therefore acting as miRNA 
antagonists.  
We considered the fact that miRNAs regulate several mRNAs as a desirable effect in a 
phenotype driven screen. It seems plausible that each miRNA targets mRNAs which act in 
concert in a functional pathway. It is likely that the diversity of mRNA targets of any particular 
miRNA is a highly specific and regulated phenomenon in order to exclude, or at least 
minimise, off-target effects.  
We therefore investigated whether modulation of miRNA abundance can regulate PrPSc 
propagation/biogenesis or PrPSc clearance in vitro. Identification of such miRNAs may prove 
invaluable in elucidation of the target mRNAs, and therefore pathways, involved in these 
processes. We reasoned that, at least in the first instance, modulation of phenotype via 
miRNA expression levels would represent an attractive strategy compared to genome-wide 
siRNA/shRNA screens, not least (a) the reduced number of synthetic molecules to screen 
and (b) the modulation of cascades of expression of functionally related genes mediated by 
each molecule compared to one-molecule, one target approach that could be achieved with 
alternative strategies. As such, we screened a library consisting of 266 synthetic murine 
precursor miRNAs in a murine neuroblastoma cell line (N2aPK1RML) chronically infected with 
the laboratory scrapie strain RML. We altered and optimised the endpoint readout of the 
Scrapie Cell Assay (SCA) (Klohn et al., 2003), which allows detection of infected cells by 
immunocytochemistry in a 96 well format such that we were able to perform this phenotype-
driven screen in the laboratory with existing equipment and use luminometry to identify either 
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increased or decreased PrPSc levels in vitro as a result of overexpression of any of these 
synthetic pre-miRs. 
We identified one such miRNA (miR-142-3p) as a strong modulator of PrPSc levels in 
N2aPK1RML cells. Overexpression of miR-142-3p resulted in elevated PrPSc levels 
independently of endogenous PrPC expression, cell number and viability, indicating a direct 
impact of miR-142-3p on PrPSc biogenesis. Furthermore, this effect of miR-142-3p held true 
in both a cell-type and prion-strain independent manner. The implications of this potentially 
indicating a target pathway which either promotes PrPSc accumulation directly or results in 
abrogation of the putative PrPSc clearance mechanism. The target mRNAs of miR 142-3p 
which mediate this process are currently under investigation. 
 
5.2 Results 
5.2.1 Quantitation of PrPSc in a SCA/96 well format  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Cell density titration and dynamic range of PrPSc measurement by luminometry. A and B) 
Denoted numbers of either N2aPK1RML cells or N2aPK1Mock cells were applied into an Elispot plate with 
subsequent PK digestion, labelling of the remaining PrPSc with the PrP binding antibody POM1 followed by a 
secondary HRP labelled antibody. After incubation with a luminescence ELISA substrate the signal was either 
detected via an imaging device (VersaDoc) (A) or signal intensities were measured with a plate reader for 
chemiluminescence (B). C) N2aPK1RML cells were mixed with N2aPK1Mock cells in the denoted ratios. D) 
Corresponding mixtures of infected and uninfected cells (in total 20.000) were applied into a Elispot plate and 
processed as described in (A). After incubation with a luminescence ELISA substrate the signal was either 
detected via an imaging device (VersaDoc) (D) or signal intensities were measured with a plate reader for 
chemiluminescence (E). E) The plot shows a broad linear correlation of the relative light units against the number 
of infected cells. 
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The Scrapie Cell Assay (SCA) allows detection and quantification of infected cells by in situ 
immunocytochemistry in a 96 well format (Klohn et al., 2003). In the SCA, prion infected 
N2aPK1 cells are filtered onto a membrane of an enzyme-linked-immunospot (Elispot) plate 
and subjected to lysis. Endogenous PrPC is digested by proteinase K (PK) and remaining PK 
resistant PrPSc is subsequently detected by an anti-PrP monoclonal antibody (POM1) 
followed by an alkaline phosphatase coupled secondary antibody. 
The quantification of positive spots, directly proportional to the number of infected cells is 
achieved by an Elispot reader, an automated microscope imaging device with corresponding 
software to identify the spots. As a consequence of lacking such a quantification system we 
sought to develop a modification of this readout to enable accurate quantification of relative 
PrPSc levels. Therefore, we established a luminometry based readout utilising a horseradish-
peroxidase (HRP) labelled secondary antibody (Figure 5.1) and subsequent luminometry. 
The broad dynamic range of PrPSc measurement by luminometry as well as the observed 
linearity of the correlation between cell numbers and relative light units demonstrates the 
applicability of this modified detection as a readout for the screen as a measure for relative 
PrPSc levels (Fig. 5.1).  
 
5.2.2 Primary screen of 266 miRNAs for the ability to alter PrPSc levels in 
N2aPK1RML cells 
Here, we screened 266 pre-miRs (see also Table 5.3 in Materials and Methods) for their 
ability to modulate PrPSc levels in a murine neuroblastoma cell line that was chronically 
infected with RML prions as an in vitro model for prion propagation (herein designated 
N2aPK1RML, whereas Mock infected control cells are hereby denoted N2aPK1Mock; see also 
chapter 4 of this thesis). As a source of miRNAs we used a library of 266 synthetic precursor 
miRNAs offered by Ambion. N2aPK1RML cells were transfected with 20nM of the 
corresponding library or control pre-miR and incubated for three days (Figure 5.2). Whilst it 
had been demonstrated that signal intensity correlates well with the number of infected cells 
in each well of the assay plate, it is very possible that individual pre-miRs alter the cell 
number or viability of the transfected N2aPK1cells We therefore decided to utilise 
mitochondrial activity as a measure of viability and a surrogate marker for cell number and 
normalized the resultant PrPSc signal to the viability signal. To achieve this, after three days 
of culture the pre-miR treated cells were split and 50% used for PrPSc detection in our 
luminometry SCA and the remaining 50% used for viability measurement. 
As controls, each screening plate contained N2aPK1Mock cells as a negative control for PrPSc 
detection, Lipofectamine only as negative control for the transfection, pre-miR negative 
control treated cells (non-biological scrambled miRNA), and siRNA1826 targeting Prnp 
mRNA as a control for successful accomplishment of the transfection and readout. 
Furthermore, we treated the N2aPK1Mock cells with fluorescently labelled control siRNA 
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(Block-it) to allow a quick estimation of the transfection efficiency. To level out technical 
variability we performed each screening plate in quadruplicate. Figure 5.3A exemplifies the 
impact of the first tested 84 pre-miRs on PrPSc levels and the viability of N2aPK1RML cells 
three days after transfection. Normalization of the PrPSc signal to viability is shown in Figure 
5.3B. N2aPK1Mock cells showed only background signal level, whereas PrPSc levels of 
Lipofectamine only treated cells (representing unaltered PrPSc levels) were set as 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Schematic of the screen for pre-miRs altering PrPSc levels in N2aPK1 cells. N2aPK1RML cells 
were transfected with 20nM of the corresponding miR or controls for three days. PrPSc levels were assessed by 
Elispot assay. 50% of the cells from a well of a 96 well plate were transferred to new 96 well plate and viability 
was determined by MTS assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega). The 
remaining 50 % of the cells were transferred to a Elispot plate. After cell lysis, PrPC was digested by proteinase K 
(PK) and epitopes on PrPSc were exposed by incubation with guanidinium thiocyanate (GTC). PrPSc was detected 
by the anti-PrP antibody POM1 (Polymenidou et al., 2005) in combination with horseradish-peroxidase-
conjugated anti-mouse IgG1. After addition of enhanced chemiluminescence substrate signal intensity was 
measured in a microplate spectrofluorometer. The PrPSc signal as well as the viability of transfection agent 
(Lipofectamine) only treated cells were set as one and PrPSc levels of the samples were normalized to this. 
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Figure 5.3: 48 candidates passed the primary screen for pre-miRs altering PrPSc levels in N2aPK1RML cells.  
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Figure 5.3: 48 candidates passed the primary screen for pre-miRs altering PrPSc levels in N2aPK1RML cells. 
A) 72 hours after transfection with pre-miRs from the library or controls PrPSc levels of N2aPK1RML cells were 
determined and normalized to viability (for a flow-chart of the screen workflow see also Figure 2). PrPSc levels and 
viability of transfection agent only treated cells were set as one (Mock transfection; light orange). N2aPK1Mock 
cells were used as a negative control for the PrPSc measurement (Mock brain cells; blue), whereas a siRNA 
targeting PrP mRNA served as a control for successful transfection and readout (PrP1826; red). Numbers on the 
x-axis represent miRNA IDs with pre-miRs from the library starting from column 5 (see also Table 5.3 in Materials 
and Methods). The PrPSc to viability ratio of the pre-miR treated cells is given as arithmetic mean plus standard 
deviation and results from four different 96 well plates. As a cut-off for the primary screen we set the bottom and 
the top of the standard deviation of the transfection agent only and the pre-miR negative treated controls. Pre-
miRs that changed PrPSc levels to an extent that its standard deviation did not overlap these boarders were 
regarded as candidates and tested in further screens (green), whereas pre-miRs missing this criteria are labelled 
in grey. B) Viability measurements of pre-miR treated N2aPK1 cells. Here, the potential to change viability in 
N2aPK1RML cells of the pre-miRs tested in screen plate 1 is shown. Only one pre-miR reduced viability more than 
50%. C-E) Results of screening plates two to four as PrPSc to viability ratios. As a result of the primary screen we 
identified 48 candidate pre-miRs to change PrPSc levels in N2aPK1RML cells. 
 
As a cut-off for the primary screen we utilised the standard deviation of the results obtained 
for the Lipofectamine only and the miR negative control treated controls. Every pre-miR that 
altered PrPSc levels to an extent that its standard deviation does not overlap these borders 
was regarded as a candidate which passed the primary screen and was further investigated 
in additional screens. Three day treatment of N2aPK1RML cells with siRNA siRNA1826 
targeting Prnp mRNA yielded a reduction of PrPSc levels of more than 40%, again showing 
the rapid clearance of PrPSc levels possible by reduction of endogenous PrPC expression. 
Corresponding results for screen plates two to four testing the remaining 162 pre-miRs are 
depicted in Figures 5.3C-E. As a result of the primary screen we identified 48 candidate pre-
miRs that change PrPSc levels in N2aPK1RML cells to levels outside the boundaries stipulated 
above. 
 
5.2.3 Secondary screen of 48 candidate miRNAs for the ability to alter 
PrPSc levels in N2aPK1RML cells 
Since several of the candidate pre-miRs that passed the primary screen altered PrPSc levels 
only moderately, we repeated measurement of this restricted set of 48 candidate pre-miRs in 
a secondary screen under conditions identical to those utilised for the primary screen (Figure 
5.4). 
This secondary screen resulted in 19 candidate pre-miRs showing similar results compared 
to the first screen, whereas 28 pre-miRs did not alter the PrPSc levels enough to pass the 
criteria set for the primary screen. One pre-miR that had decreased PrPSc levels in the 
primary screen showed elevated PrPSc levels in the secondary screen (mmu-let7c). 
Candidates in the secondary screen which did not replicate the data obtained in the primary 
screen were excluded form further analyses. In summary 19 candidates passed the 
secondary screen. 
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Figure 5.4: 19 candidates passed the secondary screen for pre-miRs altering PrPSc levels in N2aPK1RML 
cells. The screen for altering PrPSc levels normalized to viability was repeated for the 48 candidates passing the 
primary screen. Again, transfection agent only treated cells were set as one and N2aPK1Mock cells, pre-miR 
negative control and siPrP treated cells were used as controls. 19 of the 48 candidates showed the same 
behaviour as in the primary screen, whereas 28 candidates did not change PrPSc levels high enough to pass the 
screen. One pre-miR elevated PrPSc levels in the secondary screen in contrast to reduced levels in the primary 
screen (mmu-let7c) and was therefore not considered further. For miRNA IDs see also Table 5.3 in Materials and 
Methods. 
 
5.2.4 The majority of the candidates from the secondary screen also 
alter PrPC levels in uninfected N2aPK1 cells 
Since it is possible, that altered PrPSc levels may result from altered PrPC levels we 
investigated the impact of the 19 candidate miRNAs on endogenous PrPC levels in N2aPK1 
cells by ELISA (Figure 5.5). For all but three candidates (miR-1, miR-142-3p, and miR-380-
3p), overexpression of these pre-miRs resulted in reduction of endogenous PrPC levels, 
thereby indicating that observed reductions in PrPSc levels observed for these in primary and 
secondary screens likely resulted directly from reduced endogenous PrPC levels. In contrast, 
elevated PrPSc levels after overexpresssion of miR-380-3p seem to be a result of elevated 
PrPC levels. Whilst these candidates could certainly give insights into the regulation of PrPC, 
our primary focus was to elucidate those pre-miRs which modulated PrPSc levels 
independently of cell number and endogenous PrPC levels. Further efforts were therefore 
directed at miR-1 and miR-142-3p which alter PrPSc levels without altering PrPC levels, 
potentially representing direct modifiers of PrPSc biogenesis.  
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Figure 5.5: Changes in PrPSc levels correlate to PrPC alterations after treatment with all but two candidate 
pre-miRs. The screen for altering PrPSc levels normalized to viability was repeated for the 48 candidates passing 
the secondary screen. In addition PrPC levels were measured by ELISA and normalized to viability in uninfected 
N2aPK1 cells transfected with candidate pre-miRs for three days. PrPSc/C was normalized to ransfection agent 
only treated cells. For miRNA IDs see also Table 5.3 in Materials and Methods.  
 
5.2.5 miR-142-3p overexpression results in elevated PrPSc levels in 
N2aPK1RML cells 
First, we intended to verify the effect of miR-1 and miR-142-3p on PrPSc and PrPC levels in 
N2aPK1RML cells in a more focused screen (Figure 5.6A and B). However, surprisingly miR-1 
did not alter PrPSc levels in these further experiments and neither repetition experiments with 
miR-1 from the original library nor newly purchased miR-1 had an effect on PrPSc levels in 
N2aPK1RML cells (data not shown). Therefore, we concentrated further efforts on miR-142-3p 
and investigated the effect of the Antago-miR-142-3p of miR-142-3p (Figure 5.6 A and B). 
Since, Antago-miR-142-3p is a siRNA designed to silence endogenous miR-142-3p, 
endogenous expression of miRNA 142-3p is a prerequisite for any antagonistic action 
exerted by Antago-miR-142-3p to be of relevance. We did not observe any effect of in vitro 
introduction of Antago-miR-142-3p on PrPSc levels in N2aPK1RML cells. While performing 
these experiments Landgraf et al., published that miR-142-3p is not expressed in N2a cells 
(Landgraf et al., 2007). Therefore, whilst reduction of PrPSc levels as a result of sequestration 
of endogenous miRNA-142-3p would have provided further convincing evidence of biological 
relevance, the absence of an effect of the Antago-miR-142-3p on PrPSc levels in N2aPK1RML 
cells is not surprising in this instance.  
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In addition to the results of the initial screens which were performed at single dose 
concentrations, we investigated the impact of miR-142-3p on PrPSc levels in N2aPK1RML cells 
in a dose and time dependent manner (Figure 5.6). These studies revealed an increase of 
PrPSc levels in N2aPK1RML cells treated with miR-142-3p over time and similar effects of 
various doses of miR-142-3p utilized (Figures 5.6), indicating that doses utilised in initial 
screens were already at saturating levels.  
 
Figure 5.6: miR-142-3p 
elevates PrPSc levels in 
N2aPK1RML cells. A) Three days 
after transfection with miR-142-
3p or controls the PrPSc levels of 
N2aPK1RML cells were 
determined and normalized to 
viability. PrPSc levels and viability 
of transfection agent only treated 
cells were set as 1 (Mock; 
orange). N2aPK1Mock cells were 
used as a negative control for 
the PrPSc measurement (Block-it; 
blue), whereas a siRNA targeting 
PrP mRNA served as a control 
for successful accomplishment 
of the transfection and readout 
(PrP1826; red). The PrPSc to 
viability ratio of the miR treated 
cells is given as arithmetic mean 
plus standard deviation. miR-1 
was used as a further control. B) 
Three days after transfection 
with miR-142-3p or controls the 
PrPC levels of N2aPK1 cells 
were determined by ELISA and 
normalized to viability. PrPC 
levels and viability of transfection 
agent only treated cells were set 
as 1 (Mock; orange). C) miRNA-
142-3p elevated PrPSc levels in 
N2aPK1RML cells, but not PrPC 
levels in uninfected N2aPK1 
cells over a concentration range 
from 10 to 50nM. D) miR-142-3p 
elevated PrPSc levels in 
N2aPK1RML cells over time.  
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In the analyses generated so far mitochondrial activity had been used as a measure of cell 
viability and as a surrogate for total cell numbers to normalize the PrPSc levels of N2aPK1RML 
cells treated with different pre-miRs. Since it is entirely plausible that mitochondrial activity 
might be altered by certain miRNAs without altering the cell number or vice versa, it was 
important to further investigate the effects of miR-142-3p following normalisation to cell 
number in addition to viability. We therefore counted directly the cell number of N2aPK1RML 
cultures treated with miR-142-3p and controls (Figure 5.7A). We did not observe any 
difference in cell number between miR-142-3p and control treated N2aPK1RML cultures. 
Furthermore light microscopy did not reveal any obvious gross morphological differences 
between N2aPK1RML cell cultures treated with miR-142-3p or controls (Figure 5.7B).  
Whilst it was determined that total cellular PrPC levels are unaltered after treatment with miR-
142-3p by ELISA (Figure 5.6B), we next sought to investigate the possibility that altered PrPC 
trafficking (ie. altered levels of PrPC at the cell membrane) could be responsible for elevated 
PrPSc levels after miR-142-3p treatment. FACS analysis of N2aPK1Mock cells treated with 
miR-142-3p and controls revealed that surface PrPC levels were similar in treated and control 
cells (Figure 5.7C). This does not exclude the possibility of changed intracellular distribution 
of PrPC, nor the possibility of altered glycosylation levels. To investigate a possible impact of 
miR-142-3p on glycosylation and to confirm the results achieved with the luminometry 
readout PrPSc levels were assessed in N2aPK1RML cell lysates of miR-142-3p and control 
treated N2aPK1RML cells by immunoblotting for PrP (Figure 5.8). Here, no alterations in the 
glycosylation pattern of PrP after miR-142-3p treatment could be observed and in line with 
the results achieved by the luminometry readout, PrPSc levels seemed to be elevated in 
N2aPK1RML cells treated with miR-142-3p compared to control treated cells. N2aPK1 (Figure 
5.8). 
Hence, three day treatment of N2aPK1RML cells with miR-142-3p robustly led to PrPSc levels 
1.4 fold higher than controls, whereas mitochondrial activity, cell number, PrPC surface 
levels, and PrP glycosylation pattern was unaffected. In contrast, reduction of the substrate 
PrPC under the same conditions resulted in a robust 1.8 fold decrease in PrPSc levels. 
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Figure 5.7: Unchanged cell number, morphology and surface PrPC levels in N2aPK1 cultures treated with 
miR-142-3p. A) N2aPK1RML cells were treated with miR-142-3p and controls for three days. Subsequently, PrPSc 
levels, viability and cell number were determined. No changes in viability or cell number were detected. B) No 
obvious changes in morphology of miR-142-3p treated N2aPK1RML cells were observed by light microscopy. C) 
FACS analysis of miR-142-3p treated N2aPK1 cells showed unchanged PrPC abundance on the surface in 
comparison to transfection agent only or miR neg ctrl treated cells. N2aPK1 cells transfected with siRNA targeting 
PrP mRNA show reduced PrPC levels on the surface.  
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Figure 5.8: miR-142-3p elevates PrPSc levels in N2aPK1RML cells without altering the glycosylation pattern 
of PrP. N2aPK1RML cells were treated with miR-142-3p and controls for three days. Subsequent Western blot 
analysis for PrPC and PrPSc of monoclonal anti-PrP (POM1) probed protein homogenate are depicted with the 
respective controls. Proteinase K (PK) digestion visualizes protease resistant and consecutively shifted PrPSc. 70 
µg of protein were loaded for PK+, 35 µg of protein for PK- samples. Actin served as a loading control. 
 
5.2.6 miR-142-3p elevates PrPSc levels in both a cell type and prion strain 
independent manner 
Next, it was assessed whether the effect of miR-142-3p on PrPSc levels is cell type specific. 
Therefore, we measured PrPSc levels as a result of miRNA-142-3p overexpression in another 
cell culture model of prion infection. Similar to N2a cells, CAD cells are of neuronal origin, 
derived from mice and can be chronically infected with the prion strain RML (see also 
chapter 4 of this thesis). In addition to determination of PrPSc and PrPC levels, we also 
investigated the impact of miRNA-142-3p on gross cellular morphology (Figure 5.8). In line 
with results obtained from N2aPK1RML cells, miR-142-3p also elevates PrPSc levels in CADRML 
cells independently of endogenous PrPC levels. In contrast to N2aPK1RML cells however, it 
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was observed that CADRML cells overexpressing miR-142-3p showed a tendency to cluster 
when compared to controls as shown by light microscopy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: miR-142-3p elevates PrPSc levels independently of neuronal cell type. A) miR-142-3p elevated 
PrPSc levels in CADRML cells after three day treatment without influencing viability. B) miR-142-3p had no 
influence on PrPC levels in CAD cells after three day treatment. C) CADRML cells treated with miR-142-3p showed 
a tendency to cluster when compared to controls as shown by light microscopy.  
 
Furthermore, we investigated whether the effect of miR-142-3p on PrPSc levels is specific to 
the RML prion strain utilised. Therefore, we infected N2aPK1 cells with the prion strain 139A 
and established N2aPK1139A cultures, chronically infected with 139A (Figure 5.9A). Again, 
5 miR 142-3p elevates PrPSc levels in vitro   90 
 
overexpression of miR-142-3p resulted in elevated PrPSc levels in the 139A prion strain cell 
culture model (Figure 5.9B). 
In summary, elevation of PrPSc levels by miRNA142-3p overexpression is both cell type and 
prion strain independent, at least for CAD and N2a cells and RML and 139A prions. The 
exact spectrum that this holds true for remains to be investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: miR-142-3p elevates PrPSc levels independently of prion strain. A) Western blot analysis for 
PrPC and PrPSc of monoclonal anti-PrP (POM1) probed protein homogenate of N2aPK1 cells chronically infected 
with the prion strains RML, 139A and 22L. Proteinase K (PK) digestion visualizes protease resistant and 
consecutively shifted PrPSc in infected cultures, whereas signal is absent in uninfected control cells. 70 µg of 
protein were loaded for PK+, 35 µg of protein for PK- samples. B) N2aPK1139a cells show elevated PrPSc levels 
after three day treatment with miR-142-3p without changes in viability.  
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5.2.7 High density oligonucleotide arrays reveal six possible mRNA 
targets of miR-142-3p in N2aPK1RML cells 
Having identified miR-142-3p as a miRNA that modulates PrPSc levels in a cell type and prion 
strain independent manner, without altering PrPC levels, we sought to investigate the target 
mRNAs regulated by miR-142-3p. For the identification of differentially abundant mRNAs as 
a response to miR-142-3p treatment, we compared the global transcript expression profiles 
of N2aPK1RML transfected with miR-142-3p for three days against N2aPK1RML cells 
transfected with negative control miRNA. For each condition we performed four biological 
replicates, each replicate consisting of pooled cells from 12 wells of a 96 well plate after 
three days of transfection. We used the dChip 2005 algorithm and applied a 90% confidence 
interval with an equal-variance t-test significance threshold of p<0.05 and a fold change filter 
of 2.0 to the expression values. Applying the PM-only model (which disregards signal 
obtained from mismatch probes) we identified 98 probesets and applying the PM/MM model 
(which accounts for signal obtained from mismatch probes) 190 probesets were determined 
to pass these filter stringencies and the corresponding target mRNAs therefore to be 
differentially expressed between the two conditions. In order to obtain the most robust set of 
probes, the intersection of both models was utilised for further study. This resulted in 71 
distinct probesets, represent 57 redundant genes out of which 28 were down- and 29 
upregulated (Tables 5.1 and 5.2). 
The miRNA target prediction algorithms PicTar and miRanda were utilised to search this list 
of differentially expressed transcripts in order to determine whether any of these represented 
predicted mRNA targets of miR-142-3p. This approach led to identification of 6 candidate 
mRNAs (all of which appeared downregulated following miR-142-3p overexpression in our 
micorarray analyses) which harbour the miR-142-3p target sequence and could potentially 
represent bona fide targets of miR-142-3p (Table 5.2). None of the upregulated candidates 
was predicted to be a target of miR-142-3p. Hence, by combining high density 
oligonucleotide arrays and bioinformatic target predictions we identified six possible mRNA 
targets of miR-142-3p in N2aPK1RML cells. 
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Table 5.1: Genes upregulated in N2aPK1RML cells in presence of miR-142-3p.  
Gene Title 
Gene 
Symbol 
Average 
Fold 
Average 
Fold PicTar 
    
Change  
PM 
Change  
PM MM 
TargetSca
n 
secernin 3 Scrn3 10.5 3 No 
ras homolog N (RhoN) Rnd2 4.6 2.17 No 
tubulin, beta 2b Tubb2b 3.63 4.17 No 
calsyntenin 1 Clstn1 3.47 2.61 No 
SEC61, alpha subunit (S. cerevisiae) Sec61a1 3.2 3.58 No 
transmembrane 7 superfamily member 2 Tm7sf2 2.75 5.51 No 
amyloid beta (A4) precursor-like prot. 2 Aplp2 2.5 2.82 No 
lectin, galactose binding, soluble 9 Lgals9 2.61 2.85 No 
drebrin 1 Dbn1 2.6 2.3 No 
opioid growth factor receptor Ogfr 2.48 2.83 No 
NADH dehydrogenase (ubiquinone) 1  Ndufa7 2.38 2.26 No 
G protein-coupled receptor kinase 5 Gprk5 2.39 2.74 No 
phosphomannomutase 2 Pmm2 2.38 2.46 No 
transmembrane 4 superfamily member 2 Tspan7 2.35 2.58 No 
cathepsin B Ctsb 2.33 2.57 No 
basigin Bsg 2.33 2.5 No 
thioredoxin reductase 1 Txnrd1 2.33 3.04 No 
myeloblastosis oncogene Myb 2.27 2.4 No 
protein phospatase 3 Ppp3r1 2.3 2.31 No 
acetyl-Coenzyme A acyltransferase 2 Acaa2 2.25 3.09 No 
clusterin Clu 2.12 2.27 No 
Kruppel like factor 6 Klf6 2.19 2.82 No 
tetratricopeptide repeat domain 7B Ttc7b 2.13 2.33 No 
insulin-like growth factor binding prot. 6 Igfbp6 2.1 2.33 No 
eukaryotic translation initiation factor 
2B Eif2b1 2.09 3.02 No 
Mus musculus adult male hippocampus 
cDNA LOC677168 2.09 2.53 No 
glutaredoxin 1 (thioltransferase) Glrx 2.08 2.7 No 
pleckstrin homology domain-containing Plekha2 2.06 2.27 No 
phosphomannomutase 1 Pmm1 2.04 2.16 No 
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Table 5.2: Genes downregulated in N2aPK1RML cells in presence of miR 142-3p.  
Gene Title 
Gene 
Symbol 
Average 
Fold 
Average 
Fold PicTar 
    
Change  
PM 
Change  
PM MM TargetScan
ecotropic viral integration site 5 Evi5 -2 -2.14 No 
elongation of very long chain fatty acids  Elovl4 -2 -2.14 No 
ribosome binding protein 1 Rrbp1 -2 -2.12 No 
RAB2, member RAS oncogene family Rab2 -2.02 2.13 Yes 
early growth response 1 Egr1 -2.05 -2.26 No 
Wiskott-Aldrich syndrome-like (human) Wasl -2.11 -2.2 No 
CD151 antigen Cd151 -2.37 -2.45 No 
kinesin family member 5B Kif5b -2.07 -2.05 No 
NF of kappa light chain  
gene enhancer in B-cells Nfkbia -2.3 -2.35 No 
Mus musculus adult male hippocampus 
cDNA Elavl4 -2.1 -2.36 No 
transcription factor 4 Tcf4 -2.1 -2.34 No 
vesicle-associated membrane protein 3 Vamp3 -2.1 -2.14 Yes 
guanine nucleotide binding protein,  
alpha 11 Gna11 -2.18 -2.46 No 
nuclear factor I/B Nfib -2.19 2.39 No 
suppressor of cytokine signaling 2 Socs2 -2.27 -2.49 No 
ankyrin 3, epithelial Ank3  -2.28 -2.98 Yes 
myristoylated alanine rich  
protein kinase C substrate Marcks -2.51 -2.58 Yes 
transforming growth factor,  
beta receptor I Tgfbr1 -2.36 -2.55 No 
fibroblast growth factor inducible 15 Dfna5h -2.44 -2.91 No 
proviral integration site 1 --- -2.44 -2.49 No 
nerve growth factor receptor Ngfr -2.49 -2.65 No 
WD repeat domain,  
phosphoinositide interacting Wipi1 -2.52 -2.75 No 
sprouty homolog 2 (Drosophila) Spry2 -2.53 -2.89 No 
selenophosphate synthetase 2 Sps2 -2.6 -3.06 No 
myosin heavy chain IX Myh9 -2.76 -2.64 Yes 
protein kinase, cGMP-dependent, type II Prkg2 -2.78 -3.39 No 
RIKEN cDNA 1200015N20 gene --- -4.17 -5.56 No 
cofilin 2, muscle Cfl2 -3.65 -3.97 Yes 
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5.3 Discussion 
Here, efforts directed at screening of 266 pre-miRs for their potential to alter PrPSc levels in a 
cell culture model of prion infection is described. In total, 19 miRNAs that alter PrPSc levels in 
N2aPK1RML cells were identified, of which 17 also altered endogenous PrPC levels in N2aPK1 
cells. Although it is known that PrPC expression is a prerequisite for PrPSc propagation, 
knowledge regarding the molecular mechanisms underpinning PrPC to PrPSc conversion is 
sparse.  
Two miRNAs were identified (miR-1 and miR-142-3p) that altered PrPSc levels in N2aPK1RML 
cells without altering PrPC levels. However, whilst it was not possible to confirm miR-1 as a 
true candidate in further experiments, it was possible to demonstrate in several paradigms 
that miR-142-3p overexpression consistently resulted in elevated PrPSc levels, in a cell type 
and prion strain independent manner.  
miR 142-3p is expressed in mammals in the thymus, bone marrow, heart, muscle, lung, 
spleen, lymphocytes and embryonic stem cells (Lagos-Quintana et al., 2002; Houbaviy et al., 
2003) and in the thymic primordium and blood cells of Zebrafish. Neither in whole brain of 
healthy animals nor in neuronal cells could miR-142-3p expression be detected (Lagos-
Quintana et al., 2002; Landgraf et al., 2007). This suggests that in the natural situation miR-
142-3p is not involved in the regulation of PrPSc biogenesis in the CNS of prion infected 
animals, but it remains a possibility that aberrant expression of miR-142-3p occurs in the 
CNS during pathogenic situations such as prion disease. However, the purpose of these 
screens were to uncover target mRNAs and pathways which are implicated in this process, 
as a result of over- or ectopic-expression of particular miRNAs..  
The introduction of miR-142-3p in prion infected cells consistently resulted in elevated PrPSc 
levels, likely as a result of downregulation of one or more mRNA targets of miR-142-3p. It is 
important to consider that the reduction of PrPC as the direct substrate for PrPSc formation 
results in a 1.8 fold reduction in PrPSc levels under the conditions applied here, whereas miR-
142-3p results in 1.4 fold higher PrPSc levels without alterations in mitochondrial activity, cell 
number, PrPC surface levels, and PrP glycosylation pattern. This magnitude of alteration 
compared to the effect of the reduction of the direct substrate PrPC suggests downregulation 
of an important factor in (i) inhibition of PrPSc formation or (ii) degradation of PrPSc.  
To elucidate these mRNAs regulated by miR-142-3p, we performed high density 
oligonucleotide arrays and identified six candidate mRNAs which were both (a) differentially 
expressed and (b) predicted targets of miR-142-3p. Whilst downregulation of protease 
activity would have represented an attractive finding in this dataset, none of the candidates 
found to be differentially expressed and predicted as mRNA target for miR-142.-3p code for 
proteins with known protease activity. Nonetheless, it is still possible that the downregulation 
of these six candidates leads to successive alteration of a specific protease as suggested by 
the entire list of differentially expressed mRNAs after miR-142-3p treatment with 28 down- 
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and 29 upregulated candidates. In addition, alternative explanations such as reorganization 
of PrPC localization on the surface remain possible. Whether any of these targets alone or a 
combination of these is responsible for the alteration of PrPSc levels is currently under 
investigation.  
 
5.4 Outlook 
To identify the target mRNA responsible for the elevated PrPSc levels further experiments are 
in progress whereby siRNA mediated knockdown of the six target candidates by RNAi in 
N2aPK1RML cells individually is being assessed for their ability to modulate PrPSc levels. 
Therefore, potent siRNAs against these candidates in uninfected N2aPK1 cells are currently 
being identified, as assessed by qPCR. The identification of a modulator of PrPSc levels on 
the cellular level could give insights into prion biology and thereby could not only add to our 
understanding of the conversion but also may pave the way for potent inhibition of prion 
propagation.  
Whilst these 6 candidates are being utilised as a primary focus for further studies it is 
recognised that the modulation of PrPSc levels determined here may equally have resulted 
from molecular effects of miR-142-3p independent of these. As such, efforts are also being 
directed at bioinformatic pathway elucidation utilising the entire list of differentially expressed 
genes. 
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5.5 Materials and Methods 
5.5.1 Cell culture (N2aPK1 and CAD cells) 
The N2aPK1 subclone of mouse neuroblastoma N2a cells, which was selected for high 
susceptibility to prion infection, was kindly provided by Charles Weissmann and Peter Klöhn 
(MRC Prion Unit, The Institute of Neurology, London, UK) (Klohn et al., 2003). CAD cells, a 
subclone of the CNS catecholaminergic cell line Cath.a, were a gift of Dona Chikaraishi 
(Tufts University School of Medicine, Boston, Massachusetts, USA) (Qi et al., 1997). All cell 
lines were cultured in Optimem/10% FBS, Pen/Strep. N2aPK1 and CAD cells were split at 
confluency at a ratio of 1:3 every three or 1:10 every four days. For RNA isolation and 
Western blot analysis, cells were grown to approximately 75% confluence. 
 
5.5.2 Prion infection of cell lines (N2aPK1RML, N2aPK1139A and CADRML 
cells) 
Prion infection of cells was performed as reported previously (Klohn et al., 2003). Briefly, 
17’000 cells were seeded in each of six wells of a 96 well plate. After 16h of incubation cells 
were infected with a 10-2 dilution of 10% homogenate of mock CD1 brain homogenate, 10% 
homogenate of RML or 139A infected brain homogenate, respectively. After three days of 
incubation cells were split three times (1:3) and subsequently a further three times (1:10). At 
that point six wells were pooled and cells were expanded in a T75 cell culture flask. At 
approximately 75% confluency cells were harvested for RNA isolation or split 1:10 to obtain 
material for Western blot analysis. 
 
5.5.3 siRNA transfection 
10.000 N2aPK1 or CAD cells were seeded in 50µl Optimem/Pen/Strep in a 96 well plate. 
Except for the dose response experiments (Figure 6C) cells were transfected with 20nM of 
the corresponding mi/siRNA. Therefore, 50 µl transfection mix containing 0.8µl 5µM 
mi/siRNA, 1xl Lipofectamine and 48.2µl Optimem/Pen/Strep was added to the cells. 4h later 
100µl of Optimem/20% FCS/Pen/Strep was added and cell were incubated for 68 more 
hours. Cells were detached by repeated pipetting 20 times in cell culture medium for 
subsequent PrPSc and viability measurements or washed twice with PBS and pooled in 
TRIzol (Invitrogen Life Technologies) for RNA isolation. 
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Table 5.3: miRNA IDs for pre-miRs used in this study.  
miRNA ID 
Screen  
Plate  
Number 
Screen 
Plate 
Address 
N2aPK1
Cells ID 
1 1 A1 Mock Block-IT 
1 1 A2 Mock Block-IT 
1 1 A3 Mock Block-IT 
2 1 A4 RML Mock 
2 1 A5 RML Mock 
2 1 A6 RML Mock 
3 1 A7 RML pre-miR negative 1 
3 1 A8 RML pre-miR negative 1 
3 1 A9 RML pre-miR negative 1 
4 1 A10 RML PrP1826 siRNA 
4 1 A11 RML PrP1826 siRNA 
4 1 A12 RML PrP1826 siRNA 
5 1 B1 RML age-miR-22,hsa-miR-22,lca-miR-22,lla-miR-22,mml-miR-22,mmu-miR-22,mne-miR-22,ppa-miR-22,ppy-miR-22,p 
6 1 B2 RML mmu-miR-221, 
7 1 B3 RML age-miR-222,dre-miR-222,fru-miR-222,gga-miR-222a,hsa-miR-222,mmu-miR-222,rno-miR-222,tni-miR-222, 
8 1 B4 RML dre-miR-223,fru-miR-223,gga-miR-223,ggo-miR-223,hsa-miR-223,mml-miR-223,mmu-miR-223,ppa-miR-223,ppy- 
9 1 B5 RML mmu-miR-224, 
10 1 B6 RML age-miR-23a,ggo-miR-23a,hsa-miR-23a,lca-miR-23a,mml-miR-23a,mmu-miR-23a,mne-miR-23a,ppa-miR-23a,ppy- 
11 1 B7 RML gga-miR-23b,hsa-miR-23b,mmu-miR-23b,rno-miR-23b, 
12 1 B8 RML dre-miR-24,fru-miR-24,gga-miR-24,ggo-miR-24,hsa-miR-24,mml-miR-24,mmu-miR-24,mne-miR-24,ppa-miR-24,p 
13 1 B9 RML dre-miR-25,fru-miR-25,ggo-miR-25,hsa-miR-25,lla-miR-25,mml-miR-25,mmu-miR-25,mne-miR-25,ppa-miR-25,p 
14 1 B10 RML hsa-miR-27a,mmu-miR-27a,rno-miR-27a,ssc-miR-27a, 
15 1 B11 RML gga-miR-27b,hsa-miR-27b,mmu-miR-27b,rno-miR-27b, 
16 1 B12 RML age-miR-28,ggo-miR-28,hsa-miR-28,lla-miR-28,mml-miR-28,mmu-miR-28,mne-miR-28,ppa-miR-28,ppy-miR-28,p 
17 1 C1 RML mmu-miR-290,rno-miR-290, 
18 1 C2 RML mmu-miR-291a-3p,rno-miR-291-3p, 
19 1 C3 RML mmu-miR-291a-5p,rno-miR-291-5p, 
20 1 C4 RML mmu-miR-291b-3p, 
21 1 C5 RML mmu-miR-291b-5p, 
22 1 C6 RML mmu-miR-292-3p,rno-miR-292-3p, 
23 1 C7 RML mmu-miR-292-5p,rno-miR-292-5p, 
24 1 C8 RML mmu-miR-293, 
25 1 C9 RML mmu-miR-294, 
26 1 C10 RML mmu-miR-295, 
27 1 C11 RML hsa-miR-296,mmu-miR-296,rno-miR-296, 
28 1 C12 RML mmu-miR-297, 
29 1 D1 RML mmu-miR-298,rno-miR-298, 
30 1 D2 RML hsa-miR-299-5p,mmu-miR-299,rno-miR-299, 
31 1 D3 RML hsa-miR-29a,mmu-miR-29a,rno-miR-29a, 
32 1 D4 RML gga-miR-29b,hsa-miR-29b,mmu-miR-29b,rno-miR-29b, 
33 1 D5 RML gga-miR-29c,hsa-miR-29c,mmu-miR-29c,rno-miR-29c, 
34 1 D6 RML mmu-miR-300,rno-miR-300, 
35 1 D7 RML hsa-miR-301,mmu-miR-301, 
36 1 D8 RML gga-miR-302b,hsa-miR-302b,mmu-miR-302b, 
37 1 D9 RML mmu-miR-302b*, 
38 1 D10 RML mmu-miR-302c*, 
39 1 D11 RML hsa-miR-302d,mmu-miR-302d, 
40 1 D12 RML gga-miR-30a-3p,ggo-miR-30a-3p,hsa-miR-30a-3p,mml-miR-30a-3p,mmu-miR-30a-3p,ppa-miR-30a-3p,ppy-miR-30 
41 1 E1 RML gga-miR-30a-5p,ggo-miR-30a-5p,hsa-miR-30a-5p,mml-miR-30a-5p,mmu-miR-30a-5p,ppa-miR-30a-5p,ppy-miR-30 
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miRNA ID 
Screen  
Plate  
Number 
Screen 
Plate 
Address 
N2aPK1
Cells ID 
42 1 E2 RML dre-miR-30b,fru-miR-30b,gga-miR-30b,hsa-miR-30b,mmu-miR-30b,rno-miR-30b,tni-miR-30b, 
43 1 E3 RML gga-miR-30c,hsa-miR-30c,lla-miR-30c,mmu-miR-30c,mne-miR-30c,ptr-miR-30c,rno-miR-30c,ssc-miR-30c, 
44 1 E4 RML dre-miR-30d,fru-miR-30d,gga-miR-30d,ggo-miR-30d,hsa-miR-30d,mmu-miR-30d,mne-miR-30d,ppa-miR-30d,ptr- 
45 1 E5 RML mmu-miR-30e*, 
46 1 E6 RML mmu-miR-351,rno-miR-351, 
47 1 E7 RML hsa-miR-361,mmu-miR-361,rno-miR-361, 
48 1 E8 RML mmu-miR-362, 
49 1 E9 RML mmu-miR-363, 
50 1 E10 RML cfa-miR-365,dre-miR-365,fru-miR-365,gga-miR-365,hsa-miR-365,mmu-miR-365,rno-miR-365,tni-miR-365, 
51 1 E11 RML gga-miR-367,mmu-miR-367, 
52 1 E12 RML mmu-miR-369-3p,rno-miR-369-3p, 
53 1 F1 RML mmu-miR-370,rno-miR-370, 
54 1 F2 RML hsa-miR-375,mmu-miR-375, 
55 1 F3 RML mmu-miR-376a, 
56 1 F4 RML hsa-miR-376a*,mmu-miR-376a*,rno-miR-376a*, 
57 1 F5 RML mmu-miR-376b, 
58 1 F6 RML mmu-miR-376b*,rno-miR-376b*, 
59 1 F7 RML mmu-miR-376c,rno-miR-376c, 
60 1 F8 RML hsa-miR-377,mmu-miR-377, 
61 1 F9 RML hsa-miR-378,mmu-miR-378,rno-miR-378, 
62 1 F10 RML mmu-miR-379, 
63 1 F11 RML mmu-miR-380-3p, 
64 1 F12 RML hsa-miR-380-5p,mmu-miR-380-5p, 
65 1 G1 RML mmu-miR-31,rno-miR-31, 
66 1 G2 RML gga-miR-32,ggo-miR-32,hsa-miR-32,mml-miR-32,mmu-miR-32,mne-miR-32,ppa-miR-32,ppy-miR-32,ptr-miR-32,r 
67 1 G3 RML hsa-miR-320,mmu-miR-320,rno-miR-320, 
68 1 G4 RML mmu-miR-322,rno-miR-322, 
69 1 G5 RML hsa-miR-323,mmu-miR-323,rno-miR-323,ssc-miR-323, 
70 1 G6 RML hsa-miR-324-3p,mmu-miR-324-3p,rno-miR-324-3p, 
71 1 G7 RML mmu-miR-324-5p, 
72 1 G8 RML mmu-miR-325,rno-miR-325, 
73 1 G9 RML mmu-miR-326,rno-miR-326, 
74 1 G10 RML hsa-miR-328,mmu-miR-328,rno-miR-328, 
75 1 G11 RML mmu-miR-329,rno-miR-329, 
76 1 G12 RML gga-miR-33,ggo-miR-33,hsa-miR-33,mml-miR-33,mmu-miR-33,mne-miR-33,ppa-miR-33,ppy-miR-33,ptr-miR-33,r 
77 1 H1 RML mmu-miR-330,rno-miR-330, 
78 1 H2 RML hsa-miR-331,mmu-miR-331,rno-miR-331, 
79 1 H3 RML hsa-miR-335,mmu-miR-335,rno-miR-335, 
80 1 H4 RML mmu-miR-337,rno-miR-337, 
81 1 H5 RML hsa-miR-338,mmu-miR-338,rno-miR-338, 
82 1 H6 RML hsa-miR-339,mmu-miR-339,rno-miR-339, 
83 1 H7 RML hsa-miR-340,mmu-miR-340,rno-miR-340, 
84 1 H8 RML mmu-miR-341,rno-miR-341, 
85 1 H9 RML mmu-miR-344, 
86 1 H10 RML mmu-miR-345,rno-miR-345, 
87 1 H11 RML mmu-miR-346, 
88 1 H12 RML gga-miR-34a,hsa-miR-34a,mmu-miR-34a,rno-miR-34a, 
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miRNA ID 
Screen  
Plate  
Number 
Screen 
Plate 
Address 
N2aPK1
Cells ID 
1 2 A1 Mock Block-IT 
1 2 A2 Mock Block-IT 
1 2 A3 Mock Block-IT 
2 2 A4 RML Mock 
2 2 A5 RML Mock 
2 2 A6 RML Mock 
3 2 A7 RML pre-miR negative 1 
3 2 A8 RML pre-miR negative 1 
3 2 A9 RML pre-miR negative 1 
4 2 A10 RML PrP1826 siRNA 
4 2 A11 RML PrP1826 siRNA 
4 2 A12 RML PrP1826 siRNA 
89 2 B1 RML dre-miR-107,fru-miR-107,gga-miR-107,ggo-miR-107,hsa-miR-107,lla-miR-107,mml-miR-107,mmu-miR-107,mne- 
90 2 B2 RML age-miR-10a,ggo-miR-10a,hsa-miR-10a,mmu-miR-10a,ppa-miR-10a,rno-miR-10a,sla-miR-10a, 
91 2 B3 RML gga-miR-122a,hsa-miR-122a,mmu-miR-122a,rno-miR-122a,ssc-miR-122a, 
92 2 B4 RML mmu-miR-124a, 
93 2 B5 RML hsa-miR-125a,mmu-miR-125a,rno-miR-125a, 
94 2 B6 RML aga-miR-125,age-miR-125b,dme-miR-125,dps-miR-125,dre-miR-125b,fru-miR-125b,gga-miR-125b,ggo-miR-125b 
95 2 B7 RML dre-miR-126,fru-miR-126,gga-miR-126,hsa-miR-126,mmu-miR-126-3p,rno-miR-126,tni-miR-126, 
96 2 B8 RML dre-miR-126*,hsa-miR-126*,mmu-miR-126-5p,rno-miR-126*, 
97 2 B9 RML mmu-miR-127, 
98 2 B10 RML age-miR-128a,dre-miR-128,fru-miR-128,gga-miR-128a,gga-miR-128b,hsa-miR-128a,mml-miR-128a,mmu-miR-128 
99 2 B11 RML dre-miR-129*,hsa-abi-13124,mmu-miR-129-3p,rno-miR-129*, 
100 2 B12 RML dre-miR-129,fru-miR-129,mmu-miR-129-5p,rno-miR-129,tni-miR-129, 
101 2 C1 RML dre-miR-130a,hsa-miR-130a,mmu-miR-130a,rno-miR-130a, 
102 2 C2 RML hsa-miR-130b,mmu-miR-130b,rno-miR-130b, 
103 2 C3 RML dre-miR-132,fru-miR-132,hsa-miR-132,mmu-miR-132,rno-miR-132,tni-miR-132, 
104 2 C4 RML aga-miR-133,age-miR-133a,ame-miR-133,dme-miR-133,dps-miR-133,gga-miR-133a,ggo-miR-133a,hsa-miR-133a, 
105 2 C5 RML gga-miR-133b,hsa-miR-133b,mmu-miR-133b,rno-miR-133b, 
106 2 C6 RML mmu-miR-134, 
107 2 C7 RML age-miR-135,dre-miR-135a,gga-miR-135a,ggo-miR-135,hsa-miR-135a,lla-miR-135,mml-miR-135,mmu-miR-135a, 
108 2 C8 RML hsa-miR-135b,mmu-miR-135b,rno-miR-135b, 
109 2 C9 RML ggo-miR-136,hsa-miR-136,mmu-miR-136,oar-miR-136,ppa-miR-136,ppy-miR-136,ptr-miR-136,rno-miR-136,ssc- 
110 2 C10 RML mmu-miR-137, 
111 2 C11 RML gga-miR-138,hsa-miR-138,mmu-miR-138,rno-miR-138, 
112 2 C12 RML hsa-miR-139,lla-miR-139,mmu-miR-139,ppa-miR-139,rno-miR-139,ssc-miR-139, 
113 2 D1 RML mmu-miR-140*, 
114 2 D2 RML hsa-miR-141,mmu-miR-141,rno-miR-141, 
115 2 D3 RML gga-miR-142-5p,hsa-miR-142-5p,mmu-miR-142-5p,rno-miR-142-5p, 
116 2 D4 RML ggo-miR-143,hsa-miR-143,lla-miR-143,mmu-miR-143,ppa-miR-143,ppy-miR-143,ptr-miR-143,rno-miR-143, 
117 2 D5 RML hsa-miR-144,mmu-miR-144,mne-miR-144,ppy-miR-144,ptr-miR-144,rno-miR-144, 
118 2 D6 RML ggo-miR-145,hsa-miR-145,mml-miR-145,mmu-miR-145,mne-miR-145,ppy-miR-145,ptr-miR-145,rno-miR-145,ssc- 
119 2 D7 RML gga-miR-146a,hsa-miR-146a,mmu-miR-146,rno-miR-146, 
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Screen  
Plate  
Number 
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Address 
N2aPK1
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120 2 D8 RML gga-miR-148a,hsa-miR-148a,mmu-miR-148a,ssc-miR-148a, 
121 2 D9 RML hsa-miR-148b,mmu-miR-148b,rno-miR-148b, 
122 2 D10 RML hsa-miR-149,mmu-miR-149, 
123 2 D11 RML hsa-miR-150,mmu-miR-150,rno-miR-150, 
124 2 D12 RML mmu-miR-151, 
125 2 E1 RML hsa-miR-152,mmu-miR-152,rno-miR-152, 
126 2 E2 RML dre-miR-153a,fru-miR-153a,mmu-miR-153,tni-miR-153a, 
127 2 E3 RML ggo-miR-154,hsa-miR-154,mmu-miR-154,mne-miR-154,ppa-miR-154,ppy-miR-154,ptr-miR-154,rno-miR-154, 
128 2 E4 RML mmu-miR-155, 
129 2 E5 RML age-miR-15a,gga-miR-15a,ggo-miR-15a,hsa-miR-15a,lca-miR-15a,lla-miR-15a,mml-miR-15a,mmu-miR-15a,mne- 
130 2 E6 RML age-miR-15b,ggo-miR-15b,hsa-miR-15b,lla-miR-15b,mml-miR-15b,mmu-miR-15b,mne-miR-15b,ppa-miR-15b,ppy- 
131 2 E7 RML age-miR-16,ggo-miR-16,hsa-miR-16,lla-miR-16,mml-miR-16,mmu-miR-16,mne-miR-16,ppa-miR-16,ppy-miR-16,p 
132 2 E8 RML mmu-miR-17-3p, 
133 2 E9 RML age-miR-17-5p,gga-miR-17-5p,ggo-miR-17-5p,hsa-miR-17-5p,lca-miR-17-5p,lla-miR-17-5p,mml-miR-17-5p,mm 
134 2 E10 RML age-miR-18,dre-miR-18a,fru-miR-18,gga-miR-18a,ggo-miR-18,hsa-miR-18a,lca-miR-18,lla-miR-18,mml-miR-1 
135 2 E11 RML dre-miR-181a,fru-miR-181a,gga-miR-181a,ggo-miR-181a,hsa-miR-181a,lla-miR-181a,mml-miR-181a,mmu-miR-1 
136 2 E12 RML ggo-miR-181c,hsa-miR-181c,mml-miR-181c,mmu-miR-181c,ppa-miR-181c,ptr-miR-181c,rno-miR-181c,ssc-miR-1 
137 2 F1 RML dre-miR-182,hsa-miR-182,mml-miR-182,mmu-miR-182,ppy-miR-182, 
138 2 F2 RML dre-miR-183,fru-miR-183,gga-miR-183,ggo-miR-183,hsa-miR-183,mml-miR-183,mmu-miR-183,mne-miR-183,ppa- 
139 2 F3 RML gga-miR-184,hsa-miR-184,mmu-miR-184,mne-miR-184,ppy-miR-184,ptr-miR-184,rno-miR-184,ssc-miR-184, 
140 2 F4 RML hsa-miR-185,mmu-miR-185,rno-miR-185, 
141 2 F5 RML ggo-miR-186,hsa-miR-186,mmu-miR-186,ppa-miR-186,ptr-miR-186,rno-miR-186,ssc-miR-186, 
142 2 F6 RML mmu-miR-187, 
143 2 F7 RML hsa-miR-188,mml-miR-188,mmu-miR-188,mne-miR-188,ppa-miR-188,ppy-miR-188,ptr-miR-188, 
144 2 F8 RML hsa-miR-189,mml-miR-189,mmu-miR-189,mne-miR-189,ppa-miR-189,ppy-miR-189,rno-miR-189, 
145 2 F9 RML dre-miR-190,fru-miR-190,gga-miR-190,ggo-miR-190,hsa-miR-190,mml-miR-190,mmu-miR-190,ppa-miR-190,ptr- 
146 2 F10 RML hsa-miR-191,mmu-miR-191,rno-miR-191, 
147 2 F11 RML mmu-miR-192, 
148 2 F12 RML age-miR-194,gga-miR-194,ggo-miR-194,hsa-miR-194,mml-miR-194,mmu-miR-194,mne-miR-194,ppy-miR-194,ptr- 
149 2 G1 RML ggo-miR-195,hsa-miR-195,mmu-miR-195,ppa-miR-195,rno-miR-195, 
150 2 G2 RML gga-miR-196,ggo-miR-196,hsa-miR-196a,mml-miR-196,mmu-miR-196a,ppy-miR-196,rno-miR-196a,ssc-miR-196, 
151 2 G3 RML hsa-miR-196b,mmu-miR-196b,rno-miR-196b, 
152 2 G4 RML dre-miR-199,fru-miR-199,gga-miR-199a,ggo-miR-199a,hsa-miR-199a,lla-miR-199a,mml-miR-199a,mmu-miR-199 
153 2 G5 RML dre-miR-199*,hsa-miR-199a*,mmu-miR-199a*, 
154 2 G6 RML mmu-miR-199b, 
155 2 G7 RML age-miR-19a,dre-miR-19a,fru-miR-19a,gga-miR-19a,ggo-miR-19a,hsa-miR-19a,lca-miR-19a,lla-miR-19a,mml- 
156 2 G8 RML age-miR-19b,dre-miR-19b,fru-miR-19b,gga-miR-19b,ggo-miR-19b,hsa-miR-19b,lca-miR-19b,lla-miR-19b,mml- 
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157 2 G9 RML dre-miR-200a,fru-miR-200a,gga-miR-200a,hsa-miR-200a,mmu-miR-200a,rno-miR-200a,tni-miR-200a, 
158 2 G10 RML hsa-miR-200b,mmu-miR-200b,rno-miR-200b, 
159 2 G11 RML hsa-miR-200c,mmu-miR-200c,rno-miR-200c, 
160 2 G12 RML mmu-miR-201, 
161 2 H1 RML mmu-miR-202, 
162 2 H2 RML mmu-miR-203, 
163 2 H3 RML mmu-miR-204, 
164 2 H4 RML age-miR-205,dre-miR-205,fru-miR-205,gga-miR-205a,ggo-miR-205,hsa-miR-205,lla-miR-205,mmu-miR-205,mne 
165 2 H5 RML dre-miR-206,gga-miR-206,hsa-miR-206,mmu-miR-206,mne-miR-206,ppy-miR-206,rno-miR-206, 
166 2 H6 RML mmu-miR-207, 
167 2 H7 RML hsa-miR-208,mmu-miR-208,rno-miR-208, 
168 2 H8 RML dre-miR-20a,fru-miR-20,gga-miR-20a,hsa-miR-20a,mmu-miR-20a,rno-miR-20a,tni-miR-20, 
169 2 H9 RML mmu-miR-20b, 
170 2 H10 RML age-miR-21,ggo-miR-21,hsa-miR-21,mml-miR-21,mmu-miR-21,mne-miR-21,ppa-miR-21,ppy-miR-21,ptr-miR-21,r 
171 2 H11 RML hsa-miR-210,mmu-miR-210,rno-miR-210, 
172 2 H12 RML mml-miR-211,mmu-miR-211,rno-miR-211, 
1 3 A1 Mock Block-IT 
1 3 A2 Mock Block-IT 
1 3 A3 Mock Block-IT 
2 3 A4 RML Mock 
2 3 A5 RML Mock 
2 3 A6 RML Mock 
3 3 A7 RML pre-miR negative 1 
3 3 A8 RML pre-miR negative 1 
3 3 A9 RML pre-miR negative 1 
4 3 A10 RML PrP1826 siRNA 
4 3 A11 RML PrP1826 siRNA 
4 3 A12 RML PrP1826 siRNA 
173 3 B1 RML hsa-miR-342,mmu-miR-342,rno-miR-342, 
174 3 B2 RML mmu-miR-34b,rno-miR-34b, 
175 3 B3 RML gga-miR-34c,hsa-miR-34c,mmu-miR-34c,rno-miR-34c, 
176 3 B4 RML mmu-miR-350, 
177 3 B5 RML hsa-miR-381,mmu-miR-381, 
178 3 B6 RML hsa-miR-382,mmu-miR-382, 
179 3 B7 RML mmu-miR-383,rno-miR-383, 
180 3 B8 RML mmu-miR-384, 
181 3 B9 RML mmu-miR-409, 
182 3 B10 RML mmu-miR-410, 
183 3 B11 RML mmu-miR-411, 
184 3 B12 RML hsa-miR-412,mmu-miR-412,rno-miR-412, 
185 3 C1 RML hsa-miR-422b,mmu-miR-422b, 
186 3 C2 RML mmu-miR-424,rno-miR-424, 
187 3 C3 RML hsa-miR-425,mmu-miR-425, 
188 3 C4 RML cfa-miR-429,dre-miR-429,fru-miR-429,gga-miR-429,mmu-miR-429,rno-miR-429,tni-miR-429, 
189 3 C5 RML mmu-miR-431,oar-miR-431, 
190 3 C6 RML hsa-miR-433,mmu-miR-433-3p,rno-miR-433, 
191 3 C7 RML mmu-miR-433-5p, 
192 3 C8 RML mmu-miR-434-3p, 
193 3 C9 RML mmu-miR-434-5p, 
194 3 C10 RML cfa-miR-448,hsa-miR-448,mmu-miR-448,rno-miR-448, 
195 3 C11 RML cfa-miR-449,hsa-miR-449,mmu-miR-449,rno-miR-449, 
196 3 C12 RML cfa-miR-450,hsa-miR-450,mmu-miR-450, 
197 3 D1 RML dre-miR-451,mmu-miR-451,rno-miR-451, 
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198 3 D2 RML hsa-miR-452,mmu-miR-452, 
199 3 D3 RML mmu-miR-463, 
200 3 D4 RML mmu-miR-464, 
201 3 D5 RML mmu-miR-465, 
202 3 D6 RML mmu-miR-466, 
203 3 D7 RML mmu-miR-467, 
204 3 D8 RML mmu-miR-468, 
205 3 D9 RML mmu-miR-469, 
206 3 D10 RML mmu-miR-470, 
207 3 D11 RML mmu-miR-471, 
208 3 D12 RML mmu-miR-483,rno-miR-483, 
209 3 E1 RML hsa-miR-484,mmu-miR-484, 
210 3 E2 RML mmu-miR-485-3p, 
211 3 E3 RML hsa-miR-485-5p,mmu-miR-485-5p,rno-miR-485, 
212 3 E4 RML hsa-miR-486,mmu-miR-486, 
213 3 E5 RML mmu-miR-487b,rno-miR-487b, 
214 3 E6 RML mmu-miR-489, 
215 3 E7 RML mmu-miR-494,rno-miR-494, 
216 3 E8 RML mmu-miR-503, 
217 3 E9 RML hsa-miR-539,mmu-miR-539,rno-miR-539, 
218 3 E10 RML mmu-miR-540,rno-miR-540, 
219 3 E11 RML mmu-miR-541,rno-miR-541, 
220 3 E12 RML hsa-miR-542-3p,mmu-miR-542-3p, 
221 3 F1 RML mmu-miR-542-5p,rno-miR-542-5p, 
222 3 F2 RML mmu-miR-543,rno-miR-543, 
223 3 F3 RML mmu-miR-546, 
224 3 F4 RML mmu-miR-547, 
225 3 F5 RML gga-miR-7,hsa-miR-7,mmu-miR-7, 
226 3 F6 RML dre-miR-7b,mmu-miR-7b,rno-miR-7b, 
227 3 F7 RML mmu-miR-9, 
228 3 F8 RML dre-miR-9*,hsa-miR-9*,mmu-miR-9*, 
229 3 F9 RML gga-miR-92,hsa-miR-92,mmu-miR-92,rno-miR-92, 
230 3 F10 RML mmu-miR-93,rno-miR-93, 
231 3 F11 RML dre-miR-96,fru-miR-96,mmu-miR-96,rno-miR-96,tni-miR-96, 
232 3 F12 RML age-miR-98,ggo-miR-98,hsa-miR-98,mml-miR-98,mmu-miR-98,ppa-miR-98,ppy-miR-98,ptr-miR-98,rno-miR-98, 
233 3 G1 RML mmu-miR-99a, 
234 3 G2 RML hsa-miR-99b,mmu-miR-99b,rno-miR-99b, 
1 4 A1 Mock Block-IT 
1 4 A2 Mock Block-IT 
1 4 A3 Mock Block-IT 
2 4 A4 RML Mock 
2 4 A5 RML Mock 
2 4 A6 RML Mock 
3 4 A7 RML pre-miR negative 1 
3 4 A8 RML pre-miR negative 1 
3 4 A9 RML pre-miR negative 1 
4 4 A10 RML PrP1826 siRNA 
4 4 A11 RML PrP1826 siRNA 
4 4 A12 RML PrP1826 siRNA 
235 4 B1 RML dre-let-7b,fru-let-7b,gga-let-7b,hsa-let-7b,mmu-let-7b,rno-let-7b,tni-let-7b, 
236 4 B2 RML mmu-miR-101b,rno-miR-101b, 
237 4 B3 RML age-miR-103,dre-miR-103,fru-miR-103,gga-miR-103,ggo-miR-103,hsa-miR-103,lla-miR-103,mml-miR-103,mmu- 
238 4 B4 RML hsa-miR-128b,mmu-miR-128b,rno-miR-128b, 
239 4 B5 RML dre-miR-181b,fru-miR-181b,gga-miR-181b,hsa-miR-181b,mmu-miR-181b,rno-miR-181b,tni-miR-181b, 
240 4 B6 RML hsa-miR-212,mmu-miR-212,rno-miR-212, 
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241 4 B7 RML fru-miR-213,gga-miR-213,ggo-miR-213,hsa-miR-213,lla-miR-213,mml-miR-213,mmu-miR-213,mne-miR-213,ppa- 
242 4 B8 RML age-miR-214,dre-miR-214,fru-miR-214,ggo-miR-214,hsa-miR-214,mml-miR-214,mmu-miR-214,mne-miR-214,ppa- 
243 4 B9 RML mmu-miR-215,rno-miR-215, 
244 4 B10 RML gga-miR-216,ggo-miR-216,hsa-miR-216,lca-miR-216,mmu-miR-216,ppa-miR-216,ppy-miR-216,ptr-miR-216,rno- 
245 4 B11 RML mmu-miR-217,rno-miR-217, 
246 4 B12 RML gga-miR-219,ggo-miR-219,hsa-miR-219,mml-miR-219,mmu-miR-219,ppy-miR-219,rno-miR-219, 
247 4 C1 RML dme-let-7,dps-let-7,mmu-let-7a, 
248 4 C2 RML dre-let-7c,gga-let-7c,hsa-let-7c,mmu-let-7c,rno-let-7c,ssc-let-7c, 
249 4 C3 RML hsa-let-7d,mmu-let-7d,rno-let-7d, 
250 4 C4 RML hsa-let-7e,mmu-let-7e,rno-let-7e, 
251 4 C5 RML mmu-let-7f, 
252 4 C6 RML gga-let-7g,hsa-let-7g,mmu-let-7g, 
253 4 C7 RML gga-let-7i,hsa-let-7i,mmu-let-7i,rno-let-7i, 
254 4 C8 RML cbr-miR-1,cel-miR-1,gga-miR-1a,hsa-miR-1,mmu-miR-1,ppa-miR-1, 
255 4 C9 RML aga-miR-100,age-miR-100,dre-miR-100,fru-miR-100,gga-miR-100,ggo-miR-100,hsa-miR-100,lla-miR-100,mml- 
256 4 C10 RML age-miR-101,dre-miR-101a,fru-miR-101a,gga-miR-101,ggo-miR-101,hsa-miR-101,lla-miR-101,mml-miR-101,mm 
257 4 C11 RML mmu-miR-106a, 
258 4 C12 RML age-miR-106b,ggo-miR-106b,hsa-miR-106b,lla-miR-106b,mml-miR-106b,mmu-miR-106b,mne-miR-106b,ppa-miR-1 
259 4 D1 RML mmu-let-7d*,rno-let-7d*, 
260 4 D2 RML mmu-miR-10b,rno-miR-10b, 
261 4 D3 RML dre-miR-140,fru-miR-140,mmu-miR-140,tni-miR-140, 
262 4 D4 RML mmu-miR-142-3p, 
263 4 D5 RML hsa-miR-193a,mmu-miR-193,rno-miR-193, 
264 4 D6 RML age-miR-218,gga-miR-218,ggo-miR-218,hsa-miR-218,lca-miR-218,lla-miR-218,mml-miR-218,mmu-miR-218,mne- 
265 4 D7 RML gga-miR-26a,hsa-miR-26a,mmu-miR-26a,rno-miR-26a, 
266 4 D8 RML hsa-miR-26b,mmu-miR-26b,rno-miR-26b, 
267 4 D9 RML hsa-miR-302a,mmu-miR-302, 
268 4 D10 RML mmu-miR-302c, 
269 4 D11 RML gga-miR-30e,hsa-miR-30e-5p,mmu-miR-30e,rno-miR-30e, 
270 4 D12 RML mmu-miR-369-5p,rno-miR-369-5p, 
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5.5.4 Assessment of PrPSc levels in prion infected cells (N2aPK1RML, 
N2aPK1139A and CADRML cells) 
To assess PrPSc levels in prion infected cells we modified the Elispot assay described by 
Klohn et al. (Klohn et al., 2003). 50% of the cells from a well of a 96 well plate were 
transferred to new 96 well plate and viability was determined by MTS assay according to the 
manufacturer’s protocol (CellTiter 96® AQueous One Solution Cell Proliferation Assay, 
Promega) in a microplate spectrofluorometer (SpectraMax / Gemini; Molecular Devices). The 
remaining 50 % of the cells were transferred to a sterile Multi Screen Immobilon-P 96-well 
Filtration Elispot plate that had been activated with 70% ethanol (Millipore). The cell 
suspension was filtered by vacuum filtration, followed by incubation for 1h at 50°C. 
Subsequently, 50 µl of proteinase K (PK; 0.25 µg/ml in lysis buffer [(50 mM Tris·HCl, pH 
8.0/150 mM NaCl/0.5% sodium deoxycholate/0.5% Triton X-100]) was added to each well, 
and the plates incubated for 90 min at 37°C followed by removal of the proteinase K solution 
by vacuum filtration. The wells were washed several times with PBS, incubated with 2 mM 
PMSF for 10 min, and washed again several times with PBS. After incubation with 160 µl of 3 
M guanidinium thiocyanate in 10 mM Tris·HCl (pH 8.0) for 10 min, the filters were washed 
four times with PBS and incubated with 160 µl 5% TopBlock for 60 min. 50 µl of 0.4 µg/ml 
anti-PrP antibody POM1, in TBST/1% TopBlock, (Polymenidou et al., 2005) was added and 
the plates incubated at RT for 1h, followed by removal of the antibody solution. Next, the 
wells were washed eight times with TBST followed by addition of 50 µl of horseradish-
peroxidase-conjugated anti-mouse IgG1 (1:1000 in TBST/1% milk powder) was added for 1 
h. Wells were washed eight times with TBST. 100 µl of ECL substrate was added for 1 min 
according to the manufacturer’s instructions (Amersham Corporation) and the signal intensity 
was measured in a microplate spectrofluorometer (SpectraMax / Gemini; Molecular Devices). 
The PrPSc signal as well as the viability of transfection agent (Lipofectamine) only treated 
cells were set as one and PrPSc levels of the samples were normalized to this. 
 
5.5.5 Western blot detection of PrPSc  
To confirm persistent prion infection, cells were screened for PrPSc content in the different 
independent biological replicates. For PrPSc detection, cells were grown on T75 flasks until 
approximately 75% confluent. Monolayers were rinsed with PBS, harvested and lysed in 
RIPA lysis buffer (10 mM Tris–HCl (pH 7.5), 100 mM NaCl, 10 mM EDTA, 0.5% (v/v) Triton 
X-100, 0.5% (v/v) (deoxycholate) followed by three freeze-thaw cycles. Following 
centrifugation at 1000xg for 5min the supernatant was removed and protein content 
quantitated by BCA-protein assay (BioRad) to allow equal amounts of protein to be applied 
the blot after either treatment with 20 mg/ml of proteinase K for 30 minutes at 37°C for PrPSc 
detection or no treatment (for PrPC detection). Proteins were subjected to SDS-PAGE (12.5% 
Bis-Tris gels, NuPAGE, Invitrogen). PrPC and PrPSc were detected using the mouse 
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monoclonal antibody POM1 (1:10’000) followed by HRP-anti-mouse IgG1, and blots were 
developed with ECLplus according to the manufacturer’s instructions (Amersham 
Corporation).  
 
5.5.6 Preparation of labeled cRNA, microarray hybridization and data 
analysis 
Total RNA was extracted from all samples using Trizol (Invitrogen, Switzerland) according to 
the manufacturers instructions. RNA was subjected to a clean up step using RNeasy mini kit 
(Qiagen, Switzerland). RNA quality was assessed by Agilent 2100 Bioanalyzer. 5 µg total 
RNA was subjected to cDNA synthesis using a cDNA Synthesis kit (Cat.No.11917-010, 
Invitrogen, Switzerland) and primer 5’-GGCCAGTGAATTGTAATACG 
ACTCACTATAGGGAGGCGG(dT)24-3’. Biotin-labeled cRNA was synthesized, using Enzo 
BioArray HighYield RNA transcript labeling Kit (T7) (Enzo), cleaned with the RNeasy mini kit, 
quantified by spectrophotometry, and quality was assessed again by Agilent 2100 
Bioanalyzer. Typical yields ranged from 60 to 90 µg labeled cRNA. 15 µg labeled cRNA were 
fragmented in 40 mM Tris-acetate, 100 mM KOAc, 30 mM MgOAc, pH 8.1 at 95 °C for 35 
min. After fragmentation an aliquot of one representative of the replicates of each sample 
was hybridized to Affymetrix Test3 arrays to determine the quality of the probes, reflected by 
the 3’:5’ ratios, and to test all buffers. The 3’:5’ ratios of the cRNAs used was always <2. The 
samples were then hybridized to Affymetrix MOE430A chips. All hybridizations were carried 
out for 16 h at 45 °C at 60 rpm. After hybridization chips were washed and conjugated with 
streptavidin-phycoerythrin according to the manufacturers instructions on the Affymetrix 
GeneChip Fluidics Station 450 with and scanned using the Affymetrix GS Scanner 3000 in 
conjunction with Affymetrix Microarray Suite 5.0 software.  
 
5.5.7 Microarray Data Analysis  
Intensity values of all chips were normalized with dChip software (http://www.dchip.org) (Li 
and Wong, 2001) and applying the model-based expression analysis algorithm (PM-only or 
PM/MM models) the expression values were calculated. 
Datasets from miR-142-3p treated N2aPK1RML samples (4 biological replicates) and miR 
negative control treated N2aPK1RML samples (4 biological replicates) were compared 
applying a 2-fold change (using the lower 90 % confidence boundary of fold change) as the 
lower limit, with present calls of at least 75% in either of each group..  
Functional annotation of genes was performed utilizing information provided by Affymetrix 
NetAffx (http://www.affymetrix.com/analysis/index.affx), LocusLink 
(http://www.ncbi.nlm.nih.gov//), and PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) 
databases.  
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